

Preoperative/Neoadjuvant Therapy in Pancreatic Cancer Meta-analysis of Response and Resection Percentages

PLoS Medicine

7, e1000267

DOI: [10.1371/journal.pmed.1000267](https://doi.org/10.1371/journal.pmed.1000267)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Pancreatic cancer. <i>Lancet, The</i> , 2004, 363, 1049-1057.	6.3	1,761
2	Point de vue sur les traitements adjuvant et néoadjuvant du cancer du pancréas en 2010. <i>Oncologie</i> , 2010, 12, 629-635.	0.2	0
4	The role of radiotherapy in multimodal treatment of pancreatic carcinoma. <i>Radiation Oncology</i> , 2010, 5, 64.	1.2	44
5	Molecular imaging agents: impact on diagnosis and therapeutics in oncology. <i>Expert Reviews in Molecular Medicine</i> , 2010, 12, e20.	1.6	28
6	Refinement of Adjuvant Therapy for Pancreatic Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2010, 304, 1124.	3.8	26
7	Prognostic factors for resectable pancreatic adenocarcinoma. <i>Journal of Visceral Surgery</i> , 2011, 148, e232-e243.	0.4	22
9	Neoadjuvant Therapy In Pancreatic Adenocarcinoma: A Meta-Analysis Of Phase II Trials. <i>Journal of Surgical Research</i> , 2011, 165, 269.	0.8	0
10	Advances in early diagnosis and therapy of pancreatic cancer. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2011, 10, 128-135.	0.6	24
11	Current State of Surgical Management of Pancreatic Cancer. <i>Cancers</i> , 2011, 3, 1253-1273.	1.7	19
12	Pancreatic cancer. <i>Lancet, The</i> , 2011, 378, 607-620.	6.3	2,155
13	Advances in diagnosis, treatment and palliation of pancreatic carcinoma: 1990-2010. <i>World Journal of Gastroenterology</i> , 2011, 17, 867.	1.4	189
14	Neoadjuvant therapy in pancreatic adenocarcinoma: A meta-analysis of phase II trials. <i>Surgery</i> , 2011, 150, 466-473.	1.0	183
15	The role of radiochemotherapy in the multimodal treatment of pancreatic ductal adenocarcinoma: Standard procedure or individual decision?. <i>Memo - Magazine of European Medical Oncology</i> , 2011, 4, 260-264.	0.3	0
16	Adjuvant surgical therapy for patients with initially unresectable pancreatic cancer with long-term favorable responses to chemotherapy. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2011, 18, 712-716.	1.4	35
18	NeoGemTax: Gemcitabine and Docetaxel as Neoadjuvant Treatment for Locally Advanced Nonmetastasized Pancreatic Cancer. <i>World Journal of Surgery</i> , 2011, 35, 1580-1589.	0.8	50
19	Serum CA 19-9 as a Biomarker for Pancreatic Cancer—A Comprehensive Review. <i>Indian Journal of Surgical Oncology</i> , 2011, 2, 88-100.	0.3	179
20	A Systematic Review and Meta-analysis of Survival and Surgical Outcomes Following Neoadjuvant Chemoradiotherapy for Pancreatic Cancer. <i>Journal of Gastrointestinal Surgery</i> , 2011, 15, 2059-2069.	0.9	129
21	Gemcitabine/cisplatin versus 5-fluorouracil/mitomycin C chemoradiotherapy in locally advanced pancreatic cancer: a retrospective analysis of 93 patients. <i>Radiation Oncology</i> , 2011, 6, 88.	1.2	10

#	ARTICLE	IF	CITATIONS
22	Neoadjuvant GTX Chemotherapy and IMRT-based chemoradiation for borderline resectable pancreatic cancer. <i>Journal of Surgical Oncology</i> , 2011, 104, 155-161.	0.8	89
23	Neoadjuvant therapy is associated with improved survival in resectable pancreatic adenocarcinoma. <i>Cancer</i> , 2011, 117, 2044-2049.	2.0	112
24	MicroRNA-10b Expression Correlates with Response to Neoadjuvant Therapy and Survival in Pancreatic Ductal Adenocarcinoma. <i>Clinical Cancer Research</i> , 2011, 17, 5812-5821.	3.2	147
25	Therapy of locally advanced pancreatic adenocarcinoma: unresectable and borderline patients. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 1555-1565.	1.1	13
26	Everolimus-Eluting Versus Sirolimus-Eluting Stents. <i>Circulation: Cardiovascular Interventions</i> , 2011, 4, 371-377.	1.4	55
27	Neoadjuvant chemoradiotherapy has a potential role in pancreatic carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2011, 3, 27-33.	1.4	19
28	Adjuvant therapy for pancreas adenocarcinoma: where are we going?. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 173-177.	1.1	7
29	Neoadjuvant Therapy in Patients with Pancreatic Cancer: A Disappointing Therapeutic Approach?. <i>Cancers</i> , 2011, 3, 2286-2301.	1.7	3
30	Palliative Interventional and Surgical Therapy for Unresectable Pancreatic Cancer. <i>Cancers</i> , 2011, 3, 652-661.	1.7	10
31	Neoadjuvant cetuximab, twice-weekly gemcitabine, and intensity-modulated radiotherapy (IMRT) in patients with pancreatic adenocarcinoma. <i>Annals of Oncology</i> , 2012, 23, 2820-2827.	0.6	39
32	Locally Advanced Pancreatic Head Cancer: Margin-Positive Resection or Bypass?. <i>ISRN Surgery</i> , 2012, 2012, 1-6.	1.4	10
33	Pancreas Cancer Meets the Thunder God. <i>Science Translational Medicine</i> , 2012, 4, 156ps21.	5.8	7
34	A Neoadjuvant Strategy for the Management of Nonmetastatic Pancreatic Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2012, 18, 602-608.	1.0	6
35	New strategies and designs in pancreatic cancer research: consensus guidelines report from a European expert panel. <i>Annals of Oncology</i> , 2012, 23, 570-576.	0.6	69
37	Assessing Treatment Effect in Pancreatic Cancer. <i>Archives of Pathology and Laboratory Medicine</i> , 2012, 136, 100-109.	1.2	64
38	Combined modality treatments in pancreatic cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2012, 16, S71-S81.	1.5	10
39	Radiotherapy in the adjuvant management of pancreatic adenocarcinoma: is it helpful?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2012, 6, 149-161.	1.4	1
40	The role of chemoradiation for patients with resectable or potentially resectable pancreatic cancer. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 469-480.	1.1	10

#	ARTICLE	IF	CITATIONS
41	Cancer Stem Cells, EMT, and Developmental Pathway Activation in Pancreatic Tumors. <i>Cancers</i> , 2012, 4, 989-1035.	1.7	29
42	Neoadjuvant Therapy of Pancreatic Cancer: The Emerging Paradigm?. <i>Oncologist</i> , 2012, 17, 192-200.	1.9	83
43	Tumor Invasion of Muscular Vessels Predicts Poor Prognosis in Patients With Pancreatic Ductal Adenocarcinoma Who Have Received Neoadjuvant Therapy and Pancreaticoduodenectomy. <i>American Journal of Surgical Pathology</i> , 2012, 36, 552-559.	2.1	53
44	Why is pancreatic cancer difficult to treat in the elderly?. <i>Aging Health</i> , 2012, 8, 301-307.	0.3	2
45	Pancreatic Surgery: Beyond the Traditional Limits. <i>Recent Results in Cancer Research</i> , 2012, 196, 53-64.	1.8	9
46	Percutaneous Irreversible Electroporation for Downstaging and Control of Unresectable Pancreatic Adenocarcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 2012, 23, 1613-1621.	0.2	205
47	Prognostic Factors for Survival and Resection in Patients With Initial Nonresectable Locally Advanced Pancreatic Cancer Treated With Chemoradiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, 909-915.	0.4	20
48	A Dose Escalation and Pharmacodynamic Study of Triapine and Radiation in Patients With Locally Advanced Pancreas Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, e475-e481.	0.4	17
49	Pancreas cancer treatment: A surgeon's perspective today. <i>International Journal of Surgery</i> , 2012, 10, 187-189.	1.1	1
50	Cathepsins and pancreatic cancer: The 2012 update. <i>Pancreatology</i> , 2012, 12, 395-401.	0.5	19
51	Pancreatic Cancer: Medical Management (Novel Chemotherapeutics). <i>Gastroenterology Clinics of North America</i> , 2012, 41, 189-209.	1.0	31
52	Locally Advanced Pancreatic Cancer. <i>Seminars in Oncology</i> , 2012, 39, e9-e22.	0.8	5
53	Manufacturing of patient-specific pancreas models for surgical resections. , 2012, , .		5
54	Identification of a novel nanomolar inhibitor of hlcmt via a carboxylate replacement approach. <i>MedChemComm</i> , 2012, 3, 1125.	3.5	2
55	Outcomes after resection of locally advanced or borderline resectable pancreatic cancer after neoadjuvant therapy. <i>American Journal of Surgery</i> , 2012, 203, 132-139.	0.9	86
56	Palliative resections versus palliative bypass procedures in pancreatic cancer—a systematic review. <i>American Journal of Surgery</i> , 2012, 203, 496-502.	0.9	51
57	A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma. <i>BMC Cancer</i> , 2012, 12, 199.	1.1	198
59	Risk of Stroke With Coronary Artery Bypass Graft Surgery Compared With Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2012, 60, 798-805.	1.2	92

#	ARTICLE	IF	CITATIONS
60	Feasibility and safety of EUS-guided cryothermal ablation in patients with locally advanced pancreatic cancer. <i>Gastrointestinal Endoscopy</i> , 2012, 76, 1142-1151.	0.5	148
61	Prospective efficacy and safety study of neoadjuvant gemcitabine with capecitabine combination chemotherapy for borderline-resectable or unresectable locally advanced pancreatic adenocarcinoma. <i>Surgery</i> , 2012, 152, 851-862.	1.0	97
62	Resection after neoadjuvant therapy for locally advanced, "unresectable" pancreatic cancer. <i>Surgery</i> , 2012, 152, S33-S42.	1.0	118
64	The Implications of Positive Peritoneal Lavage Cytology in Potentially Resectable Pancreatic Cancer. <i>World Journal of Surgery</i> , 2012, 36, 2187-2191.	0.8	41
66	Increased COMT expression in pancreatic cancer and correlation with clinicopathologic parameters. <i>Science China Life Sciences</i> , 2012, 55, 747-752.	2.3	6
67	Neoadjuvant chemoradiation with Gemcitabine for locally advanced pancreatic cancer. <i>Radiation Oncology</i> , 2012, 7, 28.	1.2	86
68	Current Knowledge on Pancreatic Cancer. <i>Frontiers in Oncology</i> , 2012, 2, 6.	1.3	62
69	Pancreato-Biliary Cancers " Diagnosis and Management. , 0, , .		0
70	Pancreatic adenocarcinoma. <i>BMJ, The</i> , 2012, 344, e2476-e2476.	3.0	137
71	Does preoperative therapy optimize outcomes in patients with resectable pancreatic cancer?. <i>Journal of Surgical Oncology</i> , 2012, 106, 111-118.	0.8	74
72	Preoperative embolization of replaced right hepatic artery prior to pancreaticoduodenectomy. <i>Journal of Surgical Oncology</i> , 2012, 106, 509-512.	0.8	23
73	Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. <i>Cancer</i> , 2012, 118, 5749-5756.	2.0	457
74	Resectional techniques. , 2012, , 945-966.e3.		0
75	Neo-adjuvant Chemoradiation Therapy Using S-1 Followed by Surgical Resection in Patients with Pancreatic Cancer. <i>Journal of Gastrointestinal Surgery</i> , 2012, 16, 784-792.	0.9	35
76	Everolimus-eluting versus sirolimus-eluting stents: an updated meta-analysis of randomized trials. <i>Clinical Research in Cardiology</i> , 2012, 101, 461-467.	1.5	46
77	Loco-recurrence after resection for ductal adenocarcinoma of the pancreas: predictors and implications for adjuvant chemoradiotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2012, 138, 1063-1071.	1.2	56
79	Neoadjuvant/Preoperative Gemcitabine for Patients with Localized Pancreatic Cancer: A Meta-analysis of Prospective Studies. <i>Annals of Surgical Oncology</i> , 2012, 19, 1644-1662.	0.7	170
80	Post-therapy pathologic stage and survival in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation. <i>Cancer</i> , 2012, 118, 268-277.	2.0	81

#	ARTICLE	IF	CITATIONS
82	Phase 1 trial of preoperative, short-course carbon ion radiotherapy for patients with resectable pancreatic cancer. <i>Cancer</i> , 2013, 119, 45-51.	2.0	83
83	Induction gemcitabine and oxaliplatin therapy followed by a twice-weekly infusion of gemcitabine and concurrent external-beam radiation for neoadjuvant treatment of locally advanced pancreatic cancer. <i>Cancer</i> , 2013, 119, 277-284.	2.0	72
84	Chemoradiation in patients with isolated recurrent pancreatic cancer - therapeutical efficacy and probability of re-resection. <i>Radiation Oncology</i> , 2013, 8, 27.	1.2	46
85	Neoadjuvant therapy in resectable pancreatic cancer: A critical review. <i>Cancer Treatment Reviews</i> , 2013, 39, 518-524.	3.4	39
86	A treatment planning comparison of four target volume contouring guidelines for locally advanced pancreatic cancer radiotherapy. <i>Radiotherapy and Oncology</i> , 2013, 107, 200-206.	0.3	13
87	Preoperative Chemotherapy Does Not Adversely Affect Pancreatic Structure and Short-Term Outcome after Pancreatectomy. <i>Journal of Gastrointestinal Surgery</i> , 2013, 17, 488-493.	0.9	17
88	Neoadjuvant Therapy for Potentially Resectable Pancreatic Cancer: An Emerging Paradigm?. <i>Current Oncology Reports</i> , 2013, 15, 162-169.	1.8	11
89	Identification of Distinct Phenotypes of Locally Advanced Pancreatic Adenocarcinoma. <i>Journal of Gastrointestinal Cancer</i> , 2013, 44, 73-78.	0.6	1
90	Results of 100 pancreatic radiofrequency ablations in the context of a multimodal strategy for stage III ductal adenocarcinoma. <i>Langenbeck's Archives of Surgery</i> , 2013, 398, 63-69.	0.8	89
91	Role of adjuvant surgery for patients with initially unresectable pancreatic cancer with a long-term favorable response to non-surgical anti-cancer treatments: results of a project study for pancreatic surgery by the Japanese Society of Hepato-Biliary-Pancreatic Surgery. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2013, 20, 590-600.	1.4	157
92	Pathological and clinical impact of neoadjuvant chemoradiotherapy using full-dose gemcitabine and concurrent radiation for resectable pancreatic cancer. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2013, 20, 197-205.	1.4	66
93	Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer. <i>Journal of Surgical Oncology</i> , 2013, 108, 236-241.	0.8	169
94	Gemcitabine-based neoadjuvant chemotherapy for locally advanced pancreatic cancer does not affect mortality and morbidity after pancreatic resection. <i>European Surgery - Acta Chirurgica Austriaca</i> , 2013, 45, 169-178.	0.3	1
95	Borderline Resectable Pancreatic Cancer: Need for Standardization and Methods for Optimal Clinical Trial Design. <i>Annals of Surgical Oncology</i> , 2013, 20, 2787-2795.	0.7	302
96	Neoadjuvant Chemotherapy with Gemcitabine and S-1 for Resectable and Borderline Pancreatic Ductal Adenocarcinoma: Results from a Prospective Multi-institutional Phase 2 Trial. <i>Annals of Surgical Oncology</i> , 2013, 20, 3794-3801.	0.7	131
97	Notch1 Contributes to Chemoresistance to Gemcitabine and Serves as an Unfavorable Prognostic Indicator in Pancreatic Cancer. <i>World Journal of Surgery</i> , 2013, 37, 1688-1694.	0.8	15
98	Intensity modulated radiotherapy as neoadjuvant chemoradiation for the treatment of patients with locally advanced pancreatic cancer. <i>Strahlentherapie Und Onkologie</i> , 2013, 189, 738-744.	1.0	37
99	Outcome after neoadjuvant chemoradiation and correlation with nutritional status in patients with locally advanced pancreatic cancer. <i>Strahlentherapie Und Onkologie</i> , 2013, 189, 745-752.	1.0	37

#	ARTICLE	IF	CITATIONS
100	Comparison of four target volume definitions for pancreatic cancer. <i>Strahlentherapie Und Onkologie</i> , 2013, 189, 407-416.	1.0	7
101	Gemcitabine based neoadjuvant chemoradiotherapy therapy in patients with borderline resectable pancreatic cancer. <i>Pancreatology</i> , 2013, 13, 539-543.	0.5	23
102	Is tumour size an underestimated feature in the current TNM system for malignancies of the pancreatic head?. <i>Hpb</i> , 2013, 15, 872-881.	0.1	17
103	Multidisciplinary Management of Pancreatic Cancer. <i>Surgical Oncology Clinics of North America</i> , 2013, 22, 265-287.	0.6	29
104	Improvement of surgical results for pancreatic cancer. <i>Lancet Oncology, The</i> , 2013, 14, e476-e485.	5.1	307
105	An evaluation of the accuracy of CT when determining resectability of pancreatic head adenocarcinoma after neoadjuvant treatment. <i>European Journal of Radiology</i> , 2013, 82, 589-593.	1.2	121
107	Phase I study evaluating the treatment of patients with locally advanced pancreatic cancer with carbon ion radiotherapy: the PHOENIX-01 trial. <i>BMC Cancer</i> , 2013, 13, 419.	1.1	22
108	Neoadjuvant therapy for resectable and borderline resectable pancreatic cancer. <i>Journal of Radiation Oncology</i> , 2013, 2, 353-367.	0.7	4
109	Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunity. <i>Molecular Oncology</i> , 2013, 7, 308-322.	2.1	54
111	Hypofractionated Image-Guided IMRT in Advanced Pancreatic Cancer With Simultaneous Integrated Boost to Infiltrated Vessels Concomitant With Capecitabine: A Phase I Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 87, 1000-1006.	0.4	23
112	Current concepts and novel targets in advanced pancreatic cancer. <i>Gut</i> , 2013, 62, 317-326.	6.1	134
113	Multidisciplinary management of locally advanced "borderline resectable adenocarcinoma of the head of the pancreas. <i>Clinical and Translational Oncology</i> , 2013, 15, 173-181.	1.2	9
114	Safety and efficacy of everolimus- versus sirolimus-eluting stents: A systematic review and meta-analysis of 11 randomized trials. <i>American Heart Journal</i> , 2013, 165, 241-250.e4.	1.2	66
115	Advanced-stage pancreatic cancer: therapy options. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 323-333.	12.5	183
116	Mechanisms of resistance to chemotherapeutic and anti-angiogenic drugs as novel targets for pancreatic cancer therapy. <i>Frontiers in Pharmacology</i> , 2013, 4, 56.	1.6	79
117	Novel Multimodality Treatment Sequencing for Extrahepatic (Mid and Distal) Cholangiocarcinoma. <i>Annals of Surgical Oncology</i> , 2013, 20, 1230-1239.	0.7	11
118	The Cost-Effectiveness of Neoadjuvant Chemoradiation is Superior to a Surgery-First Approach in the Treatment of Pancreatic Head Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2013, 20, 500-508.	0.7	61
119	Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma. <i>Cancer Medicine</i> , 2013, 2, 185-195.	1.3	36

#	ARTICLE	IF	CITATIONS
120	Controversial issues of neoadjuvant treatment in borderline resectable pancreatic cancer. <i>Surgical Oncology</i> , 2013, 22, 123-131.	0.8	15
121	Thermosensitive Liposomes for the Delivery of Gemcitabine and Oxaliplatin to Tumors. <i>Molecular Pharmaceutics</i> , 2013, 10, 4499-4508.	2.3	47
122	Complete Pathological Remission of Locally Advanced, Unresectable Pancreatic Cancer (LAPC) after Intensified Neoadjuvant Chemotherapy. <i>Onkologie</i> , 2013, 36, 123-125.	1.1	23
123	Unresectable Locally Advanced Pancreatic Cancer: Treatment With Neoadjuvant Leucovorin, Fluorouracil, Irinotecan, and Oxaliplatin and Assessment of Surgical Resectability. <i>Journal of Clinical Oncology</i> , 2013, 31, e37-e39.	0.8	13
124	Healthcare costs, treatment patterns, and resource utilization among pancreatic cancer patients in a managed care population. <i>Journal of Medical Economics</i> , 2013, 16, 1379-1386.	1.0	17
125	Pancreatic Cancer: Current Options for Diagnosis, Staging and Therapeutic Management. <i>Gastrointestinal Tumors</i> , 2014, 1, 41-52.	0.3	16
126	Randomized Phase III Multi-Institutional Study of TNFerade Biologic With Fluorouracil and Radiotherapy for Locally Advanced Pancreatic Cancer: Final Results. <i>Journal of Clinical Oncology</i> , 2013, 31, 886-894.	0.8	173
127	Value of Carbohydrate Antigen 19-9 in Predicting Response and Therapy Control in Patients with Metastatic Pancreatic Cancer Undergoing First-Line Therapy. <i>Frontiers in Oncology</i> , 2013, 3, 155.	1.3	26
128	Neoadjuvant treatment of borderline resectable and non-resectable pancreatic cancer. <i>Annals of Oncology</i> , 2013, 24, 2484-2492.	0.6	102
129	Diagnosis and management of pancreatic cancer. <i>Cmaj</i> , 2013, 185, 1219-1226.	0.9	68
130	Recent progress in pancreatic cancer. <i>Ca-A Cancer Journal for Clinicians</i> , 2013, 63, 318-348.	157.7	743
131	Conditionally replicative adenoviral vectors for imaging the effect of chemotherapy on pancreatic cancer cells. <i>Cancer Science</i> , 2013, 104, 1083-1090.	1.7	5
132	Does preoperative chemoradiation for initially unresectable or borderline resectable pancreatic adenocarcinoma increase postoperative morbidity? A case-matched analysis. <i>Hpb</i> , 2013, 15, 574-580.	0.1	34
134	Preoperative Gemcitabine-Based Chemoradiation Therapy for Resectable and Borderline Resectable Pancreatic Cancer. <i>Annals of Surgery</i> , 2013, 258, 1040-1050.	2.1	128
135	Development and Histopathological Characterization of Tumorgraft Models of Pancreatic Ductal Adenocarcinoma. <i>PLoS ONE</i> , 2013, 8, e78183.	1.1	23
136	Neoadjuvant therapy in borderline resectable pancreatic ductal adenocarcinoma: A single institution review. <i>Journal of Solid Tumors</i> , 2014, 4, .	0.1	1
137	Borderline resectable pancreatic cancer: Definitions and management. <i>World Journal of Gastroenterology</i> , 2014, 20, 10740.	1.4	135
138	Neoadjuvant therapy for pancreas cancer: Past lessons and future therapies. <i>World Journal of Gastroenterology</i> , 2014, 20, 15564.	1.4	39

#	ARTICLE	IF	CITATIONS
139	Role of Neoadjuvant Therapy in the Management of Pancreatic Cancer: Is the Era of Biomarker-Directed Therapy Here?. <i>Current Oncology</i> , 2014, 21, 650-657.	0.9	9
140	Therapeutic options for the management of pancreatic cancer. <i>World Journal of Gastroenterology</i> , 2014, 20, 11142.	1.4	114
141	Chemotherapy, radiotherapy, chemoradiotherapy and combination therapy in localised and locally advanced pancreatic cancer. <i>The Cochrane Library</i> , 0, , .	1.5	2
143	Downregulation of CPE regulates cell proliferation and chemosensitivity in pancreatic cancer. <i>Tumor Biology</i> , 2014, 35, 12459-12465.	0.8	17
145	Predictors for resectability and survival in locally advanced pancreatic cancer after gemcitabine-based neoadjuvant therapy. <i>BMC Surgery</i> , 2014, 14, 72.	0.6	13
146	Epidemiology of syphilis infection among drug users at methadone maintenance treatment clinics in China: systematic review and meta-analysis. <i>International Journal of STD and AIDS</i> , 2014, 25, 550-558.	0.5	9
147	Borderline resectable pancreatic adenocarcinoma, is conversion therapy realistic?. <i>Acta Oncol</i> 33gica, 2014, 53, 1268-1271.	0.8	1
148	Epidemiology, Treatment, and Outcome of Pancreatic Cancer. , 2014, , 3-9.		2
149	Investigation and management of pancreatic tumours. <i>Frontline Gastroenterology</i> , 2014, 5, 144-152.	0.9	2
150	Neoadjuvant Therapy in Pancreatic Cancer: An Emerging Strategy. <i>Gastroenterology Research and Practice</i> , 2014, 2014, 1-9.	0.7	31
151	Progress in the knowledge and treatment of advanced pancreatic cancer: From benchside to bedside. <i>Cancer Treatment Reviews</i> , 2014, 40, 1039-1047.	3.4	86
152	Computer assisted surgery, preoperative planning and navigation for pancreatic cancer. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2014, 21, 251-255.	1.4	14
153	Neoadjuvant Gemcitabine-based Accelerated Hyperfractionation Chemoradiotherapy for Patients with Borderline Resectable Pancreatic Adenocarcinoma. <i>Japanese Journal of Clinical Oncology</i> , 2014, 44, 1172-1180.	0.6	26
154	Neoadjuvant FOLFIRINOX Application in Borderline Resectable Pancreatic Adenocarcinoma. <i>Medicine (United States)</i> , 2014, 93, e198.	0.4	56
155	Locally Advanced Pancreatic Cancer. <i>JAMA Surgery</i> , 2014, 149, 145.	2.2	45
156	Improving outcomes in pancreatic cancer: Key points in perioperative management. <i>World Journal of Gastroenterology</i> , 2014, 20, 14237.	1.4	15
157	Intensified Neoadjuvant Chemotherapy with Nab-Paclitaxel plus Gemcitabine Followed by FOLFIRINOX in a Patient with Locally Advanced Unresectable Pancreatic Cancer. <i>Case Reports in Oncology</i> , 2014, 7, 648-655.	0.3	19
158	Post-brushing and fine-needle aspiration biopsy follow-up and treatment options for patients with pancreatobiliary lesions: The Papanicolaou Society of Cytopathology Guidelines. <i>CytoJournal</i> , 2014, 11, 40.	0.8	5

#	ARTICLE	IF	CITATIONS
159	Pancreatic Adenocarcinoma: Treating a Systemic Disease With Systemic Therapy. Journal of the National Cancer Institute, 2014, 106, dju011-dju011.	3.0	141
160	Complementary Induction of Immunogenic Cell Death by Oncolytic Parvovirus H-1PV and Gemcitabine in Pancreatic Cancer. Journal of Virology, 2014, 88, 5263-5276.	1.5	62
161	Alteration of the Intrinsic Apoptosis Pathway Is Involved in Notch-induced Chemoresistance to Gemcitabine in Pancreatic Cancer. Archives of Medical Research, 2014, 45, 15-20.	1.5	16
163	Neoadjuvant therapy in pancreatic cancer. Current Medicine Research and Practice, 2014, 4, 56-61.	0.1	3
164	A Meta-Analysis of Randomized Trials: Immediate Stent Placement vs. Surgical Bypass in the Palliative Management of Malignant Biliary Obstruction. Journal of Pain and Symptom Management, 2014, 47, 307-314.	0.6	73
165	Preparing for Prospective Clinical Trials: A National Initiative of an Excellence Registry for Consecutive Pancreatic Cancer Resections. World Journal of Surgery, 2014, 38, 456-462.	0.8	10
167	Extended Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer Demonstrates Promising Postoperative Outcomes and Survival. Annals of Surgical Oncology, 2014, 21, 1530-1537.	0.7	127
168	Neoadjuvant vs Adjuvant Therapy for Resectable Pancreatic Cancer: The Evolving Role of Radiation. Seminars in Radiation Oncology, 2014, 24, 113-125.	1.0	17
169	Opportunities for translation: Targeting DNA repair pathways in pancreatic cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1846, 45-54.	3.3	8
170	Resectable, Borderline Resectable, and Locally Advanced Pancreatic Cancer: What Does It Matter?. Current Oncology Reports, 2014, 16, 366.	1.8	26
171	Delaying chemoradiation until after completion of adjuvant chemotherapy for pancreatic cancer may not impact local control. Practical Radiation Oncology, 2014, 4, e117-e123.	1.1	4
172	The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacological Research, 2014, 79, 34-74.	3.1	1,028
173	Use of a temporary intraoperative mesentericoportal shunt for pancreatic resection for locally advanced pancreatic cancer with portal vein occlusion and portal hypertension. Surgery, 2014, 155, 449-456.	1.0	36
174	Multimodal Therapies for Pancreatic Cancer. , 2014, , 39-73.		0
175	Influence of preoperative anti-cancer therapy on resectability and perioperative outcomes in patients with pancreatic cancer: Project study by the Japanese Society of Hepato-Biliary-Pancreatic Surgery. Journal of Hepato-Biliary-Pancreatic Sciences, 2014, 21, 148-158.	1.4	45
176	FOLFIRINOX for Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma: The Royal Marsden Experience. Clinical Colorectal Cancer, 2014, 13, 232-238.	1.0	60
177	MicroRNA-100 regulates pancreatic cancer cells growth and sensitivity to chemotherapy through targeting FGFR3. Tumor Biology, 2014, 35, 11751-11759.	0.8	44
178	Locally advanced pancreatic cancer: open questions on terminology, diagnosis and management. Updates in Surgery, 2014, 66, 227-228.	0.9	0

#	ARTICLE	IF	CITATIONS
179	Vascular resection during radical resection of pancreatic adenocarcinomas: evolution over the past 15 years. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2014, 21, 623-638.	1.4	19
180	Role of Chemoradiotherapy in the Adjuvant and Neoadjuvant Settings for Resectable Pancreatic Cancer. <i>Clinical Oncology</i> , 2014, 26, 551-559.	0.6	16
181	Locally Advanced Pancreatic Cancer: The Role of Definitive Chemoradiotherapy. <i>Clinical Oncology</i> , 2014, 26, 560-568.	0.6	42
182	The Role of Radiotherapy in the Management of Upper Gastrointestinal and Hepato-biliary and Pancreatic Cancers: Current Status and Future Directions. <i>Clinical Oncology</i> , 2014, 26, 519-521.	0.6	1
183	Immune-based therapies in pancreatic and colorectal cancers and biomarkers of responsiveness. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 1219-1228.	1.1	1
184	Complete pathological response after FOLFIRINOX for locally advanced pancreatic cancer. The beginning of a new era? Case report and review of the literature. <i>Pancreatology</i> , 2014, 14, 425-430.	0.5	21
185	Outcome of superior mesenteric-portal vein resection during pancreatectomy for borderline ductal adenocarcinoma: results of a prospective comparative study. <i>Langenbeck's Archives of Surgery</i> , 2014, 399, 659-665.	0.8	15
186	Effect of chemoradiotherapy and neoadjuvant chemoradiotherapy in resectable pancreatic cancer: a systematic review and meta-analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 549-559.	1.2	52
187	Prognostic Impact of CA 19-9 on Outcome after Neoadjuvant Chemoradiation in Patients with Locally Advanced Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , 2014, 21, 2801-2807.	0.7	31
188	Prosthetic Graft for Superior Mesenteric-Portal Vein Reconstruction in Pancreaticoduodenectomy: A Retrospective, Multicenter Study. <i>Journal of Gastrointestinal Surgery</i> , 2014, 18, 1452-1461.	0.9	44
189	Management Options in Locally Advanced Pancreatic Cancer. <i>Current Oncology Reports</i> , 2014, 16, 388.	1.8	29
190	Sequential neoadjuvant chemoradiotherapy (CRT) followed by curative surgery vs. primary surgery alone for resectable, non-metastasized pancreatic adenocarcinoma: NEOPA- a randomized multicenter phase III study (NCT01900327, DRKS00003893, ISRCTN82191749). <i>BMC Cancer</i> , 2014, 14, 411.	1.1	75
191	Extended pancreatectomy in pancreatic ductal adenocarcinoma: Definition and consensus of the International Study Group for Pancreatic Surgery (ISGPS). <i>Surgery</i> , 2014, 156, 1-14.	1.0	226
192	EUS-guided fiducial markers placement with a 22-gauge needle for image-guided radiation therapy in pancreatic cancer. <i>Gastrointestinal Endoscopy</i> , 2014, 79, 851-855.	0.5	60
193	Tumour-stroma interactions in pancreatic ductal adenocarcinoma: Rationale and current evidence for new therapeutic strategies. <i>Cancer Treatment Reviews</i> , 2014, 40, 118-128.	3.4	108
194	Selection criteria in resectable pancreatic cancer: A biological and morphological approach. <i>World Journal of Gastroenterology</i> , 2014, 20, 11210.	1.4	31
195	Pancreatic Adenocarcinoma, Version 2.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 1083-1093.	2.3	307
196	A Single-Arm, Nonrandomized Phase II Trial of Neoadjuvant Gemcitabine and Oxaliplatin in Patients With Resectable Pancreas Adenocarcinoma. <i>Annals of Surgery</i> , 2014, 260, 142-148.	2.1	121

#	ARTICLE	IF	CITATIONS
197	Pathological Complete Remission of Pancreatic Cancer Following Neoadjuvant Chemoradiation Therapy; Not the End of Battles. <i>Medicine (United States)</i> , 2015, 94, e2168.	0.4	18
198	Trends in the use of pre-operative radiation for adenocarcinoma of the pancreas in the United States. <i>Hpb</i> , 2015, 17, 542-550.	0.1	4
199	Borderline Resectable Adenocarcinoma of the Pancreas. , 2015, , 415-450.		0
200	Upregulation of microRNA-138-5p inhibits pancreatic cancer cell migration and increases chemotherapy sensitivity. <i>Molecular Medicine Reports</i> , 2015, 12, 5135-5140.	1.1	17
203	Conditional survival of pancreatic ductal adenocarcinoma in surgical and nonsurgical patients: a retrospective analysis report from a single institution in China. <i>World Journal of Surgical Oncology</i> , 2015, 13, 196.	0.8	6
204	Optimization of carbon ion and proton treatment plans using the raster-scanning technique for patients with unresectable pancreatic cancer. <i>Radiation Oncology</i> , 2015, 10, 237.	1.2	15
205	FOLFIRINOX-Based Neoadjuvant Therapy in Borderline Resectable or Unresectable Pancreatic Cancer. <i>Pancreas</i> , 2015, 44, 515-521.	0.5	156
206	Irreversible Electroporation of the Pancreas Is Feasible and Safe in a Porcine Survival Model. <i>Pancreas</i> , 2015, 44, 791-798.	0.5	24
207	Significance of Radiologic Location and Extent of Portal Venous Involvement on Prognosis After Resection for Pancreatic Adenocarcinoma. <i>Pancreas</i> , 2015, 44, 665-671.	0.5	12
208	Eastern Canadian Gastrointestinal Cancer Consensus Conference 2014. <i>Current Oncology</i> , 2015, 22, 305-315.	0.9	0
209	Objective Assessment of Surgical Restaging after Concurrent Chemoradiation for Locally Advanced Pancreatic Cancer. <i>Journal of Korean Medical Science</i> , 2015, 30, 917.	1.1	5
210	Pancreatic cancer vaccine: a unique potential therapy. <i>Gastrointestinal Cancer: Targets and Therapy</i> , 2015, , 1.	5.5	0
211	RUNX3 Controls a Metastatic Switch in Pancreatic Ductal Adenocarcinoma. <i>Cell</i> , 2015, 161, 1345-1360.	18.5	175
212	The Papanicolaou Society of Cytopathology System for Reporting Pancreaticobiliary Cytology. , 2015, , .		57
213	Long-Term Safety of Drug-Eluting and Bare-Metal Stents. <i>Journal of the American College of Cardiology</i> , 2015, 65, 2496-2507.	1.2	396
214	Pancreatic Adenocarcinoma. , 2015, , 283-313.		3
215	Surgery for Pancreatic Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2015, 29, 701-716.	0.9	53
216	Stent placement as a bridge to surgery in malignant biliary obstruction (pancreatic cancer, distal bile) Tj ETQq1 1 0.784314 rgBT /Ove	0.1	0

#	ARTICLE	IF	CITATIONS
217	Inverse Probability of Treatment Weighting Analysis of Upfront Surgery Versus Neoadjuvant Chemoradiotherapy Followed by Surgery for Pancreatic Adenocarcinoma with Arterial Abutment. <i>Medicine (United States)</i> , 2015, 94, e1647.	0.4	55
218	Multidisciplinary neoadjuvant management for potentially curable pancreatic cancer. <i>Cancer Medicine</i> , 2015, 4, 1224-1239.	1.3	16
220	Adjuvant/Perioperative Therapy in Pancreatic and Periampullary Cancer. <i>Indian Journal of Surgery</i> , 2015, 77, 403-408.	0.2	2
221	Improving Survival of Pancreatic Cancer. What Have We Learnt?. <i>Indian Journal of Surgery</i> , 2015, 77, 436-445.	0.2	0
223	Patterns of radiotherapy practice for pancreatic cancer: Results of the Gastrointestinal Radiation Oncology Study Group multi-institutional survey. <i>Oncology Reports</i> , 2015, 34, 382-390.	1.2	1
224	SBRT in pancreatic cancer: What is the therapeutic window?. <i>Radiotherapy and Oncology</i> , 2015, 114, 109-116.	0.3	85
225	Adjuvant and Neoadjuvant Systemic Therapy for Pancreas Adenocarcinoma. <i>Seminars in Oncology</i> , 2015, 42, 134-143.	0.8	17
226	Neoadjuvant therapy for Non-metastatic Pancreatic Ductal Adenocarcinoma. <i>Seminars in Oncology</i> , 2015, 42, 86-97.	0.8	20
227	Surgical Management of Pancreatic Cancer—Distal Pancreatectomy. <i>Seminars in Oncology</i> , 2015, 42, 110-122.	0.8	37
228	Comparison of toxicity after IMRT and 3D-conformal radiotherapy for patients with pancreatic cancer — A systematic review. <i>Radiotherapy and Oncology</i> , 2015, 114, 117-121.	0.3	73
229	Perfusion CT Estimates Photosensitizer Uptake and Biodistribution in a Rabbit Orthotopic Pancreatic Cancer Model. <i>Academic Radiology</i> , 2015, 22, 572-579.	1.3	13
230	Pancreatic Adenocarcinoma with Venous Involvement: Is Up-Front Synchronous Portal-Superior Mesenteric Vein Resection Still Justified? A Survey of the Association Française de Chirurgie. <i>Annals of Surgical Oncology</i> , 2015, 22, 1874-1883.	0.7	96
231	Non-radical resection versus bypass procedure for pancreatic cancer — A consecutive series and systematic review. <i>European Journal of Surgical Oncology</i> , 2015, 41, 220-227.	0.5	35
232	FOLFIRINOX for Locally Advanced Pancreatic Adenocarcinoma: Results of an AGEO Multicenter Prospective Observational Cohort. <i>Annals of Surgical Oncology</i> , 2015, 22, 295-301.	0.7	145
233	Neoadjuvante Radiochemotherapie mit Gemcitabin/Cisplatin gefolgt von Resektion versus primärer Resektion bei resektablem Pankreaskopfkarcinom. <i>Strahlentherapie Und Onkologie</i> , 2015, 191, 7-16.	1.0	255
234	FOLFIRINOX: Desert, Oasis, or Mirage?. <i>Annals of Surgical Oncology</i> , 2015, 22, 1059-1060.	0.7	2
235	Diagnosis and Management of Borderline Resectable Pancreatic Adenocarcinoma. <i>Hematology/Oncology Clinics of North America</i> , 2015, 29, 727-740.	0.9	19
237	Pancreatic cancer: Patient and caregiver perceptions on diagnosis, psychological impact, and importance of support. <i>Pancreatology</i> , 2015, 15, 701-707.	0.5	32

#	ARTICLE	IF	CITATIONS
238	Individualized radiotherapy (iRT) concepts for locally advanced pancreatic cancer (LAPC): indications and prognostic factors. <i>Langenbeck's Archives of Surgery</i> , 2015, 400, 749-756.	0.8	2
239	Approach to Patients With Pancreatic Cancer Without Detectable Metastases. <i>Journal of Clinical Oncology</i> , 2015, 33, 1770-1778.	0.8	117
240	MicroRNA-138-5p regulates pancreatic cancer cell growth through targeting FOXC1. <i>Cellular Oncology (Dordrecht)</i> , 2015, 38, 173-181.	2.1	74
241	Concomitant major vessel resection in pancreatic adenocarcinoma. <i>Postgraduate Medicine</i> , 2015, 127, 273-276.	0.9	1
242	Stage III pancreatic cancer and the role of irreversible electroporation. <i>BMJ, The</i> , 2015, 350, h521-h521.	3.0	38
243	Resection of Borderline Resectable and Locally Advanced Pancreatic Adenocarcinomas after Neoadjuvant Chemotherapy. <i>Oncology</i> , 2015, 89, 37-46.	0.9	32
244	Feasibility and safety of electrochemotherapy (ECT) in the pancreas: a pre-clinical investigation. <i>Radiology and Oncology</i> , 2015, 49, 147-154.	0.6	50
246	Pancreatic cancer: from state-of-the-art treatments to promising novel therapies. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 319-334.	12.5	489
247	Radiological and Surgical Implications of Neoadjuvant Treatment With FOLFIRINOX for Locally Advanced and Borderline Resectable Pancreatic Cancer. <i>Annals of Surgery</i> , 2015, 261, 12-17.	2.1	717
248	Local iontophoretic administration of cytotoxic therapies to solid tumors. <i>Science Translational Medicine</i> , 2015, 7, 273ra14.	5.8	56
249	Feasibility of pre-operative chemoradiotherapy with gemcitabine to treat pancreatic cancer in patients with impaired renal function. <i>Japanese Journal of Clinical Oncology</i> , 2015, 45, 343-348.	0.6	3
250	Percutaneous Approach to Irreversible Electroporation of the Pancreas: Miami Protocol. <i>Techniques in Vascular and Interventional Radiology</i> , 2015, 18, 153-158.	0.4	11
252	Neoadjuvant Chemoradiotherapy and Surgery Versus Surgery Alone in Resectable Pancreatic Cancer: A Single-Center Prospective, Randomized, Controlled Trial Which Failed to Achieve Accrual Targets. <i>Journal of Gastrointestinal Surgery</i> , 2015, 19, 1802-1812.	0.9	166
253	Full dose neoadjuvant FOLFIRINOX is associated with prolonged survival in patients with locally advanced pancreatic adenocarcinoma. <i>Pancreatology</i> , 2015, 15, 667-673.	0.5	73
254	Pathologic Major Response After FOLFIRINOX is Prognostic for Patients Secondary Resected for Borderline or Locally Advanced Pancreatic Adenocarcinoma: An AGEO-FRENCH, Prospective, Multicentric Cohort. <i>Annals of Surgical Oncology</i> , 2015, 22, 1196-1205.	0.7	70
255	Percutaneous CT-guided irreversible electroporation followed by chemotherapy as a novel neoadjuvant protocol in locally advanced pancreatic cancer: Our preliminary experience. <i>International Journal of Surgery</i> , 2015, 21, S34-S39.	1.1	55
256	Surgical resection strategies for locally advanced pancreatic cancer. <i>Langenbeck's Archives of Surgery</i> , 2015, 400, 757-765.	0.8	10
257	Phase I Clinical Trial to Determine the Feasibility and Maximum Tolerated Dose of Panitumumab to Standard Gemcitabine-Based Chemoradiation in Locally Advanced Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 4569-4575.	3.2	12

#	ARTICLE	IF	CITATIONS
258	Efficacy of Neoadjuvant Versus Adjuvant Therapy for Resectable Pancreatic Adenocarcinoma: A Decision Analysis. <i>Annals of Surgical Oncology</i> , 2015, 22, 1229-1237.	0.7	24
259	Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2015, 26, v56-v68.	0.6	1,015
260	Prognostic Significance of Muscle Attenuation in Pancreatic Cancer Patients Treated with Neoadjuvant Chemoradiotherapy. <i>World Journal of Surgery</i> , 2015, 39, 2975-2982.	0.8	45
261	Resectability After First-Line FOLFIRINOX in Initially Unresectable Locally Advanced Pancreatic Cancer: A Single-Center Experience. <i>Annals of Surgical Oncology</i> , 2015, 22, 1212-1220.	0.7	77
262	Preoperative ultrasound ablation for borderline resectable pancreatic cancer: A report of 30 cases. <i>Ultrasonics Sonochemistry</i> , 2015, 27, 694-702.	3.8	15
263	State of the art and future directions of pancreatic ductal adenocarcinoma therapy. , 2015, 155, 80-104.		82
264	Multidisciplinary management of locally advanced pancreatic ductal adenocarcinoma. <i>Current Problems in Surgery</i> , 2015, 52, 362-398.	0.6	8
265	Outcome after pancreaticoduodenectomy for T3 adenocarcinoma: A multivariable analysis from the UK Vascular Resection for Pancreatic Cancer Study Group. <i>European Journal of Surgical Oncology</i> , 2015, 41, 1500-1507.	0.5	36
266	The isoattenuating pancreatic adenocarcinoma: Review of the literature and critical analysis. <i>Surgical Oncology</i> , 2015, 24, 322-328.	0.8	18
267	Personalized medicine in pancreatic cancer: the revolution has begun. <i>Personalized Medicine</i> , 2015, 12, 515-523.	0.8	1
268	CA 19-9: Biochemical and Clinical Aspects. <i>Advances in Experimental Medicine and Biology</i> , 2015, 867, 247-260.	0.8	218
269	The Role of Radiation Therapy in Pancreatic Ductal Adenocarcinoma in the Neoadjuvant and Adjuvant Settings. <i>Seminars in Oncology</i> , 2015, 42, 144-162.	0.8	21
270	Addressing the challenges of pancreatic cancer: Future directions for improving outcomes. <i>Pancreatology</i> , 2015, 15, 8-18.	0.5	404
271	Pathology reporting of pancreatic cancer following neoadjuvant therapy: Challenges and uncertainties. <i>Cancer Treatment Reviews</i> , 2015, 41, 17-26.	3.4	103
272	Neoadjuvant Modified (m) FOLFIRINOX for Locally Advanced Unresectable (LAPC) and Borderline Resectable (BRPC) Adenocarcinoma of the Pancreas. <i>Annals of Surgical Oncology</i> , 2015, 22, 1153-1159.	0.7	215
273	Improving Outcome in Gastrointestinal and Hepatopancreaticobiliary Surgical Oncology by Preoperative Risk Assessment and Optimization of Perioperative Care. , 2016, , .		1
274	Neoadjuvant therapy for advanced pancreatic neuroendocrine tumors: an emerging treatment modality?. <i>Hormones</i> , 2016, 15, 15-22.	0.9	26
275	Changing paradigm in pancreatic cancer: from adjuvant to neoadjuvant chemoradiation. <i>Journal of Gastrointestinal Oncology</i> , 2016, 6, 1004-1010.	0.6	2

#	ARTICLE	IF	CITATIONS
276	Current therapeutic strategies for advanced pancreatic cancer: A review for clinicians. World Journal of Clinical Oncology, 2016, 7, 27.	0.9	71
277	Localized Pancreatic Cancer: Multidisciplinary Management. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e217-e226.	1.8	23
278	How grim is pancreatic cancer?. Oncology Reviews, 2016, 10, 294.	0.8	38
279	Adjuvant, neoadjuvant, and experimental regimens in overcoming pancreatic ductal adenocarcinoma. Przegląd Gastroenterologiczny, 2016, 3, 155-162.	0.3	9
280	Pancreatic Cancer from Molecular Pathways to Treatment Opinion. Journal of Cancer, 2016, 7, 1328-1339.	1.2	30
281	Neoadjuvant Gemcitabine Chemotherapy followed by Concurrent IMRT Simultaneous Boost Achieves High R0 Resection in Borderline Resectable Pancreatic Cancer Patients. PLoS ONE, 2016, 11, e0166606.	1.1	9
282	Generation and molecular characterization of pancreatic cancer patient-derived xenografts reveals their heterologous nature. Oncotarget, 2016, 7, 62533-62546.	0.8	46
283	Neoadjuvant Therapy for Pancreatic Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2016, 39, 302-313.	0.6	78
284	Circulating Tumor Cell Phenotype Predicts Recurrence and Survival in Pancreatic Adenocarcinoma. Annals of Surgery, 2016, 264, 1073-1081.	2.1	131
285	Surgical Resection for Pancreatic Cancer Using the International Study Group of Pancreatic Surgery (ISGPS) Classifications. , 2016, , 1-18.		0
286	New Japanese Classification of Pancreatic Cancer. , 2016, , 1-17.		1
287	Pancreatic cancer: a review with future directions. Journal of Radiation Oncology, 2016, 5, 231-238.	0.7	0
288	Locally Advanced Pancreatic Cancer. Annals of Surgery, 2016, 264, 457-463.	2.1	399
289	Recommendations for the diagnosis, staging and treatment of pre-malignant lesions and pancreatic adenocarcinoma. Medicina Clínica (English Edition), 2016, 147, 465.e1-465.e8.	0.1	1
290	Chemoradiation of pancreatic carcinoma. Journal of Oncological Science, 2016, 2, 43-47.	0.1	0
291	Establishment and Characterization of a Novel Cell Line, ASAN-PaCa, Derived From Human Adenocarcinoma Arising in Intraductal Papillary Mucinous Neoplasm of the Pancreas. Pancreas, 2016, 45, 1452-1460.	0.5	16
293	Common variables in European pancreatic cancer registries: The introduction of the EURECCA pancreatic cancer project. European Journal of Surgical Oncology, 2016, 42, 1414-1419.	0.5	10
294	The McGill Brisbane Symptom Score in relation to survival in pancreatic adenocarcinoma: a validation study. Cancer Causes and Control, 2016, 27, 941-946.	0.8	6

#	ARTICLE	IF	CITATIONS
295	Hypofractionated radiotherapy in pancreatic cancer: Lessons from the past in the era of stereotactic body radiation therapy. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 103, 49-61.	2.0	26
297	Adenocarcinoma of the Pancreas. , 2016, , 251-266.		0
298	Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 1844.	3.8	801
299	Neoadjuvant therapy for pancreatic cancer: an ongoing debate. <i>Therapeutic Advances in Gastroenterology</i> , 2016, 9, 429-436.	1.4	10
301	Robotic and open distal pancreatectomy with celiac axis resection for locally advanced pancreatic body tumors: a single institutional assessment of perioperative outcomes and survival. <i>Hpb</i> , 2016, 18, 835-842.	0.1	62
302	Symptoms and patient factors associated with diagnostic intervals for pancreatic cancer (SYMPTOM) Tj ETQq1 1 0.784314 rgBT /Ove 298-306.	3.7	114
303	Radiological evaluation of response to neoadjuvant treatment in pancreatic cancer. <i>Diagnostic and Interventional Imaging</i> , 2016, 97, 1225-1232.	1.8	34
304	Outcomes after extended pancreatectomy in patients with borderline resectable and locally advanced pancreatic cancer. <i>British Journal of Surgery</i> , 2016, 103, 1683-1694.	0.1	138
305	Recent Advances in Pancreatic Cancer Surgery of Relevance to the Practicing Pathologist. <i>Surgical Pathology Clinics</i> , 2016, 9, 539-545.	0.7	6
306	Cancer du pancrÃ©as et traitement nÃ©oadjuvantÂ: Ã©valuation de la rÃ©ponse en imagerie. <i>Diagnostic and Interventional Imaging</i> , 2016, 97, 501-508.	0.0	0
307	Identification of a tumor-reactive T-cell repertoire in the immune infiltrate of patients with resectable pancreatic ductal adenocarcinoma. <i>Oncolmmunology</i> , 2016, 5, e1240859.	2.1	75
308	Treatment of Locally Advanced Pancreatic Ductal Adenocarcinoma. <i>Advances in Surgery</i> , 2016, 50, 115-128.	0.6	6
309	Impact of treatment duration of neoadjuvant FIRINOX in patients with borderline resectable pancreatic cancer: a pilot trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 719-726.	1.1	22
310	Recent Advances and Prospects for Multimodality Therapy in Pancreatic Cancer. <i>Seminars in Radiation Oncology</i> , 2016, 26, 320-337.	1.0	21
312	Borderline resectable pancreatic cancer and the role of neoadjuvant chemoradiotherapy. <i>Updates in Surgery</i> , 2016, 68, 235-239.	0.9	8
313	Pancreatic cancer chemoradiotherapy. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2016, 30, 617-628.	1.0	11
314	Survival impact of neoadjuvant therapy in resected pancreatic cancer: A Prospective Cohort Study involving 18,332 patients from the National Cancer Data Base. <i>International Journal of Surgery</i> , 2016, 34, 96-102.	1.1	43
315	Sampling para-aortic lymph nodes in pancreatic and biliary cancersÂwith EUS-guided FNA: diagnostic, clinical, and therapeuticÂimplications. <i>Gastrointestinal Endoscopy</i> , 2016, 84, 476-478.	0.5	3

#	ARTICLE	IF	CITATIONS
316	Preoperative FOLFIRINOX for borderline resectable pancreatic cancer: Is radiation necessary in the modern era of chemotherapy?. <i>Journal of Surgical Oncology</i> , 2016, 114, 587-596.	0.8	35
317	Perioperative chemotherapy is associated with a survival advantage in early stage adenocarcinoma of the pancreatic head. <i>Surgery</i> , 2016, 160, 714-724.	1.0	42
318	Endothelial Nitric Oxide Synthase Traffic Inducer (NOSTRIN) is a Negative Regulator of Disease Aggressiveness in Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 5992-6001.	3.2	32
319	Regression grading in post neoadjuvant treated pancreatic cancer. <i>Diagnostic Histopathology</i> , 2016, 22, 219-225.	0.2	3
320	Preoperative Chemoradiation for Pancreatic Adenocarcinoma Does Not Increase 90-Day Postoperative Morbidity or Mortality. <i>Journal of Gastrointestinal Surgery</i> , 2016, 20, 1975-1985.	0.9	42
321	Current and Emerging Targeting Strategies for Treatment of Pancreatic Cancer. <i>Progress in Molecular Biology and Translational Science</i> , 2016, 144, 277-320.	0.9	9
322	A phase-I trial of preoperative, margin intensive, stereotactic body radiation therapy for pancreatic cancer: the "SPARC" trial protocol. <i>BMC Cancer</i> , 2016, 16, 728.	1.1	13
323	Pancreatic cancer. <i>Nature Reviews Disease Primers</i> , 2016, 2, 16022.	18.1	1,301
324	Treatment of Locally Advanced Pancreatic Ductal Adenocarcinoma. <i>Digestive Surgery</i> , 2016, 33, 343-350.	0.6	13
325	Liver Resection and Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria. <i>Annals of Surgery</i> , 2016, 264, 650-658.	2.1	63
326	Complete pathological response following neoadjuvant FOLFIRINOX in borderline resectable pancreatic cancer - a case report and review. <i>BMC Cancer</i> , 2016, 16, 786.	1.1	26
327	Stereotactic Body Radiation Therapy for Pancreatic Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2016, 22, 290-295.	1.0	9
328	Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer. <i>JAMA Surgery</i> , 2016, 151, e161137.	2.2	365
329	Preoperative cognitive function predicts survival in patients with resectable pancreatic ductal adenocarcinoma. <i>Hpb</i> , 2016, 18, 247-254.	0.1	14
330	Efficacy of Neo-Adjuvant Chemoradiotherapy for Resectable Pancreatic Adenocarcinoma. <i>Medicine (United States)</i> , 2016, 95, e3009.	0.4	6
331	Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2016, 34, 2654-2668.	0.8	292
332	Preoperative radiochemotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC trial): study protocol for a multicentre randomized controlled trial. <i>Trials</i> , 2016, 17, 127.	0.7	131
333	Metformin Use Is Associated with Improved Survival in Patients Undergoing Resection for Pancreatic Cancer. <i>Journal of Gastrointestinal Surgery</i> , 2016, 20, 1572-1580.	0.9	38

#	ARTICLE	IF	CITATIONS
334	Identifying Factors Influencing Pancreatic Cancer Management to Inform Quality Improvement Efforts and Future Research. <i>Pancreas</i> , 2016, 45, 161-166.	0.5	10
335	Pancreatic cancer. <i>Lancet</i> , The, 2016, 388, 73-85.	6.3	1,826
336	Meta-analyses of treatment standards for pancreatic cancer. <i>Molecular and Clinical Oncology</i> , 2016, 4, 315-325.	0.4	31
337	Operative Trends for Pancreatic Diseases in the USA: Analysis of the Nationwide Inpatient Sample from 1998-2011. <i>Journal of Gastrointestinal Surgery</i> , 2016, 20, 803-811.	0.9	18
338	EGFR-targeted gelatin nanoparticles for systemic administration of gemcitabine in an orthotopic pancreatic cancer model. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2016, 12, 589-600.	1.7	51
339	Concurrent gemcitabine+S-1 neoadjuvant chemotherapy contributes to the improved survival of patients with small borderline-resectable pancreatic cancer tumors. <i>Surgery Today</i> , 2016, 46, 1282-1289.	0.7	20
340	Pancreatic adenocarcinoma. <i>Current Problems in Surgery</i> , 2016, 53, 107-154.	0.6	6
341	The role of neoadjuvant therapy in pancreatic cancer: a review. <i>Future Oncology</i> , 2016, 12, 669-685.	1.1	32
342	Current standards and new innovative approaches for treatment of pancreatic cancer. <i>European Journal of Cancer</i> , 2016, 57, 10-22.	1.3	138
343	Outcomes of a Clinical Pathway for Borderline Resectable Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , 2016, 23, 1371-1379.	0.7	32
344	Multidetector CT of pancreatic ductal adenocarcinoma: Effect of tube voltage and iodine load on tumour conspicuity and image quality. <i>European Radiology</i> , 2016, 26, 4021-4029.	2.3	13
345	Borderline resectable pancreatic cancer. <i>Cancer Letters</i> , 2016, 375, 231-237.	3.2	45
346	Current Controversies in the Surgical Management of Pancreatic Cancer. , 2016, , 121-132.		0
347	Neoadjuvant therapy for patients with borderline resectable pancreatic cancer: A systematic review and meta-analysis of response and resection percentages. <i>Pancreatology</i> , 2016, 16, 28-37.	0.5	120
348	Is There a Role for Laparoscopic and/or Robotic Techniques for Borderline Resectable Tumors?. , 2016, , 187-202.		0
349	The Role and Techniques of Vascular Resection. , 2016, , 203-222.		0
350	Artery-First Approaches to Pancreaticoduodenectomy. , 2016, , 223-236.		1
351	Surgery for Borderline Resectable Pancreatic Cancer: The Japanese Experience. , 2016, , 265-287.		6

#	ARTICLE	IF	CITATIONS
352	Overview of Multimodality Therapy. , 2016, , 73-89.		0
353	Role of Systemic Therapy. , 2016, , 91-106.		0
354	Assessment of Response to Preoperative Therapy. , 2016, , 143-157.		0
356	Next-generation metabolic imaging in pancreatic cancer. <i>Gut</i> , 2016, 65, 367-369.	6.1	2
357	Three-Dimensional Printing and Medical Imaging: A Review of the Methods and Applications. <i>Current Problems in Diagnostic Radiology</i> , 2016, 45, 2-9.	0.6	296
358	The BET bromodomain inhibitor JQ1 suppresses growth of pancreatic ductal adenocarcinoma in patient-derived xenograft models. <i>Oncogene</i> , 2016, 35, 833-845.	2.6	112
359	Pancreatic Cancer Surgery. <i>Annals of Surgery</i> , 2017, 265, 565-573.	2.1	258
360	Clinical benefits of neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreatic head: an observational study using inverse probability of treatment weighting. <i>Journal of Gastroenterology</i> , 2017, 52, 81-93.	2.3	51
361	Percutaneous Radiofrequency Ablation of Unresectable Locally Advanced Pancreatic Cancer: Preliminary Results. <i>Technology in Cancer Research and Treatment</i> , 2017, 16, 285-294.	0.8	41
362	Reply to the Letter to the Editor "Laparoscopic Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma. <i>Annals of Surgery</i> , 2017, 266, e85-e86.	2.1	1
363	A Multidisciplinary Approach to Pancreas Cancer in 2016: A Review. <i>American Journal of Gastroenterology</i> , 2017, 112, 537-554.	0.2	123
364	Regression grading in neoadjuvant treated pancreatic cancer: an interobserver study. <i>Journal of Clinical Pathology</i> , 2017, 70, 237-243.	1.0	40
365	The significance of Trk receptors in pancreatic cancer. <i>Tumor Biology</i> , 2017, 39, 101042831769225.	0.8	8
366	Controversies in Surgery for Pancreatic Cancer. <i>GI Surgery Annual</i> , 2017, , 117-135.	0.0	0
367	The association between dietary zinc intake and risk of pancreatic cancer: a meta-analysis. <i>Bioscience Reports</i> , 2017, 37, .	1.1	20
368	Borderline resectable pancreatic cancer: conceptual evolution and current approach to image-based classification. <i>Annals of Oncology</i> , 2017, 28, 2067-2076.	0.6	75
369	MicroRNA-181b, ETS1, and the Met pathway exacerbate the prognosis of pancreatic ductal adenocarcinoma after radiation therapy. <i>Cancer Science</i> , 2017, 108, 398-407.	1.7	27
371	Improved oncologic outcome with chemoradiotherapy followed by surgery in unresectable intrahepatic cholangiocarcinoma. <i>Strahlentherapie Und Onkologie</i> , 2017, 193, 620-629.	1.0	17

#	ARTICLE	IF	CITATIONS
372	Sterol regulatory element-binding protein 1 inhibitors decrease pancreatic cancer cell viability and proliferation. <i>Biochemical and Biophysical Research Communications</i> , 2017, 488, 136-140.	1.0	52
373	3rd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of pancreatic cancer. <i>European Journal of Cancer</i> , 2017, 79, 41-49.	1.3	43
374	Dose escalation in locally advanced pancreatic cancer patients receiving chemoradiotherapy. <i>Radiotherapy and Oncology</i> , 2017, 123, 438-445.	0.3	48
375	What treatment in 2017 for inoperable pancreatic cancers?. <i>Annals of Oncology</i> , 2017, 28, 1473-1483.	0.6	30
376	Epidemiology of pancreatic cancer in France: descriptive study from the French national hospital database. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 904-908.	0.8	14
377	Immunohistochemical Antibody Panel for the Differential Diagnosis of Pancreatic Ductal Carcinoma From Gastrointestinal Contamination and Benign Pancreatic Duct Epithelium in Endoscopic Ultrasound-Guided Fine-Needle Aspiration. <i>Pancreas</i> , 2017, 46, 531-538.	0.5	16
378	Resectable pancreatic adenocarcinomas: will neoadjuvant FOLFIRINOX replace upfront surgery in the standard of care?. <i>Future Oncology</i> , 2017, 13, 951-953.	1.1	3
379	Multiagent induction chemotherapy followed by chemoradiation is associated with improved survival in locally advanced pancreatic cancer. <i>Cancer</i> , 2017, 123, 3816-3824.	2.0	35
380	Peritoneal metastasis from pancreatic cancer treated with pressurized intraperitoneal aerosol chemotherapy (PIPAC). <i>Clinical and Experimental Metastasis</i> , 2017, 34, 309-314.	1.7	55
381	Downstaging in Stage IV Pancreatic Cancer: A New Population Eligible for Surgery?. <i>Annals of Surgical Oncology</i> , 2017, 24, 2397-2403.	0.7	83
382	Clinical outcomes with percutaneous coronary revascularization vs coronary artery bypass grafting surgery in patients with unprotected left main coronary artery disease: A meta-analysis of 6 randomized trials and 4,686 patients. <i>American Heart Journal</i> , 2017, 190, 54-63.	1.2	78
383	Overcoming the resistance of pancreatic cancer to immune checkpoint inhibitors. <i>Journal of Surgical Oncology</i> , 2017, 116, 55-62.	0.8	46
384	Treatment outcomes of concurrent hyperthermia and chemoradiotherapy for pancreatic cancer: Insights into the significance of hyperthermia treatment. <i>Oncology Letters</i> , 2017, 13, 4959-4964.	0.8	15
385	Neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of prospective studies. <i>Cancer Medicine</i> , 2017, 6, 1201-1219.	1.3	111
386	Impact of Intraoperative Re-resection to Achieve R0 Status on Survival in Patients With Pancreatic Cancer. <i>Annals of Surgery</i> , 2017, 265, 1219-1225.	2.1	39
387	Neoadjuvant chemotherapy for pancreatic cancer: Effects on cancer tissue and novel perspectives. <i>Oncology Letters</i> , 2017, 13, 3975-3981.	0.8	11
388	Induction Chemotherapy Followed by Resection or Irreversible Electroporation in Locally Advanced Pancreatic Cancer (IMPALA): A Prospective Cohort Study. <i>Annals of Surgical Oncology</i> , 2017, 24, 2734-2743.	0.7	70
389	Phase II study of induction gemcitabine and S-1 followed by chemoradiotherapy and systemic chemotherapy using S-1 for locally advanced pancreatic cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 195-202.	1.1	11

#	ARTICLE	IF	CITATIONS
390	Quality assurance of the PREOPANC trial (2012-003181-40) for preoperative radiochemotherapy in pancreatic cancer. <i>Strahlentherapie Und Onkologie</i> , 2017, 193, 630-638.	1.0	7
391	Diagnostic Laparoscopy Prior to Neoadjuvant Therapy in Pancreatic Cancer Is High Yield: an Analysis of Outcomes and Costs. <i>Journal of Gastrointestinal Surgery</i> , 2017, 21, 1420-1427.	0.9	22
392	What is the impact of neoadjuvant chemoradiation on outcomes in gastro-intestinal cancer?. <i>Journal of Visceral Surgery</i> , 2017, 154, 185-195.	0.4	6
393	A Prospective Phase II Trial of Neoadjuvant S-1 with Concurrent Hypofractionated Radiotherapy in Patients with Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2017, 24, 2777-2784.	0.7	44
394	Techniques of pancreatic resection. , 2017, , 1007-1023.e3.		2
395	Personalized Management of Pancreatic Ductal Adenocarcinoma Patients through Computational Modeling. <i>Cancer Research</i> , 2017, 77, 3325-3335.	0.4	11
396	The impact of neoadjuvant therapy on the histopathological features of pancreatic ductal adenocarcinoma – A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2017, 55, 96-106.	3.4	83
397	Increased semaphorin 3c expression promotes tumor growth and metastasis in pancreatic ductal adenocarcinoma by activating the ERK1/2 signaling pathway. <i>Cancer Letters</i> , 2017, 397, 12-22.	3.2	36
398	Neoadjuvant external beam radiation is associated with No benefit in overall survival for early stage pancreatic cancer. <i>American Journal of Surgery</i> , 2017, 213, 521-525.	0.9	15
399	Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain. <i>Clinical and Translational Oncology</i> , 2017, 19, 667-681.	1.2	27
400	Borderline resectable pancreatic cancer: More than an anatomical concept. <i>Digestive and Liver Disease</i> , 2017, 49, 223-226.	0.4	15
401	Synergistic effect of a drug loaded electrospun patch and systemic chemotherapy in pancreatic cancer xenograft. <i>Scientific Reports</i> , 2017, 7, 12381.	1.6	18
402	Resection of Locally Advanced Pancreatic Neoplasms after Neoadjuvant Chemotherapy with Nab-Paclitaxel and Gemcitabine following FOLFIRINOX Failure. <i>Case Reports in Gastroenterology</i> , 2017, 11, 422-427.	0.3	6
403	Neoadjuvant chemoradiation for non-metastatic pancreatic cancer increases margin-negative and node-negative rates at resection. <i>Journal of Digestive Diseases</i> , 2017, 18, 642-649.	0.7	7
404	Selecting patients for resection after primary chemotherapy for non-metastatic pancreatic adenocarcinoma. <i>Annals of Oncology</i> , 2017, 28, 2786-2792.	0.6	87
405	Current challenges in optimizing systemic therapy for patients with pancreatic cancer: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 951-964.	1.1	2
406	How to treat pancreatic adenocarcinoma in elderly: How far can we go in 2017?. <i>Journal of Geriatric Oncology</i> , 2017, 8, 407-412.	0.5	10
407	Factors influencing survival of patients with pancreatic adenocarcinoma and synchronous liver metastases receiving palliative care. <i>Pancreatology</i> , 2017, 17, 773-781.	0.5	14

#	ARTICLE	IF	CITATIONS
408	Can Neoadjuvant Therapy in Pancreatic Cancer Increase the Pool of Patients Eligible for Pancreaticoduodenectomy?. <i>Advances in Surgery</i> , 2017, 51, 1-10.	0.6	14
409	Disease-free survival is not a surrogate endpoint for overall survival in adjuvant trials of pancreatic cancer: a Systematic review of randomized trials. <i>Hpb</i> , 2017, 19, 944-950.	0.1	7
410	Case 4: Pancreatic Adenocarcinoma, Borderline Resectable. , 2017, , 15-17.		0
411	Neoadjuvant treatment for borderline and resectable pancreatic ductal adenocarcinoma. <i>Clinical and Translational Oncology</i> , 2017, 19, 1193-1198.	1.2	3
412	Clinical Management. <i>Cancer Journal (Sudbury, Mass)</i> , 2017, 23, 343-349.	1.0	14
413	Role and technique of endoscopic ultrasound placement of fiducial markers in gastrointestinal malignancies. <i>Techniques in Gastrointestinal Endoscopy</i> , 2017, 19, 213-218.	0.3	3
414	Phytotherapeutics oridonin and ponidicin show additive effects combined with irradiation in pancreatic cancer <i>in vitro</i> . <i>Radiology and Oncology</i> , 2017, 51, 407-414.	0.6	7
415	The Multidisciplinary Approach to Localized Pancreatic Adenocarcinoma. <i>Current Treatment Options in Oncology</i> , 2017, 18, 73.	1.3	5
416	MicroRNAs and their role for T stage determination and lymph node metastasis in early colon carcinoma. <i>Clinical and Experimental Metastasis</i> , 2017, 34, 431-440.	1.7	13
417	Quel impact de la radiochimiothérapie avant une chirurgie pour cancer digestif?. <i>Journal De Chirurgie Viscérale</i> , 2017, 154, 192-203.	0.0	0
418	The role of irreversible electroporation (IRE) for locally advanced pancreatic cancer: a systematic review of safety and efficacy. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 1165-1171.	0.6	63
419	Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal Adenocarcinoma. <i>JAMA Surgery</i> , 2017, 152, 1048.	2.2	82
420	Neoadjuvant Treatment in Locally Advanced and Borderline Resectable Pancreatic Cancer vs Primary Resectable Pancreatic Cancer. <i>JAMA Surgery</i> , 2017, 152, 1057.	2.2	8
421	Extended Pancreatectomy: Does It Have a Role in the Contemporary Management of Pancreatic Adenocarcinoma?. <i>Digestive Surgery</i> , 2017, 34, 441-446.	0.6	7
422	Pancreatic adenocarcinoma: A simple CT score for predicting margin-positive resection in patients with resectable disease. <i>European Journal of Radiology</i> , 2017, 95, 33-38.	1.2	13
423	Retrospective cohort analysis of neoadjuvant treatment and survival in resectable and borderline resectable pancreatic ductal adenocarcinoma in a high volume referral centre. <i>European Journal of Surgical Oncology</i> , 2017, 43, 1711-1717.	0.5	28
424	CT texture features are associated with overall survival in pancreatic ductal adenocarcinoma – a quantitative analysis. <i>BMC Medical Imaging</i> , 2017, 17, 38.	1.4	112
425	Review of radiological classifications of pancreatic cancer with peripancreatic vessel invasion: are new grading criteria required?. <i>Cancer Imaging</i> , 2017, 17, 14.	1.2	16

#	ARTICLE	IF	CITATIONS
427	Recommendations for MRI-based contouring of gross tumor volume and organs at risk for radiation therapy of pancreatic cancer. <i>Practical Radiation Oncology</i> , 2017, 7, 126-136.	1.1	44
428	Tumor-Vessel Relationships in Pancreatic Ductal Adenocarcinoma at Multidetector CT: Different Classification Systems and Their Influence on Treatment Planning. <i>Radiographics</i> , 2017, 37, 93-112.	1.4	70
429	Predictors and survival for pathologic tumor response grade in borderline resectable and locally advanced pancreatic cancer treated with induction chemotherapy and neoadjuvant stereotactic body radiotherapy. <i>Acta Oncologica</i> , 2017, 56, 391-397.	0.8	68
430	Preoperative chemoradiotherapy does not compromise the feasibility of adjuvant chemotherapy for patients with pancreatic ductal adenocarcinoma. <i>Surgery Today</i> , 2017, 47, 218-226.	0.7	23
431	Neoadjuvant Therapy Followed by Resection Versus Upfront Resection for Resectable Pancreatic Cancer: A Propensity Score Matched Analysis. <i>Journal of Clinical Oncology</i> , 2017, 35, 515-522.	0.8	325
433	CDGSH Iron Sulfur Domain 2 Activates Proliferation and EMT of Pancreatic Cancer Cells via Wnt/ β^2 -Catenin Pathway and Has Prognostic Value in Human Pancreatic Cancer. <i>Oncology Research</i> , 2017, 25, 605-615.	0.6	22
434	Stent patency in patients with distal malignant biliary obstruction receiving chemo(radio)therapy. <i>Endoscopy International Open</i> , 2017, 05, E1035-E1043.	0.9	7
435	Chemotherapy and radiotherapy for pancreatic cancer. , 2017, , 1032-1041.e3.		0
436	Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1338.	1.8	431
437	Neoadjuvant Therapy of Pancreatic Cancer: Definitions and Benefits. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1622.	1.8	92
438	Neoadjuvant therapy for resectable pancreatic cancer. <i>World Journal of Gastrointestinal Oncology</i> , 2017, 9, 457-465.	0.8	21
439	Sulforaphane enhances irradiation effects in terms of perturbed cell cycle progression and increased DNA damage in pancreatic cancer cells. <i>PLoS ONE</i> , 2017, 12, e0180940.	1.1	21
440	A practical approach to pancreatic cancer immunotherapy using resected tumor lysate vaccines processed to express β -gal epitopes. <i>PLoS ONE</i> , 2017, 12, e0184901.	1.1	10
441	Preliminary study of tumor heterogeneity in imaging predicts two year survival in pancreatic cancer patients. <i>PLoS ONE</i> , 2017, 12, e0188022.	1.1	69
442	Chemotherapy and tumor microenvironment of pancreatic cancer. <i>Cancer Cell International</i> , 2017, 17, 68.	1.8	91
443	Neoadjuvant treatment of pancreatic adenocarcinoma: a systematic review and meta-analysis of 5520 patients. <i>World Journal of Surgical Oncology</i> , 2017, 15, 183.	0.8	112
444	Effective radiotherapeutic treatment intensification in patients with pancreatic cancer: higher doses alone, higher RBE or both?. <i>Radiation Oncology</i> , 2017, 12, 203.	1.2	9
445	Gambogic acid sensitizes gemcitabine efficacy in pancreatic cancer by reducing the expression of ribonucleotide reductase subunit-M2 (RRM2). <i>Journal of Experimental and Clinical Cancer Research</i> , 2017, 36, 107.	3.5	63

#	ARTICLE	IF	CITATIONS
446	A long-term survival case treated with conversion surgery following chemotherapy after diagnostic metastasectomy for pancreatic cancer with synchronous liver metastasis. <i>Surgical Case Reports</i> , 2017, 3, 132.	0.2	6
447	Role of surgery in pancreatic cancer. <i>World Journal of Gastroenterology</i> , 2017, 23, 3765.	1.4	31
448	Complete Response after Treatment with Neoadjuvant Chemoradiation with Prolonged Chemotherapy for Locally Advanced, Unresectable Adenocarcinoma of the Pancreas. <i>Case Reports in Oncological Medicine</i> , 2017, 2017, 1-7.	0.2	7
449	TWELVE YEARS OF EXPERIENCE USING CHOLECYSTOJEJUNAL BY-PASS FOR PALLIATIVE TREATMENT OF ADVANCED PANCREATIC CANCER. <i>Arquivos Brasileiros De Cirurgia Digestiva: ABCD = Brazilian Archives of Digestive Surgery</i> , 2017, 30, 201-204.	0.5	1
450	Association between ERCC2 Lys751Gln polymorphism and the risk of pancreatic cancer, especially among Asians: evidence from a meta-analysis. <i>Oncotarget</i> , 2017, 8, 50124-50132.	0.8	6
451	Gastrointestinal Cancer: Pancreas. <i>Medical Radiology</i> , 2017, , 211-227.	0.0	0
452	Locally Advanced Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline Summary. <i>Journal of Oncology Practice</i> , 2017, 13, 265-269.	2.5	56
453	The concept of "borderline resectable" pancreatic cancer: limited foundations and limited future?. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 189-193.	0.6	18
454	The role of induction chemotherapy + chemoradiotherapy in localised pancreatic cancer: initial experience in Scotland. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 683-695.	0.6	12
455	Prognostic impact of carbohydrate antigen 19-9 level at diagnosis in resected stage III pancreatic adenocarcinoma: a U.S. population study. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 778-788.	0.6	16
456	Neoadjuvant therapy prior to surgical resection for previously explored pancreatic cancer patients is associated with improved survival. <i>Hepatobiliary Surgery and Nutrition</i> , 2017, 14, 144-153.	0.7	6
457	Survivorship after treatment of pancreatic cancer: insights via an Internet-based survivorship care plan tool. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 890-896.	0.6	5
458	Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer. <i>Annals of Surgery</i> , 2018, 268, 215-222.	2.1	497
459	Stroma "A Double-Edged Sword in Pancreatic Cancer. <i>Pancreas</i> , 2018, 47, 382-389.	0.5	23
460	Preoperative MDCT Assessment of Resectability in Borderline Resectable Pancreatic Cancer: Effect of Neoadjuvant Chemoradiation Therapy. <i>American Journal of Roentgenology</i> , 2018, 210, 1059-1065.	1.0	21
461	Surgery after FOLFIRINOX treatment for locally advanced and borderline resectable pancreatic cancer: increase in tumour attenuation on CT correlates with R0 resection. <i>European Radiology</i> , 2018, 28, 4265-4273.	2.3	34
462	Vitamin D Supplementation is a Promising Therapy for Pancreatic Ductal Adenocarcinoma in Conjunction with Current Chemoradiation Therapy. <i>Annals of Surgical Oncology</i> , 2018, 25, 1868-1879.	0.7	32
463	Linac-based stereotactic body radiation therapy for unresectable locally advanced pancreatic cancer: risk-adapted dose prescription and image-guided delivery. <i>Strahlentherapie Und Onkologie</i> , 2018, 194, 835-842.	1.0	30

#	ARTICLE	IF	CITATIONS
464	Pancreatic Adenocarcinoma Staging in the Era of Preoperative Chemotherapy and Radiation Therapy. <i>Radiology</i> , 2018, 287, 374-390.	3.6	121
465	Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2â€“3 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 413-423.	3.7	180
467	Circulating Tumor Cells Predict Occult Metastatic Disease and Prognosis in Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , 2018, 25, 1000-1008.	0.7	77
470	Neoadjuvant therapy affects margins and margins affect all: perioperative and survival outcomes in resected pancreatic adenocarcinoma. <i>Hpb</i> , 2018, 20, 573-581.	0.1	24
471	Correlation of clinical and pathological staging and response to neoadjuvant therapy in resected pancreatic cancer. <i>International Journal of Surgery</i> , 2018, 52, 221-228.	1.1	7
472	Value of surgical resection and timing of therapy in patients with pancreatic cancer at high risk for positive margins. <i>ESMO Open</i> , 2018, 3, e000282.	2.0	21
473	Is a Pathological Complete Response Following Neoadjuvant Chemoradiation Associated With Prolonged Survival in Patients With Pancreatic Cancer?. <i>Annals of Surgery</i> , 2018, 268, 1-8.	2.1	139
474	A look at the progress of treating pancreatic cancer over the past 20 years. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 295-304.	1.1	23
475	Significance of Glucose Transporter Type 1 (GLUT-1) Expression in the Therapeutic Strategy for Pancreatic Ductal Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2018, 25, 1432-1439.	0.7	28
478	Extended pancreatectomy as defined by the ISGPS: useful in selected cases of pancreatic cancer but invaluable in other complex pancreatic tumors. <i>Langenbeck's Archives of Surgery</i> , 2018, 403, 203-212.	0.8	9
480	Clinical significance of defining borderline resectable pancreatic cancer. <i>Pancreatology</i> , 2018, 18, 139-145.	0.5	9
481	Current update of a thermosensitive liposomes composed of DPPC and Brij78. <i>Journal of Drug Targeting</i> , 2018, 26, 407-419.	2.1	14
482	Fluorescenceâ€“and multispectral optoacoustic imaging for an optimized detection of deeply located tumors in an orthotopic mouse model of pancreatic carcinoma. <i>International Journal of Cancer</i> , 2018, 142, 2118-2129.	2.3	8
483	Resectable and Borderline Resectable Pancreatic Cancer. <i>Practical Guides in Radiation Oncology</i> , 2018, , 199-229.	0.0	0
484	Microscopic Venous Invasion in Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , 2018, 25, 1043-1051.	0.7	30
485	Relationship between mismatch repair immunophenotype and long-term survival in patients with resected periampullary adenocarcinoma. <i>Journal of Translational Medicine</i> , 2018, 16, 66.	1.8	18
486	Meta-analysis of the impact of neoadjuvant therapy on patterns of recurrence in pancreatic ductal adenocarcinoma. <i>BJS Open</i> , 2018, 2, 52-61.	0.7	29
487	Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer. <i>British Journal of Surgery</i> , 2018, 105, 946-958.	0.1	384

#	ARTICLE	IF	CITATIONS
488	Therapeutic developments in pancreatic cancer: current and future perspectives. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018, 15, 333-348.	8.2	762
489	Borderline Resectable Pancreatic Cancer. , 2018, , 1001-1020.		0
490	Surgical Resection for Pancreatic Cancer Using the International Study Group of Pancreatic Surgery (ISGPS) Classifications. , 2018, , 923-940.		0
491	New Japanese Classification of Pancreatic Cancer. , 2018, , 1021-1037.		15
492	Neoadjuvant Chemotherapy in Pancreatic Cancer. , 2018, , 1187-1202.		1
493	Combined Systemic Chemotherapy and CT-Guided High-Dose-Rate Brachytherapy for Isolated Local Manifestation of Pancreatic Cancer after Surgical Resection. <i>Digestion</i> , 2018, 98, 69-74.	1.2	5
494	Postoperative complications after resection of borderline resectable and locally advanced pancreatic cancer: The impact of neoadjuvant chemotherapy with conventional radiation or stereotactic body radiation therapy. <i>Surgery</i> , 2018, 163, 1090-1096.	1.0	35
495	Dynamic quantitative detection of ABC transporter family promoter methylation by MS ² -HRM for predicting MDR in pancreatic cancer. <i>Oncology Letters</i> , 2018, 15, 5602-5610.	0.8	7
496	Does Second Reader Opinion Affect Patient Management in Pancreatic Ductal Adenocarcinoma?. <i>Academic Radiology</i> , 2018, 25, 825-832.	1.3	14
497	Significance of combined preoperative serum Alb and dNLR for diagnosis of pancreatic cancer. <i>Future Oncology</i> , 2018, 14, 229-239.	1.1	21
498	LncRNA BC032020 suppresses the survival of human pancreatic ductal adenocarcinoma cells by targeting ZNF451. <i>International Journal of Oncology</i> , 2018, 52, 1224-1234.	1.4	6
499	The Role of Venous and Arterial Resection in Pancreatic Cancer Surgery. <i>Annals of Surgical Oncology</i> , 2018, 25, 51-58.	0.7	41
500	Prolonged Neoadjuvant Therapy for Locally Advanced Pancreatic Cancer. <i>Digestive Surgery</i> , 2018, 35, 70-76.	0.6	14
501	Age 80 years and over is not associated with increased morbidity and mortality following pancreaticoduodenectomy. <i>ANZ Journal of Surgery</i> , 2018, 88, E445-E450.	0.3	19
502	Intraoperative Radiotherapy in the Era of Intensive Neoadjuvant Chemotherapy and Chemoradiotherapy for Pancreatic Adenocarcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 607-612.	0.6	32
503	Primary systemic therapy in resectable pancreatic ductal adenocarcinoma using mFOLFIRINOX: A pilot study. <i>Journal of Surgical Oncology</i> , 2018, 117, 354-362.	0.8	26
504	Essential role of radiation therapy for the treatment of pancreatic cancer. <i>Strahlentherapie Und Onkologie</i> , 2018, 194, 185-195.	1.0	21
505	Clinical Characteristics of Patients Experiencing Pathologic Complete Response Following Neoadjuvant Therapy for Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 982-985.	0.6	17

#	ARTICLE	IF	CITATIONS
506	The clinical benefit of hyperthermia in pancreatic cancer: a systematic review. <i>International Journal of Hyperthermia</i> , 2018, 34, 969-979.	1.1	41
507	Response assessment in pancreatic ductal adenocarcinoma: role of imaging. <i>Abdominal Radiology</i> , 2018, 43, 435-444.	1.0	32
508	Improving prognosis and reducing decision regret for pancreatic cancer treatment using artificial neural networks. <i>Decision Support Systems</i> , 2018, 106, 110-118.	3.5	59
509	Adjuvant or Neoadjuvant Therapy in the Treatment in Pancreatic Malignancies. <i>Surgical Clinics of North America</i> , 2018, 98, 95-111.	0.5	25
510	The Evolving Role of Radiation in Pancreatic Cancer. <i>Surgical Clinics of North America</i> , 2018, 98, 113-125.	0.5	21
511	Is distal pancreatectomy with en-bloc celiac axis resection effective for patients with locally advanced pancreatic ductal adenocarcinoma? -Multicenter surgical group study. <i>Pancreatology</i> , 2018, 18, 106-113.	0.5	36
512	Locally advanced pancreatic cancer: An emerging entity. <i>Current Problems in Cancer</i> , 2018, 42, 12-25.	1.0	13
513	Recent advances in the management of pancreatic adenocarcinoma. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 51-62.	1.1	17
514	Pathologic assessment of gastrointestinal tract and pancreatic carcinoma after neoadjuvant therapy. <i>Modern Pathology</i> , 2018, 31, 4-23.	2.9	31
515	FOLFIRINOX treatment leading to pathologic complete response of a locally advanced pancreatic cancer. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, E9-E12.	0.6	16
516	Correlation of tumor size and survival in pancreatic cancer. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 910-921.	0.6	11
517	Preoperative prediction of peripancreatic vein invasion by pancreatic head cancer. <i>Cancer Imaging</i> , 2018, 18, 49.	1.2	10
518	Neoadjuvant Treatment for Nonmetastatic Pancreatic Cancer. , 2018, , .		1
519	Large database utilization in health outcomes research in pancreatic cancer: an update. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 996-1004.	0.6	8
520	Conversion surgery for an initially unresectable, locally advanced pancreatic cancer after induction chemotherapy and carbon-ion radiotherapy: a case report. <i>Surgical Case Reports</i> , 2018, 4, 112.	0.2	2
521	Recent advances in radiation therapy of pancreatic cancer. <i>F1000Research</i> , 2018, 7, 1931.	0.8	12
522	Clinical Significance of Histological Effect and Intratumor Stromal Expression of Tenascin-C in Resected Specimens After Chemoradiotherapy for Initially Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma. <i>Pancreas</i> , 2018, 47, 390-399.	0.5	7
523	Thermal ablation of pancreatic cancer: A systematic literature review of clinical practice and pre-clinical studies. <i>International Journal of Hyperthermia</i> , 2018, 35, 398-418.	1.1	62

#	ARTICLE	IF	CITATIONS
524	Surgery for Pancreatic Cancer after neoadjuvant treatment. <i>Annals of Gastroenterological Surgery</i> , 2018, 2, 413-418.	1.2	39
525	Calcium-activated chloride channel regulator 1 as a prognostic biomarker in pancreatic ductal adenocarcinoma. <i>BMC Cancer</i> , 2018, 18, 1096.	1.1	14
526	Betulinic acid inhibits stemness and EMT of pancreatic cancer cells via activation of AMPK signaling. <i>International Journal of Oncology</i> , 2019, 54, 98-110.	1.4	37
527	Neoadjuvant and adjuvant chemotherapy in pancreatic cancer. <i>Langenbeck's Archives of Surgery</i> , 2018, 403, 917-932.	0.8	67
528	Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group. <i>BMC Cancer</i> , 2018, 18, 1298.	1.1	63
529	Dose escalation of radiation therapy with or without induction chemotherapy for unresectable locally advanced pancreatic cancer. <i>Radiation Oncology</i> , 2018, 13, 214.	1.2	12
530	Pancreatic cancer chemo-resistance is driven by tumor phenotype rather than tumor genotype. <i>Heliyon</i> , 2018, 4, e01055.	1.4	43
531	Genetic Drivers of Pancreatic Cancer Are Identical Between the Primary Tumor and a Secondary Lesion in a Long-Term (>5 Years) Survivor After a Whipple Procedure. <i>Journal of Pancreatic Cancer</i> , 2018, 4, 81-87.	1.6	4
532	Recent treatment patterns and survival outcomes in pancreatic cancer according to clinical stage based on single-center large-cohort data. <i>Annals of Hepato-biliary-pancreatic Surgery</i> , 2018, 22, 386.	0.1	17
533	The Role of Neoadjuvant Therapy in Surgical Treatment of Pancreatic Cancer. , 2018, , .		0
534	THE ROLE OF IMMUNOINFLAMMATORY MARKERS IN THE PROGNOSIS AND RESECTABILITY OF PANCREATIC ADENOCARCINOMA. <i>Arquivos Brasileiros De Cirurgia Digestiva: ABCD = Brazilian Archives of Digestive Surgery</i> , 2018, 31, e1366.	0.5	1
535	Role of angiogenesis in pancreatic cancer biology and therapy. <i>Biomedicine and Pharmacotherapy</i> , 2018, 108, 1135-1140.	2.5	46
536	Current Therapeutic Options for Pancreatic Ductal Adenocarcinoma. <i>Oncology Research and Treatment</i> , 2018, 41, 590-594.	0.8	9
537	Radiation Therapy in Pancreatic Cancer. , 2018, , 1-11.		0
538	Cost-effectiveness analysis of adjuvant treatment for resected pancreatic cancer in China based on the ESPAC-4 trial. <i>Cancer Management and Research</i> , 2018, Volume 10, 4065-4072.	0.9	7
539	The Significant Value of Preoperative Prognostic Nutritional Index for Survival in Pancreatic Cancers. <i>Pancreas</i> , 2018, 47, 793-799.	0.5	15
540	Trends in treatment and survival of patients with nonresected, nonmetastatic pancreatic cancer: A population-based study. <i>Cancer Medicine</i> , 2018, 7, 4943-4951.	1.3	23
541	Resectable Distal Pancreas Cancer: Time to Reconsider the Role of Upfront Surgery. <i>Annals of Surgical Oncology</i> , 2018, 25, 4012-4019.	0.7	16

#	ARTICLE	IF	CITATIONS
542	Endoscopic ultrasound-guided fine needle aspiration for pancreatic cancer. <i>Fukushima Journal of Medical Sciences</i> , 2018, 64, 111-115.	0.1	5
543	Antitumor effect of gemcitabine-loaded albumin nanoparticle on gemcitabine-resistant pancreatic cancer induced by low hENT1 expression. <i>International Journal of Nanomedicine</i> , 2018, Volume 13, 4869-4880.	3.3	27
544	Advanced EUS Guided Tissue Acquisition Methods for Pancreatic Cancer. <i>Cancers</i> , 2018, 10, 54.	1.7	10
545	Optimal resection area for superior mesenteric artery nerve plexuses after neoadjuvant chemoradiotherapy for locally advanced pancreatic carcinoma. <i>Medicine (United States)</i> , 2018, 97, e11309.	0.4	5
546	Differences in Treatment and Outcome of Pancreatic Adenocarcinoma Stage I and II in the EURECCA Pancreas Consortium. <i>Annals of Surgical Oncology</i> , 2018, 25, 3492-3501.	0.7	4
547	Integrating MicroRNA Expression Profiling Studies to Systematically Evaluate the Diagnostic Value of MicroRNAs in Pancreatic Cancer and Validate Their Prognostic Significance with the Cancer Genome Atlas Data. <i>Cellular Physiology and Biochemistry</i> , 2018, 49, 678-695.	1.1	28
548	Irreversible Electroporation in Pancreatic Cancer. , 0, , .		2
549	FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel for Neoadjuvant Treatment of Resectable and Borderline Resectable Pancreatic Head Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2018, 25, 1896-1903.	0.7	88
550	Technique, safety, and feasibility of EUS-guided radiofrequency ablation in unresectable pancreatic cancer. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2018, 32, 4022-4028.	1.3	84
551	A Therapeutic Strategy for Resectable Pancreatic Cancer Based on Risk Factors of Early Recurrence. <i>Pancreas</i> , 2018, 47, 753-758.	0.5	30
552	High-Density Infiltration of V-domain Immunoglobulin Suppressor of T-cell Activation Up-regulated Immune Cells in Human Pancreatic Cancer. <i>Pancreas</i> , 2018, 47, 725-731.	0.5	27
553	Validation of prognostic risk scores for patients undergoing resection for pancreatic cancer. <i>Pancreatology</i> , 2018, 18, 585-591.	0.5	11
554	Does mesenteric venous imaging assessment accurately predict pathologic invasion in localized pancreatic ductal adenocarcinoma?. <i>Hpb</i> , 2018, 20, 925-931.	0.1	6
555	MicroRNA-1179 inhibits the proliferation, migration and invasion of human pancreatic cancer cells by targeting E2F5. <i>Chemico-Biological Interactions</i> , 2018, 291, 65-71.	1.7	36
556	Prediction of overall survival for metastatic pancreatic cancer: Development and validation of a prognostic nomogram with data from open clinical trial and real-world study. <i>Cancer Medicine</i> , 2018, 7, 2974-2984.	1.3	32
557	A preoperative nomogram predicts prognosis of up front resectable patients with pancreatic head cancer and suspected venous invasion. <i>Hpb</i> , 2018, 20, 1034-1043.	0.1	12
558	Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study). <i>BMC Cancer</i> , 2018, 18, 762.	1.1	77
559	The Impact of Hospital Neoadjuvant Therapy Utilization on Survival Outcomes for Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , 2018, 25, 2661-2668.	0.7	7

#	ARTICLE	IF	CITATIONS
560	WIPF1 antagonizes the tumor suppressive effect of miR-141/200c and is associated with poor survival in patients with PDAC. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 167.	3.5	26
561	Intraoperative Radiation “Boost” to the Surgical Resection Bed following Pancreaticoduodenectomy for a Borderline Resectable Pancreatic Carcinoma: A Case Report. <i>Frontiers in Oncology</i> , 2018, 8, 12.	1.3	1
562	Next Generation Immunotherapy for Pancreatic Cancer: DNA Vaccination is Seeking New Combo Partners. <i>Cancers</i> , 2018, 10, 51.	1.7	21
563	Molecular Imaging of Pancreatic Duct Adenocarcinoma Using a Type 2 Cannabinoid Receptor-Targeted Near-Infrared Fluorescent Probe. <i>Translational Oncology</i> , 2018, 11, 1065-1073.	1.7	12
564	Contemporary Management of Localized Resectable Pancreatic Cancer. <i>Cancers</i> , 2018, 10, 24.	1.7	62
565	Prognostic Factors for Pancreatic Cancer Patients Treated with Immune-cell Therapy. <i>Anticancer Research</i> , 2018, 38, 4353-4360.	0.5	6
567	Photodynamic diagnosis of peritoneal metastasis in human pancreatic cancer using 5-aminolevulinic acid during staging laparoscopy. <i>Oncology Letters</i> , 2018, 16, 821-828.	0.8	10
568	Comprehensive molecular profiling of the B7 family in gastrointestinal cancer. <i>Cell Proliferation</i> , 2018, 51, e12468.	2.4	9
569	Novel agents for pancreatic ductal adenocarcinoma: emerging therapeutics and future directions. <i>Journal of Hematology and Oncology</i> , 2018, 11, 14.	6.9	33
571	Clinical Impact of Neoadjuvant Therapy on Nutritional Status in Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , 2018, 25, 3365-3371.	0.7	27
572	A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma. <i>European Journal of Cancer</i> , 2018, 102, 95-102.	1.3	50
573	Impact of neoadjuvant therapy on postoperative outcomes after pancreaticoduodenectomy. <i>Journal of Surgical Oncology</i> , 2018, 118, 455-462.	0.8	35
574	CT Texture Analysis of Ductal Adenocarcinoma Downstaged After Chemotherapy. <i>Anticancer Research</i> , 2018, 38, 4889-4895.	0.5	34
575	Glypican-1-antibody-conjugated Gd-Au nanoclusters for FI/MRI dual-modal targeted detection of pancreatic cancer. <i>International Journal of Nanomedicine</i> , 2018, Volume 13, 2585-2599.	3.3	26
576	Pancreaticoduodenectomy with the Superior Mesenteric Artery Approach: How I Do It. , 2018, , 161-169.		0
577	Molecular pathogenesis of pancreatic ductal adenocarcinoma: Impact of passenger strand of pre-miR-148a on gene regulation. <i>Cancer Science</i> , 2018, 109, 2013-2026.	1.7	40
578	Inactivation of human pancreatic ductal adenocarcinoma with atmospheric plasma treated media and water: a comparative study. <i>Journal Physics D: Applied Physics</i> , 2018, 51, 255401.	1.3	27
579	Borderline resectable pancreatic cancer. Challenges and controversies. <i>Cancer Treatment Reviews</i> , 2018, 68, 124-135.	3.4	27

#	ARTICLE	IF	CITATIONS
580	Intra-arterial therapies for unresectable and chemorefractory colorectal cancer liver metastases: a systematic review and meta-analysis. <i>Hpb</i> , 2018, 20, 905-915.	0.1	37
581	Use of iontophoresis for the treatment of cancer. <i>Journal of Controlled Release</i> , 2018, 284, 144-151.	4.8	53
582	An Innovation for Treating Orthotopic Pancreatic Cancer by Preoperative Screening and Imaging-Guided Surgery. <i>Molecular Imaging and Biology</i> , 2019, 21, 67-77.	1.3	12
583	CT prediction of resectability and prognosis in patients with pancreatic ductal adenocarcinoma after neoadjuvant treatment using image findings and texture analysis. <i>European Radiology</i> , 2019, 29, 362-372.	2.3	49
585	A pharmacogenomic analysis using L1000CDS2 identifies BX-795 as a potential anticancer drug for primary pancreatic ductal adenocarcinoma cells. <i>Cancer Letters</i> , 2019, 465, 82-93.	3.2	13
586	Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches. <i>Radiation Oncology</i> , 2019, 14, 141.	1.2	285
587	Neoadjuvant therapy and pancreatic cancer: a national cancer database analysis. <i>Journal of Gastrointestinal Oncology</i> , 2019, 10, 663-673.	0.6	17
588	Nab-paclitaxel plus gemcitabine as first-line treatment for advanced pancreatic cancer: a systematic review and meta-analysis. <i>Journal of Cancer</i> , 2019, 10, 4420-4429.	1.2	20
590	Systemic neoadjuvant chemotherapy in modern pancreatic cancer treatment: a systematic review and meta-analysis. <i>Annals of the Royal College of Surgeons of England</i> , 2019, 101, 453-462.	0.3	33
591	Venous resection during pancreatectomy for pancreatic cancer: a systematic review. <i>Translational Gastroenterology and Hepatology</i> , 2019, 4, 46-46.	1.5	20
592	Is hepatic artery coil embolization useful in distal pancreatectomy with en bloc celiac axis resection for locally advanced pancreatic cancer?. <i>World Journal of Surgical Oncology</i> , 2019, 17, 124.	0.8	23
593	Identification of key candidate genes for pancreatic cancer by bioinformatics analysis. <i>Experimental and Therapeutic Medicine</i> , 2019, 18, 451-458.	0.8	4
594	Neoadjuvant chemotherapy with gemcitabine-based regimens improves the prognosis of node positive resectable pancreatic head cancer. <i>Molecular and Clinical Oncology</i> , 2019, 11, 157-166.	0.4	7
595	Microbiologic Changes Induced by Biliary Drainage Require Adapted Antibiotic Prophylaxis during Duodenopancreatectomy. <i>Surgical Infections</i> , 2019, 20, 677-682.	0.7	7
596	Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma. <i>JAMA Surgery</i> , 2019, 154, 932.	2.2	97
597	Status of 5-Year Survivors of the Whipple Procedure for Pancreatic Adenocarcinoma. <i>Advances in Surgery</i> , 2019, 53, 253-269.	0.6	4
598	Utilising network pharmacology to explore the underlying mechanism of Wumei Pill in treating pancreatic neoplasms. <i>BMC Complementary and Alternative Medicine</i> , 2019, 19, 158.	3.7	80
599	Determining Optimal Routes to Surgery for Borderline Resectable Venous Pancreatic Cancer—Where Is the Least Harm and Most Benefit?. <i>Frontiers in Oncology</i> , 2019, 9, 1060.	1.3	0

#	ARTICLE	IF	CITATIONS
600	<p></p>Circulating microRNAs as promising diagnostic biomarkers for pancreatic cancer: a systematic review</p>. OncoTargets and Therapy, 2019, Volume 12, 6665-6684.	1.0	13
601	Stereotactic Body Radiation and Interleukin-12 Combination Therapy Eradicates Pancreatic Tumors by Repolarizing the Immune Microenvironment. Cell Reports, 2019, 29, 406-421.e5.	2.9	55
602	An update on treatment options for pancreatic adenocarcinoma. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591987556.	1.4	144
603	Long-term outcomes by response to neoadjuvant chemotherapy or chemoradiation in patients with resected pancreatic adenocarcinoma. Journal of Gastrointestinal Oncology, 2019, 10, 918-927.	0.6	6
604	Neoadjuvant therapy versus upfront surgery in resectable pancreatic cancer according to intention-to-treat and per-protocol analysis: A systematic review and meta-analysis. Scientific Reports, 2019, 9, 15662.	1.6	38
605	Exosomes and pancreatic diseases: status, challenges, and hopes. International Journal of Biological Sciences, 2019, 15, 1846-1860.	2.6	22
606	Clinical Significance of Neoadjuvant Chemotherapy With Gemcitabine Plus S-1 for Resectable Pancreatic Ductal Adenocarcinoma. In Vivo, 2019, 33, 2027-2035.	0.6	8
607	Are We Sure that Adjuvant Chemotherapy is the Best Approach for Resectable Pancreatic Cancer? Are We in the Era of Neoadjuvant Treatment? A Review of Current Literature. Journal of Clinical Medicine, 2019, 8, 1922.	1.0	22
608	Conversion Surgery for Advanced Pancreatic Cancer. Journal of Clinical Medicine, 2019, 8, 1945.	1.0	20
609	The role of interleukin-18 in pancreatitis and pancreatic cancer. Cytokine and Growth Factor Reviews, 2019, 50, 1-12.	3.2	37
611	Survival benefit of neoadjuvant therapy in patients with non-metastatic pancreatic ductal adenocarcinoma: A propensity matching and intention-to-treat analysis. Journal of Surgical Oncology, 2019, 120, 976-984.	0.8	35
612	Irreversible Electroporation of the Pancreas. Seminars in Interventional Radiology, 2019, 36, 213-220.	0.3	12
613	A Prospective, Open-Label, Multicenter Phase 2 Trial of Neoadjuvant Therapy Using Full-Dose Gemcitabine and S-1 Concurrent with Radiation for Resectable Pancreatic Ductal Adenocarcinoma. Annals of Surgical Oncology, 2019, 26, 4498-4505.	0.7	34
614	Pancreas's Microbiota Cross Talk in Health and Disease. Annual Review of Nutrition, 2019, 39, 249-266.	4.3	28
615	Liquid biopsies in pancreatic cancer. Expert Review of Anticancer Therapy, 2019, 19, 869-878.	1.1	24
616	Development of Patient-Derived Preclinical Platform for Metastatic Pancreatic Cancer: PDOX and a Subsequent Organoid Model System Using Percutaneous Biopsy Samples. Frontiers in Oncology, 2019, 9, 875.	1.3	33
617	Preoperative chemotherapy and carbon ions therapy for treatment of resectable and borderline resectable pancreatic adenocarcinoma: a prospective, phase II, multicentre, single-arm study. BMC Cancer, 2019, 19, 922.	1.1	29
618	Initial Diagnosis and Staging of Pancreatic Cancer Including Main Differentials. Seminars in Ultrasound, CT and MRI, 2019, 40, 436-468.	0.7	10

#	ARTICLE	IF	CITATIONS
619	Primarily resectable pancreatic adenocarcinoma – to operate or to refer the patient to an oncologist?. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 135, 95-102.	2.0	6
620	Transforming growth factor- β^2 in pancreatic diseases: Mechanisms and therapeutic potential. <i>Pharmacological Research</i> , 2019, 142, 58-69.	3.1	19
621	Role of surgical resection in the era of <sc>FOLFIRINOX</sc> for advanced pancreatic cancer. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2019, 26, 416-425.	1.4	33
622	Contemporary management of borderline resectable pancreatic ductal adenocarcinoma. <i>Annals of Hepato-biliary-pancreatic Surgery</i> , 2019, 23, 97.	0.1	15
623	Waiting time to surgery and pancreatic cancer survival: A nationwide population-based cohort study. <i>European Journal of Surgical Oncology</i> , 2019, 45, 1901-1905.	0.5	10
624	Dual inhibition of the PI3K and MAPK pathways enhances nab-paclitaxel/gemcitabine chemotherapy response in preclinical models of pancreatic cancer. <i>Cancer Letters</i> , 2019, 459, 41-49.	3.2	35
626	Unraveling altered RNA metabolism in pancreatic cancer cells by liquid-chromatography coupling to ion mobility mass spectrometry. <i>Analytical and Bioanalytical Chemistry</i> , 2019, 411, 6319-6328.	1.9	9
627	Clinical Significance of Plasma Apolipoprotein-All Isoforms as a Marker of Pancreatic Exocrine Disorder for Patients with Pancreatic Adenocarcinoma Undergoing Chemoradiotherapy, Paying Attention to Pancreatic Morphological Changes. <i>BioMed Research International</i> , 2019, 2019, 1-12.	0.9	11
628	Significance of radiographic splenic vessel involvement in the pancreatic ductal adenocarcinoma of the body and tail of the gland. <i>Journal of Surgical Oncology</i> , 2019, 120, 262-269.	0.8	18
629	The role of 2-arachidonoylglycerol in the regulation of the tumor-immune microenvironment in murine models of pancreatic cancer. <i>Biomedicine and Pharmacotherapy</i> , 2019, 115, 108952.	2.5	25
630	Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2019, 111, 782-794.	3.0	223
631	Cutting-edge strategies for borderline resectable pancreatic cancer. <i>Annals of Gastroenterological Surgery</i> , 2019, 3, 368-372.	1.2	15
632	FOLFIRINOX-based neoadjuvant chemoradiotherapy for borderline and locally advanced pancreatic cancer: A pilot study from a tertiary centre. <i>Digestive and Liver Disease</i> , 2019, 51, 1043-1049.	0.4	11
633	Conversion surgery for initially unresectable pancreatic ductal adenocarcinoma with synchronous liver metastasis after treatment with FOLFIRINOX. <i>Clinical Journal of Gastroenterology</i> , 2019, 12, 603-608.	0.4	4
634	Tumor location as an indicator of survival in T1 resectable pancreatic ductal adenocarcinoma: a propensity score-matched analysis. <i>BMC Gastroenterology</i> , 2019, 19, 59.	0.8	18
635	Computational modeling of pancreatic cancer patients receiving FOLFIRINOX and gemcitabine-based therapies identifies optimum intervention strategies. <i>PLoS ONE</i> , 2019, 14, e0215409.	1.1	7
636	MicroRNA-200b and -301 are associated with gemcitabine response as biomarkers in pancreatic carcinoma cells. <i>International Journal of Oncology</i> , 2019, 54, 991-1000.	1.4	14
637	Preoperative Imaging Evaluation after Downstaging of Pancreatic Ductal Adenocarcinoma: A Multi-Center Study. <i>Cancers</i> , 2019, 11, 267.	1.7	24

#	ARTICLE	IF	CITATIONS
638	<p>HIFU is safe, effective, and feasible in pancreatic cancer patients: a monocentric retrospective study among 523 patients</p>. OncoTargets and Therapy, 2019, Volume 12, 1021-1029.	1.0	38
639	Neoadjuvant therapy versus upfront surgery for potentially resectable pancreatic cancer: A Markov decision analysis. PLoS ONE, 2019, 14, e0212805.	1.1	9
640	Pancreatic Cancer and Possible Therapeutic Options. , 2019, , 57-85.		0
641	<p>Spotlight on liposomal irinotecan for metastatic pancreatic cancer: patient selection and perspectives</p>. OncoTargets and Therapy, 2019, Volume 12, 1455-1463.	1.0	18
643	LncRNA SNHG16 promotes tumor growth of pancreatic cancer by targeting miR-218-5p. Biomedicine and Pharmacotherapy, 2019, 114, 108862.	2.5	52
644	Recurrence after neoadjuvant therapy and resection of borderline resectable and locally advanced pancreatic cancer. European Journal of Surgical Oncology, 2019, 45, 1674-1683.	0.5	62
645	Treatment of pancreatic cancer”neoadjuvant treatment in resectable pancreatic cancer (PDAC). Translational Gastroenterology and Hepatology, 2019, 4, 21-21.	1.5	42
646	Neo-adjuvant therapy for pancreatic cancer: hope for the future. Expert Review of Gastroenterology and Hepatology, 2019, 13, 579-589.	1.4	6
648	Prognostic Value of CT Radiomic Features in Resectable Pancreatic Ductal Adenocarcinoma. Scientific Reports, 2019, 9, 5449.	1.6	61
649	Comparisons of different neoadjuvant chemotherapy regimens with or without stereotactic body radiation therapy for borderline resectable pancreatic cancer: study protocol of a prospective, randomized phase II trial (BRPCNC-1). Radiation Oncology, 2019, 14, 52.	1.2	15
650	Integrating radiation oncology into the management of pancreatic cancer. European Surgery - Acta Chirurgica Austriaca, 2019, 51, 139-145.	0.3	2
651	Therapeutic efficacy of anti&MMP9 antibody in combination with nab&paclitaxel&based chemotherapy in pre&clinical models of pancreatic cancer. Journal of Cellular and Molecular Medicine, 2019, 23, 3878-3887.	1.6	22
652	Endoscopic ultrasound in pancreatic cancer treatment: Facts and hopes. Clinics and Research in Hepatology and Gastroenterology, 2019, 43, 513-521.	0.7	6
653	Diagnostic and therapeutic recommendations in pancreatic ductal adenocarcinoma. Recommendations of the Working Group of the Polish Pancreatic Club. Przegląd Gastroenterologiczny, 2019, 14, 1-18.	0.3	64
654	Conversion surgery for initially unresectable pancreatic cancer: current status and unresolved issues. Surgery Today, 2019, 49, 894-906.	0.7	25
655	Patient-Derived Xenografts Can Be Reliably Generated from Patient Clinical Biopsy Specimens. Journal of Gastrointestinal Surgery, 2019, 23, 818-824.	0.9	24
656	Surgical palliation of biliary obstruction: Bypass in the era of drainage. Journal of Surgical Oncology, 2019, 120, 65-66.	0.8	3
657	Bilan initial d&TMimagerie de l&TMad&Cnocarcinome pancr&Ctique&: donn&Ces de la litt&Cature sur la place actuelle de la tomographie par &Cmission de positons au 18F-fluorod&Coxyglucose (TEP FDG). Medecine Nucleaire, 2019, 43, 270-274.	0.2	0

#	ARTICLE	IF	CITATIONS
658	Study protocol: a multi-centre randomised study of induction chemotherapy followed by capecitabine ± nelfinavir with high- or standard-dose radiotherapy for locally advanced pancreatic cancer (SCALOP-2). <i>BMC Cancer</i> , 2019, 19, 121.	1.1	11
659	Irreversible electroporation combined with chemotherapy for unresectable pancreatic carcinoma: a prospective cohort study. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 1341-1350.	1.0	14
660	Gold Nanoparticle-Incorporated Molecularly Imprinted Microgels as Radiation Sensitizers in Pancreatic Cancer. <i>ACS Applied Bio Materials</i> , 2019, 2, 1177-1183.	2.3	27
661	Pancreatic cancer treated with SBRT: Effect of anatomical interfraction variations on dose to organs at risk. <i>Radiotherapy and Oncology</i> , 2019, 134, 67-73.	0.3	23
662	Fisetin induces autophagy in pancreatic cancer cells via endoplasmic reticulum stress- and mitochondrial stress-dependent pathways. <i>Cell Death and Disease</i> , 2019, 10, 142.	2.7	85
663	Evolving trends in pancreatic cancer therapeutic development. <i>Annals of Pancreatic Cancer</i> , 2019, 2, 17-17.	1.2	1
664	Identification of differentially expressed genes in pancreatic ductal adenocarcinoma and normal pancreatic tissues based on microarray datasets. <i>Molecular Medicine Reports</i> , 2019, 20, 1901-1914.	1.1	17
665	Disparities in Care: Impact of Socioeconomic Factors on Pancreatic Surgery: Exploring the National Cancer Database. <i>American Surgeon</i> , 2019, 85, 327-334.	0.4	16
666	Maintenance Therapy with FOLFIRI after FOLFIRINOX for Advanced Pancreatic Ductal Adenocarcinoma: A Retrospective Single-Center Analysis. <i>Journal of Oncology</i> , 2019, 2019, 1-5.	0.6	12
667	Pathologic Complete Response of Pancreatic Cancer following Neoadjuvant FOLFIRINOX Treatment in Hepatic Metastasized Pancreatic Cancer. <i>Visceral Medicine</i> , 2019, 35, 387-391.	0.5	10
668	Long-term survival after surgery of pancreatic primary squamous cell carcinoma: A case report and literature review. <i>Clinical Case Reports (discontinued)</i> , 2019, 7, 2092-2101.	0.2	4
669	Prognostic values of 18F-FDG PET/CT metabolic parameters and clinical figures in locally advanced pancreatic cancer underwent chemotherapy combined with stereotactic body radiation therapy. <i>Medicine (United States)</i> , 2019, 98, e15064.	0.4	8
670	Longitudinal monitoring of KRAS-mutated circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer. <i>PLoS ONE</i> , 2019, 14, e0227366.	1.1	57
671	Genetic polymorphisms and pancreatic cancer risk. <i>Medicine (United States)</i> , 2019, 98, e16541.	0.4	7
672	Comment on "Surgery Improves Survival After Neoadjuvant Therapy for Borderline and Locally Advanced Pancreatic Cancer". <i>Annals of Surgery</i> , 2019, 270, e138-e139.	2.1	2
673	Clinical significance of stromal ER and PR expression in periampullary adenocarcinoma. <i>Biomarker Research</i> , 2019, 7, 26.	2.8	1
674	Epidermal Growth Factor Receptor and Its Role in Pancreatic Cancer Treatment Mediated by Nanoparticles. <i>International Journal of Nanomedicine</i> , 2019, Volume 14, 9693-9706.	3.3	41
675	Advances of pathological complete response after neoadjuvant therapy for pancreatic cancer. <i>Journal of Pancreatology</i> , 2019, 2, 11-15.	0.3	9

#	ARTICLE	IF	CITATIONS
676	A case report of a dramatic response to olaparib in a patient with metastatic pancreatic cancer harboring a germline BRCA2 mutation. <i>Medicine (United States)</i> , 2019, 98, e17443.	0.4	5
677	Study on the treatment of pancreatic cancer with integrated traditional Chinese and Western medicine. <i>Medicine (United States)</i> , 2019, 98, e17975.	0.4	3
678	Phase I/II Trial of Neoadjuvant Oregovomab-based Chemoimmunotherapy Followed by Stereotactic Body Radiotherapy and Nelfinavir For Locally Advanced Pancreatic Adenocarcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 755-760.	0.6	17
679	Pancreatic cancer surgery with vascular resection: current concepts and perspectives. <i>Journal of Pancreatology</i> , 2019, 2, 1-5.	0.3	17
680	Minimally Invasive Surgical Site Infection in Procedure-Targeted ACS NSQIP Pancreaticoduodenectomies. <i>Journal of Surgical Research</i> , 2019, 233, 183-191.	0.8	10
681	A single-arm, phase II trial of neoadjuvant gemcitabine and S1 in patients with resectable and borderline resectable pancreatic adenocarcinoma: PREP-01 study. <i>Journal of Gastroenterology</i> , 2019, 54, 194-203.	2.3	61
682	A review of lifestyle, metabolic risk factors, and blood-based biomarkers for early diagnosis of pancreatic ductal adenocarcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 330-345.	1.4	16
683	Phase I trial of concurrent stereotactic body radiotherapy and nelfinavir for locally advanced borderline or unresectable pancreatic adenocarcinoma. <i>Radiotherapy and Oncology</i> , 2019, 132, 55-62.	0.3	24
684	Neoadjuvant Treatment for Pancreatic Cancer. <i>Seminars in Oncology</i> , 2019, 46, 19-27.	0.8	76
685	Potential use of aptamers for diagnosis and treatment of pancreatic cancer. <i>Journal of Drug Targeting</i> , 2019, 27, 853-865.	2.1	6
686	Targeting carbon nanotubes based on IGF-1R for photothermal therapy of orthotopic pancreatic cancer guided by optical imaging. <i>Biomaterials</i> , 2019, 195, 13-22.	5.7	94
687	Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis. <i>Oncologist</i> , 2019, 24, 945-954.	1.9	13
688	“Shades of Gray” in pancreatic ductal adenocarcinoma: Reappraisals on resectability criteria. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 133, 17-24.	2.0	3
689	Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma. <i>Digestive Surgery</i> , 2019, 36, 455-461.	0.6	26
690	EUS-Guided Fiducial Placement. , 2019, , 95-107.		1
691	Biliary Metal Stent Insertion. , 2019, , 206-215.e2.		0
692	Significance of neoadjuvant therapy for borderline resectable pancreatic cancer: a multicenter retrospective study. <i>Langenbeck's Archives of Surgery</i> , 2019, 404, 167-174.	0.8	20
693	Selecting chemotherapy for pancreatic cancer: Far away or so close?. <i>Seminars in Oncology</i> , 2019, 46, 39-47.	0.8	12

#	ARTICLE	IF	CITATIONS
694	Optimizing the outcomes of pancreatic cancer surgery. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 11-26.	12.5	546
695	Total Serum Cholesterol and Pancreatic Cancer: A Nested Caseâ€“Control Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 363-369.	1.1	23
696	Meta-analysis of FOLFIRINOX regimen as the first-line chemotherapy for locally advanced pancreatic cancer and borderline resectable pancreatic cancer. <i>Clinical and Experimental Medicine</i> , 2019, 19, 149-157.	1.9	10
697	Outcome of Patients with Borderline Resectable Pancreatic Cancer in the Contemporary Era of Neoadjuvant Chemotherapy. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 112-121.	0.9	54
698	Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX. <i>Annals of Surgery</i> , 2019, 269, 733-740.	2.1	235
699	A Novel Approach for Hepatic Arterial Reconstruction after Total Pancreatectomy with Common Hepatic Artery Resection Using Inferior Phrenic Artery. <i>Digestive Surgery</i> , 2019, 36, 99-103.	0.6	4
700	Plasma miR-181a-5p Downregulation Predicts Response and Improved Survival After FOLFIRINOX in Pancreatic Ductal Adenocarcinoma. <i>Annals of Surgery</i> , 2020, 271, 1137-1147.	2.1	47
701	Phase 2 Trial of Neoadjuvant FOLFIRINOX and Intensity Modulated Radiation Therapy Concurrent With Fixed-Dose Rate-Gemcitabine in Patients With Borderline Resectable Pancreatic Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 124-133.	0.4	28
702	Novel Prognostic Implications of DUPAN-2 in the Era of Initial Systemic Therapy for Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , 2020, 27, 2081-2089.	0.7	12
703	Screening and Identification of Key Biomarkers in Pancreatic Cancer: Evidence from Bioinformatic Analysis. <i>Journal of Computational Biology</i> , 2020, 27, 1079-1091.	0.8	2
704	A unifying paradigm for transcriptional heterogeneity and squamous features in pancreatic ductal adenocarcinoma. <i>Nature Cancer</i> , 2020, 1, 59-74.	5.7	124
705	Update on Management Periampullary/Pancreatic Head Cancer. <i>Indian Journal of Surgery</i> , 2020, , 1.	0.2	1
706	Oncologic impact of preoperative prognostic nutritional index change in resected pancreatic cancer following neoadjuvant chemotherapy. <i>Pancreatology</i> , 2020, 20, 247-253.	0.5	20
707	Development of a Novel Multiparametric MRI Radiomic Nomogram for Preoperative Evaluation of Early Recurrence in Resectable Pancreatic Cancer. <i>Journal of Magnetic Resonance Imaging</i> , 2020, 52, 231-245.	1.9	58
708	Survival benefits of neoadjuvant chemo(radio)therapy versus surgery first in patients with resectable or borderline resectable pancreatic cancer: a systematic review and meta-analysis. <i>World Journal of Surgical Oncology</i> , 2020, 18, 1.	0.8	86
709	Impact of Neoadjuvant Therapy in Resected Pancreatic Ductal Adenocarcinoma of the Pancreatic Body or Tail on Surgical and Oncological Outcome: A Propensity-Score Matched Multicenter Study. <i>Annals of Surgical Oncology</i> , 2020, 27, 1986-1996.	0.7	31
710	Carcinoma of the Pancreas. , 2020, , 1342-1360.e7.		1
711	Identification of chemoresistanceâ€“related mRNAs based on gemcitabineâ€“resistant pancreatic cancer cell lines. <i>Cancer Medicine</i> , 2020, 9, 1115-1130.	1.3	19

#	ARTICLE	IF	CITATIONS
712	Intraoperative Radiation Therapy (IORT) for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (BR/LA PDAC) in the Era of Modern Neoadjuvant Treatment: Short-Term and Long-Term Outcomes. <i>Annals of Surgical Oncology</i> , 2020, 27, 1400-1406.	0.7	22
713	Metastasis in Pancreatic Ductal Adenocarcinoma: Current Standing and Methodologies. <i>Genes</i> , 2020, 11, 6.	1.0	31
714	Immune checkpoint inhibitors combined with chemotherapy for the treatment of advanced pancreatic cancer patients. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 365-372.	2.0	18
715	SMAD4-Expressing Pancreatic Ductal Adenocarcinomas Have Better Response to Neoadjuvant Therapy and Significantly Lower Lymph Node Metastasis Rates. <i>Pancreas</i> , 2020, 49, 1153-1160.	0.5	5
716	Neoadjuvant therapy in elderly patients receiving FOLFIRINOX or gemcitabine/nab-paclitaxel for borderline resectable or locally advanced pancreatic cancer is feasible and lead to a similar oncological outcome compared to non-aged patients – Results of the RESPECT-Study. <i>Surgical Oncology</i> , 2020, 35, 285-297.	0.8	6
717	Neoadjuvant Chemotherapy in Pancreatic Cancer: An Appraisal of the Current High-Level Evidence. <i>Pharmacology</i> , 2021, 106, 143-153.	0.9	61
718	Cannabidiol and Oxygen-Ozone Combination Induce Cytotoxicity in Human Pancreatic Ductal Adenocarcinoma Cell Lines. <i>Cancers</i> , 2020, 12, 2774.	1.7	20
719	Fisetin inhibits proliferation of pancreatic adenocarcinoma by inducing DNA damage via RFXAP/KDM4A-dependent histone H3K36 demethylation. <i>Cell Death and Disease</i> , 2020, 11, 893.	2.7	31
720	Commentary: Anatomic versus biologic resectability: The role of predictive biomarkers in guiding surgical management. <i>Surgery</i> , 2020, 168, 1017-1018.	1.0	3
721	Non-coding RNA biomarkers in pancreatic ductal adenocarcinoma. <i>Seminars in Cancer Biology</i> , 2021, 75, 153-168.	4.3	32
722	The identification of candidate effective combination regimens for pancreatic cancer using the histoculture drug response assay. <i>Scientific Reports</i> , 2020, 10, 12004.	1.6	6
723	The Impact of Prolonged Chemotherapy to Surgery Interval and Neoadjuvant Radiotherapy on Pathological Complete Response and Overall Survival in Pancreatic Cancer Patients. <i>Clinical Medicine Insights: Oncology</i> , 2020, 14, 117955492091940.	0.6	2
724	Neoadjuvant Phase II Trial of Chemoradiotherapy in Patients With Resectable and Borderline Resectable Pancreatic Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 435-441.	0.6	9
725	Radiographic portal or superior mesenteric vein invasion is an independent prognostic factor in non-metastatic pancreatic ductal adenocarcinoma: A missing block of clinical T staging?. <i>Pancreatology</i> , 2020, 20, 952-959.	0.5	2
726	Oligometastatic Pancreatic Cancer to the Liver in the Era of Neoadjuvant Chemotherapy: Which Role for Conversion Surgery? A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2020, 12, 3402.	1.7	23
727	The Present Status of Immuno-Oncolytic Viruses in the Treatment of Pancreatic Cancer. <i>Viruses</i> , 2020, 12, 1318.	1.5	12
728	Utilization of chemoradiation therapy provides strongest protective effect for avoidance of postoperative pancreatic fistula following pancreaticoduodenectomy: A NSQIP analysis. <i>Journal of Surgical Oncology</i> , 2020, 122, 1604-1611.	0.8	5
729	Identification of Patients with Pancreatic Cancer by Electron Paramagnetic Resonance Spectroscopy of Fatty Acid Binding to Human Serum Albumin. <i>ACS Pharmacology and Translational Science</i> , 2020, 3, 1188-1198.	2.5	4

#	ARTICLE	IF	CITATIONS
730	Chemotherapeutic efficacy of cucurmosin for pancreatic cancer as an alternative of gemcitabine: a comparative metabolomic study. <i>Gland Surgery</i> , 2020, 9, 1428-1442.	0.5	3
731	Impact of neoadjuvant chemotherapy and stereotactic body radiation therapy (SBRT) on R0 resection rate for borderline resectable and locally advanced pancreatic cancer. <i>Hpb</i> , 2021, 23, 1072-1083.	0.1	16
732	A machine learning approach identified a diagnostic model for pancreatic cancer through using circulating microRNA signatures. <i>Pancreatology</i> , 2020, 20, 1195-1204.	0.5	41
733	Gemcitabine-Based Neoadjuvant Treatment in Borderline Resectable Pancreatic Ductal Adenocarcinoma: A Meta-Analysis of Individual Patient Data. <i>Frontiers in Oncology</i> , 2020, 10, 1112.	1.3	12
734	Neoadjuvant therapy in pancreatic cancer: what is the true oncological benefit?. <i>Langenbeck's Archives of Surgery</i> , 2020, 405, 879-887.	0.8	7
735	Neoadjuvant Therapy. <i>Advances in Surgery</i> , 2020, 54, 49-68.	0.6	5
736	Novel strategies using modern radiotherapy to improve pancreatic cancer outcomes: toward a new standard?. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592093609.	1.4	21
737	<p>Enhancement of Antitumor Efficacy of Paclitaxel-Loaded PEGylated Liposomes by N,N-Dimethyl Tertiary Amino Moiety in Pancreatic Cancer</p>. <i>Drug Design, Development and Therapy</i> , 2020, Volume 14, 2945-2957.	2.0	6
738	The safety and efficacy of endoscopic ultrasound-guided ablation therapy for solid pancreatic tumors: a systematic review. <i>Scandinavian Journal of Gastroenterology</i> , 2020, 55, 1121-1131.	0.6	19
739	Immunological combination treatment holds the key to improving survival in pancreatic cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 2897-2911.	1.2	14
740	Advanced Pancreatic Ductal Adenocarcinoma: Moving Forward. <i>Cancers</i> , 2020, 12, 1955.	1.7	26
741	Diverse transitions in diabetes status during the clinical course of patients with resectable pancreatic cancer. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 1403-1411.	0.6	6
742	Prognostic Impact of Coagulation Activity in Patients Undergoing Curative Resection for Pancreatic Ductal Adenocarcinoma. <i>In Vivo</i> , 2020, 34, 2845-2850.	0.6	4
743	Radiographic Response of Vessel Involvement and Resectability After Neoadjuvant Chemoradiation in Patients With Locally Advanced Pancreatic Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 776-783.	0.6	1
744	Objective assessment of tumor regression in post-neoadjuvant therapy resections for pancreatic ductal adenocarcinoma: comparison of multiple tumor regression grading systems. <i>Scientific Reports</i> , 2020, 10, 18278.	1.6	29
745	Elaborating piperazinyl-fuopyrimidine based scaffolds as phosphoinositol-3-kinase enzyme alpha (PI3K±) inhibitors to combat pancreatic cancer. <i>RSC Advances</i> , 2020, 10, 32103-32112.	1.7	6
746	Sarcopenia as a prognostic factor in patients with recurrent pancreatic cancer: a retrospective study. <i>World Journal of Surgical Oncology</i> , 2020, 18, 221.	0.8	19
747	US-Guided Percutaneous Radiofrequency Ablation of Locally Advanced Pancreatic Adenocarcinoma: A 5-Year High-Volume Center's Experience. <i>Ultraschall in Der Medizin</i> , 2022, 43, 380-386.	0.8	6

#	ARTICLE	IF	CITATIONS
748	A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pancreatic cancer: the nITRO trial. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592094796.	1.4	9
749	Arterial resection during pancreatectomy for pancreatic ductal adenocarcinoma with arterial invasion. <i>Medicine (United States)</i> , 2020, 99, e22115.	0.4	9
750	Role of miR-30a-3p Regulation of Oncogenic Targets in Pancreatic Ductal Adenocarcinoma Pathogenesis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6459.	1.8	13
751	Gemcitabine/nab-paclitaxel with pamrevlumab: a novel drug combination and trial design for the treatment of locally advanced pancreatic cancer. <i>ESMO Open</i> , 2020, 5, e000668.	2.0	45
752	Diversity in the Extracellular Vesicle-Derived Microbiome of Tissues According to Tumor Progression in Pancreatic Cancer. <i>Cancers</i> , 2020, 12, 2346.	1.7	19
753	<p>Locally Advanced Pancreatic Ductal Adenocarcinoma: Challenges and Progress</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 12705-12720.	1.0	16
754	Changes and prognostic impact of inflammatory nutritional factors during neoadjuvant chemoradiotherapy for patients with resectable and borderline resectable pancreatic cancer. <i>BMC Gastroenterology</i> , 2020, 20, 423.	0.8	10
755	The Emerging Role of miRNAs for the Radiation Treatment of Pancreatic Cancer. <i>Cancers</i> , 2020, 12, 3703.	1.7	13
756	Gastric cancer following pancreaticoduodenectomy: Experience from a high-volume center and review of existing literature. <i>Surgery Open Science</i> , 2020, 2, 32-40.	0.5	5
757	Long-term survival after pancreaticoduodenectomy in patients with ductal adenocarcinoma of the pancreatic head. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2021, 20, 271-278.	0.6	7
758	Target Lesion Failure With Current Drug-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 2868-2878.	1.1	22
759	Relationship between surgical R0 resectability and findings of peripancreatic vascular invasion on CT imaging after neoadjuvant S-1 and concurrent radiotherapy in patients with borderline resectable pancreatic cancer. <i>BMC Cancer</i> , 2020, 20, 1184.	1.1	3
760	The Role of Endoscopic Ultrasound in Pancreatic Cancer Staging in the Era of Neoadjuvant Therapy and Personalised Medicine. <i>GE Portuguese Journal of Gastroenterology</i> , 2021, 28, 111-120.	0.3	4
761	Mechanistic target of rapamycin in the tumor microenvironment and its potential as a therapeutic target for pancreatic cancer. <i>Cancer Letters</i> , 2020, 485, 1-13.	3.2	10
762	H₂Mab-19 Anti-Human Epidermal Growth Factor Receptor 2 Monoclonal Antibody Therapy Exerts Antitumor Activity in Pancreatic Cancer Xenograft Models. <i>Monoclonal Antibodies in Immunodiagnosis and Immunotherapy</i> , 2020, 39, 61-65.	0.8	6
763	The Roles of Frequently Mutated Genes of Pancreatic Cancer in Regulation of Tumor Microenvironment. <i>Technology in Cancer Research and Treatment</i> , 2020, 19, 153303382092096.	0.8	14
764	Polymer nanoparticle-assisted chemotherapy of pancreatic cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592091597.	1.4	24
765	Distal pancreatectomy with en bloc celiac axis resection for pancreatic cancer: a pooled analysis of 109 cases. <i>Updates in Surgery</i> , 2020, 72, 709-715.	0.9	1

#	ARTICLE	IF	CITATIONS
766	Preoperative Chemotherapy for Pancreatic Cancer Improves Survival and R0 Rate Even in Early Stage I. <i>Journal of Gastrointestinal Surgery</i> , 2020, 24, 2409-2415.	0.9	15
767	Targeting immune checkpoints: Building better therapeutic puzzle in pancreatic cancer combination therapy. <i>European Journal of Cancer Care</i> , 2020, 29, e13268.	0.7	4
768	Benefits of Conversion Surgery after Multimodal Treatment for Unresectable Pancreatic Ductal Adenocarcinoma. <i>Cancers</i> , 2020, 12, 1428.	1.7	10
769	Biomarker Panel for the Diagnosis of Pancreatic Ductal Adenocarcinoma. <i>Cancers</i> , 2020, 12, 1443.	1.7	21
770	Metabolic Profiling of Early and Late Recurrent Pancreatic Ductal Adenocarcinoma Using Patient-Derived Organoid Cultures. <i>Cancers</i> , 2020, 12, 1440.	1.7	16
771	A novel natural product, britanin, inhibits tumor growth of pancreatic cancer by suppressing nuclear factor- κ B activation. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 699-709.	1.1	9
772	Landscape of Health-Related Quality of Life in Patients With Early-Stage Pancreatic Cancer Receiving Adjuvant or Neoadjuvant Chemotherapy. <i>Pancreas</i> , 2020, 49, 393-407.	0.5	15
773	Immunotherapy and radiation therapy for gastrointestinal malignancies: hope or hype?. <i>Translational Gastroenterology and Hepatology</i> , 2020, 5, 21-21.	1.5	2
774	Myeloid derived suppressor cells are reduced and T regulatory cells stabilised in patients with advanced pancreatic cancer treated with gemcitabine and intravenous omega 3. <i>Annals of Translational Medicine</i> , 2020, 8, 172-172.	0.7	8
775	Isolation and mutational assessment of pancreatic cancer extracellular vesicles using a microfluidic platform. <i>Biomedical Microdevices</i> , 2020, 22, 23.	1.4	28
776	PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications. <i>Molecular Cancer</i> , 2020, 19, 49.	7.9	145
777	Neoadjuvant or Adjuvant Therapy for Resectable or Borderline Resectable Pancreatic Cancer: Which Is Preferred?. <i>Journal of Clinical Oncology</i> , 2020, 38, 1757-1759.	0.8	19
778	Pathologic complete response following neoadjuvant therapy for pancreatic ductal adenocarcinoma: defining the incidence, predictors, and outcomes. <i>Hpb</i> , 2020, 22, 1569-1576.	0.1	22
779	Carbon Ion Radiotherapy in the Treatment of Pancreatic Cancer. <i>Pancreas</i> , 2020, 49, 737-743.	0.5	5
780	Could Protons and Carbon Ions Be the Silver Bullets Against Pancreatic Cancer?. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4767.	1.8	7
781	Radiation as a Single-Modality Treatment in Localized Pancreatic Cancer. <i>Pancreas</i> , 2020, 49, 822-829.	0.5	2
782	Recurrence Patterns for Pancreatic Ductal Adenocarcinoma after Upfront Resection Versus Resection Following Neoadjuvant Therapy: A Comprehensive Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2020, 9, 2132.	1.0	15
783	Inflammatory IFIT3 renders chemotherapy resistance by regulating post-translational modification of VDAC2 in pancreatic cancer. <i>Theranostics</i> , 2020, 10, 7178-7192.	4.6	29

#	ARTICLE	IF	CITATIONS
784	CYR61/CCN1 expression in resected pancreatic ductal adenocarcinoma: A retrospective pilot study of the interaction between the tumors and their surrounding microenvironment. <i>Heliyon</i> , 2020, 6, e03842.	1.4	4
785	Respect - A multicenter retrospective study on preoperative chemotherapy in locally advanced and borderline resectable pancreatic cancer. <i>Pancreatology</i> , 2020, 20, 1131-1138.	0.5	16
786	Prognostic and Clinicopathological Significance of C-Reactive Protein to Albumin Ratio in Patients With Pancreatic Cancer: A Meta-Analysis. <i>Dose-Response</i> , 2020, 18, 155932582093129.	0.7	11
787	Real-World Assessment of Health Care Costs for Patients with Metastatic Pancreatic Cancer Following Initiation of First-Line Chemotherapy. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2020, 26, 872-878.	0.5	0
788	A phase 1b trial of concurrent immunotherapy and irreversible electroporation in the treatment of locally advanced pancreatic adenocarcinoma. <i>Surgery</i> , 2020, 168, 610-616.	1.0	33
789	Neoadjuvant Treatment in Patients With Resectable and Borderline Resectable Pancreatic Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 41.	1.3	68
790	Serotonin-RhoA/ROCK axis promotes acinar-to-ductal metaplasia in caerulein-induced chronic pancreatitis. <i>Biomedicine and Pharmacotherapy</i> , 2020, 125, 109999.	2.5	26
791	MiR-139-5p/SLC7A11 inhibits the proliferation, invasion and metastasis of pancreatic carcinoma via PI3K/Akt signaling pathway. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2020, 1866, 165747.	1.8	44
792	Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 1763-1773.	0.8	665
793	Borderline or locally advanced pancreatic adenocarcinoma: A single center experience on the FOLFIRINOX induction regimen. <i>European Journal of Surgical Oncology</i> , 2020, 46, 1510-1515.	0.5	11
794	Role of lymphadenectomy, adjuvant chemotherapy, and treatment at high-volume centers in patients with resected pancreatic cancer—a distinct view on lymph node yield. <i>Langenbeck's Archives of Surgery</i> , 2020, 405, 43-54.	0.8	13
796	A prospective observational study of the clinical and pathological impact of stereotactic body radiotherapy (SBRT) as a neoadjuvant strategy of chemoradiation in pancreatic cancer. <i>Clinical and Translational Oncology</i> , 2020, 22, 1499-1505.	1.2	15
797	Glycofullerenes as non-receptor tyrosine kinase inhibitors- towards better nanotherapeutics for pancreatic cancer treatment. <i>Scientific Reports</i> , 2020, 10, 260.	1.6	20
798	Does neoadjuvant therapy for pancreatic head adenocarcinoma increase postoperative morbidity? A systematic review of the literature with meta-analysis. <i>Journal of Surgical Oncology</i> , 2020, 121, 881-892.	0.8	14
799	The AGITG GAP Study: A Phase II Study of Perioperative Gemcitabine and Nab-Paclitaxel for Resectable Pancreas Cancer. <i>Annals of Surgical Oncology</i> , 2020, 27, 2506-2515.	0.7	18
800	High expression of olfactomedin-4 is correlated with chemoresistance and poor prognosis in pancreatic cancer. <i>PLoS ONE</i> , 2020, 15, e0226707.	1.1	16
802	Targeting hallmarks of cancer to enhance radiosensitivity in gastrointestinal cancers. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 298-313.	8.2	151
803	Imaging diagnosis and staging of pancreatic ductal adenocarcinoma: a comprehensive review. <i>Insights Into Imaging</i> , 2020, 11, 58.	1.6	66

#	ARTICLE	IF	CITATIONS
804	The role of intraoperative radiation therapy in resectable pancreatic cancer: a systematic review and meta-analysis. <i>Radiation Oncology</i> , 2020, 15, 76.	1.2	9
805	Sustained Carbohydrate Antigen 19-9 Response to Neoadjuvant Chemotherapy in Borderline Resectable Pancreatic Cancer Predicts Progression and Survival. <i>Oncologist</i> , 2020, 25, 859-866.	1.9	21
806	In Vivo Flow Cytometric Evaluation of Circulating Metastatic Pancreatic Tumor Cells after High-Intensity Focused Ultrasound Therapy. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2020, 97, 900-908.	1.1	6
807	Multidisciplinary consensus statement on the clinical management of patients with pancreatic cancer. <i>Clinical and Translational Oncology</i> , 2020, 22, 1963-1975.	1.2	26
808	Usefulness of ¹⁸ F-fluorodeoxyglucose positron emission tomography/computed tomography for predicting the prognosis and treatment response of neoadjuvant therapy for pancreatic ductal adenocarcinoma. <i>Cancer Medicine</i> , 2020, 9, 4059-4068.	1.3	23
809	The Outcome of <i>Ex Vivo</i> TIL Expansion Is Highly Influenced by Spatial Heterogeneity of the Tumor T-Cell Repertoire and Differences in Intrinsic <i>In Vitro</i> Growth Capacity between T-Cell Clones. <i>Clinical Cancer Research</i> , 2020, 26, 4289-4301.	3.2	46
810	Synchronous arterial resections in pancreatic cancer – still a matter of debate?. <i>European Journal of Surgical Oncology</i> , 2021, 47, 480-482.	0.5	6
811	Prognostic significance of dissecting the nerve plexus around the common hepatic artery in pancreatic cancer. <i>Langenbeck's Archives of Surgery</i> , 2021, 406, 679-689.	0.8	3
812	<i>Gastrointestinal.</i> , 2021,, 135-144.e6.		0
813	Prognostic factors in patients with locally advanced or borderline resectable pancreatic ductal adenocarcinoma: chemotherapy vs. chemoradiotherapy. <i>Abdominal Radiology</i> , 2021, 46, 655-666.	1.0	6
814	Vascular resection during pancreatotomy for pancreatic head cancer: A technical issue or a prognostic sign?. <i>Surgery</i> , 2021, 169, 403-410.	1.0	18
815	Temporal Assessment of Prognostic Factors in Patients With Pancreatic Ductal Adenocarcinoma Undergoing Neoadjuvant Treatment and Resection. <i>Journal of Surgical Research</i> , 2021, 257, 605-615.	0.8	7
816	Periadventitial dissection of the superior mesenteric artery for locally advanced pancreatic cancer: Surgical planning with the halo sign and string sign. <i>Surgery</i> , 2021, 169, 1026-1031.	1.0	37
817	An iodine-125 seed strand combined with a metal stent versus a metal stent alone for obstructive jaundice caused by pancreatic ductal adenocarcinoma. <i>Brachytherapy</i> , 2021, 20, 446-453.	0.2	2
818	SPARC, a phase-I trial of preoperative, margin intensified, stereotactic body radiation therapy for pancreatic cancer. <i>Radiotherapy and Oncology</i> , 2021, 155, 278-284.	0.3	11
819	Reshaping preoperative treatment of pancreatic cancer in the era of precision medicine. <i>Annals of Oncology</i> , 2021, 32, 183-196.	0.6	48
820	Radiotherapy for Resectable and Borderline Resectable Pancreas Cancer: When and Why?. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 843-848.	0.9	11
821	Important CT and histopathological findings for recurrence and overall survival in patients with pancreatic ductal adenocarcinoma who underwent surgery after neoadjuvant FOLFIRINOX. <i>European Radiology</i> , 2021, 31, 3616-3626.	2.3	4

#	ARTICLE	IF	CITATIONS
822	Neoadjuvant chemoradiation is associated with decreased lymph node ratio in borderline resectable pancreatic cancer: A propensity score matched analysis. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2021, 20, 74-79.	0.6	3
823	Prognostic Factors of Survival After Neoadjuvant Treatment and Resection for Initially Unresectable Pancreatic Cancer. <i>Annals of Surgery</i> , 2021, 273, 154-162.	2.1	87
824	Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer. <i>Annals of Surgery</i> , 2021, 273, 341-349.	2.1	268
825	A pilot study of estrogen receptor (ER) expression in pancreatic ductal adenocarcinoma (PDAC). <i>Translational Gastroenterology and Hepatology</i> , 2021, 6, 9-9.	1.5	7
826	Overexpressed CA12 has prognostic value in pancreatic cancer and promotes tumor cell apoptosis via NF- κ B signaling. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 1557-1564.	1.2	7
827	Induction Chemotherapy for Primarily Unresectable Locally Advanced Pancreatic Adenocarcinoma—Who Will Benefit from a Secondary Resection?. <i>Medicina (Lithuania)</i> , 2021, 57, 77.	0.8	1
828	High ARHGEF2 (GEF-H1) Expression is Associated with Poor Prognosis Via Cell Cycle Regulation in Patients with Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 4733-4743.	0.7	6
829	Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Cancer. , 2021, , 61-74.		0
830	Internal medicine treatment of pancreatic lesions. , 2021, , 141-180.		0
832	Quantitative assessment of the diagnostic role of mucin family members in pancreatic cancer: a meta-analysis. <i>Annals of Translational Medicine</i> , 2021, 9, 192-192.	0.7	9
833	Prognostic Value and Molecular Mechanisms of Proteasome 26S Subunit, Non-ATPase Family Genes for Pancreatic Ductal Adenocarcinoma Patients after Pancreaticoduodenectomy. <i>Journal of Investigative Surgery</i> , 2022, 35, 330-346.	0.6	13
834	Survival equivalence in patients treated for borderline resectable and unresectable locally advanced pancreatic ductal adenocarcinoma: a systematic review and network meta-analysis. <i>Hpb</i> , 2021, 23, 173-186.	0.1	7
835	Improved pentamethine cyanine nanosensors for optoacoustic imaging of pancreatic cancer. <i>Scientific Reports</i> , 2021, 11, 4366.	1.6	9
836	m6A-Mediated Upregulation of LINC00857 Promotes Pancreatic Cancer Tumorigenesis by Regulating the miR-150-5p/E2F3 Axis. <i>Frontiers in Oncology</i> , 2021, 11, 629947.	1.3	24
837	Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 128-138.	3.7	89
838	Impact of multidisciplinary approach and radiologic review on surgical outcome and overall survival of patients with pancreatic cancer: a retrospective cohort study. <i>Tumori</i> , 2022, 108, 147-156.	0.6	2
839	Pancreatic Frozen Section Guides Operative Management With Few Deferrals and Errors. <i>Archives of Pathology and Laboratory Medicine</i> , 2022, 146, 84-91.	1.2	1
840	Personalized Approach to the Role of Endoscopic Ultrasound in the Diagnosis and Management of Pancreaticobiliary Malignancies. <i>Journal of Personalized Medicine</i> , 2021, 11, 180.	1.1	1

#	ARTICLE	IF	CITATIONS
841	Survival after Margin-Positive Resection in the Era of Modern Chemotherapy for Pancreatic Cancer: Do Patients Still Benefit?. <i>Journal of the American College of Surgeons</i> , 2021, 233, 100-109.	0.2	10
842	Pancreatic cancer driver mutations are targetable through distant alternative RNA splicing dependencies. <i>Oncotarget</i> , 2021, 12, 525-533.	0.8	4
843	Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma. <i>JAMA Oncology</i> , 2021, 7, 421.	3.4	159
844	ĐjT and MRI in the assessment of resectable and borderline resectable pancreatic tumors. <i>Annals of HPB Surgery</i> , 2021, 26, 34-47.	0.1	1
845	NUCB1 Suppresses Growth and Shows Additive Effects With Gemcitabine in Pancreatic Ductal Adenocarcinoma via the Unfolded Protein Response. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 641836.	1.8	19
846	Effect and limitation of neoadjuvant chemotherapy for pancreatic ductal adenocarcinoma: consideration from a new perspective. <i>World Journal of Surgical Oncology</i> , 2021, 19, 85.	0.8	6
847	Combination of preoperative fibrinogen and D-dimer as a prognostic indicator in pancreatic ductal adenocarcinoma patients undergoing R0 resection. <i>World Journal of Gastrointestinal Surgery</i> , 2021, 13, 279-302.	0.8	7
848	Supplemental 18F-FDG-PET/CT for Detection of Malignant Transformation of IPMN—A Model-Based Cost-Effectiveness Analysis. <i>Cancers</i> , 2021, 13, 1365.	1.7	1
849	TGFB1/INHBA Homodimer/Nodal-SMAD2/3 Signaling Network: A Pivotal Molecular Target in PDAC Treatment. <i>Molecular Therapy</i> , 2021, 29, 920-936.	3.7	31
850	Mitochondrial uncoupler MB1-47 is efficacious in treating hepatic metastasis of pancreatic cancer in murine tumor transplantation models. <i>Oncogene</i> , 2021, 40, 2285-2295.	2.6	4
851	Clinical Benefits of Conversion Surgery for Unresectable Pancreatic Ductal Adenocarcinoma: A Single-Institution, Retrospective Analysis. <i>Cancers</i> , 2021, 13, 1057.	1.7	8
852	Physical plasma-derived oxidants sensitize pancreatic cancer cells to ferroptotic cell death. <i>Free Radical Biology and Medicine</i> , 2021, 166, 187-200.	1.3	24
853	Multidisciplinary management of locally advanced pancreatic adenocarcinoma: Biology is King. <i>Journal of Surgical Oncology</i> , 2021, 123, 1395-1404.	0.8	2
854	A review of response in neoadjuvant therapy for exocrine pancreatic cancer. <i>Journal of Surgical Oncology</i> , 2021, 123, 1449-1459.	0.8	0
856	The Role of Microtubules in Pancreatic Cancer: Therapeutic Progress. <i>Frontiers in Oncology</i> , 2021, 11, 640863.	1.3	14
857	Change in neoadjuvant chemotherapy could alter the prognosis of patients with pancreatic adenocarcinoma: A case report. <i>World Journal of Clinical Cases</i> , 2021, 9, 3418-3423.	0.3	1
858	Comparison of Clinical Outcomes of Borderline Resectable Pancreatic Cancer According to the Neoadjuvant Chemo-Regimens: Gemcitabine versus FOLFIRINOX. <i>Gut and Liver</i> , 2021, 15, 466-475.	1.4	11
859	Contemporary Reappraisal of Intraoperative Neck Margin Assessment During Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma. <i>JAMA Surgery</i> , 2021, 156, 489.	2.2	8

#	ARTICLE	IF	CITATIONS
860	KRAS, A Prime Mediator in Pancreatic Lipid Synthesis through Extra Mitochondrial Glutamine and Citrate Metabolism. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5070.	1.8	7
861	A Cancer Cell Cluster Marked by LincRNA MEG3 Leads Pancreatic Ductal Adenocarcinoma Metastasis. <i>Frontiers in Oncology</i> , 2021, 11, 656564.	1.3	13
862	Quantifying and Assessing the Dosimetric Impact of Changing Gas Volumes Throughout the Course of VMAT Radiation Therapy of Upper Gastrointestinal Tumors. <i>Advances in Radiation Oncology</i> , 2021, 6, 100650.	0.6	0
863	Development and Validation of a 7-Gene Prognostic Signature to Improve Survival Prediction in Pancreatic Ductal Adenocarcinoma. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 676291.	1.6	7
864	The first real-time intrafraction target position monitoring in pancreas SBRT on an Elekta linear accelerator. <i>Physical and Engineering Sciences in Medicine</i> , 2021, 44, 625-638.	1.3	5
865	The Landmark Series: Preoperative Therapy for Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 4104-4129.	0.7	17
866	Near Complete Pathologic Response to PD-1 Inhibitor and Radiotherapy in a Patient with Locally Advanced Pancreatic Ductal Adenocarcinoma. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 3537-3544.	1.0	7
867	MicroRNA-203-3p inhibits the proliferation, invasion and migration of pancreatic cancer cells by downregulating fibroblast growth factor-2. <i>Oncology Letters</i> , 2021, 22, 626.	0.8	7
868	Impact of DNA repair and reactive oxygen species levels on radioresistance in pancreatic cancer. <i>Radiotherapy and Oncology</i> , 2021, 159, 265-276.	0.3	9
869	Added Value of Radiotherapy Following Neoadjuvant FOLFIRINOX for Resectable and Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis. <i>Annals of Surgical Oncology</i> , 2021, 28, 8297-8308.	0.7	19
870	Borderline resectable pancreatic cancer: Certainties and controversies. <i>World Journal of Gastrointestinal Surgery</i> , 2021, 13, 516-528.	0.8	6
871	The Impact of Thromboprophylaxis on the Survival of Patients with Advanced Pancreatic Cancer. The Pancreatic Cancer and Tinzaparin (PaCT) Study. <i>Cancers</i> , 2021, 13, 2884.	1.7	11
872	An Improved Staging System for Locally Advanced Pancreatic Cancer: A Critical Need in the Multidisciplinary Era. <i>Annals of Surgical Oncology</i> , 2021, 28, 6201-6210.	0.7	12
873	Trends in the treatment of pancreatic cancer in Japan. <i>BioScience Trends</i> , 2021, 15, 135-137.	1.1	5
875	How to approach pancreatic cancer after neoadjuvant treatment: assessment of resectability using multidetector CT and tumor markers. <i>European Radiology</i> , 2022, 32, 56-66.	2.3	11
876	Mir-320b Inhibits Pancreatic Cancer Cell Proliferation by Targeting FOXM1. <i>Current Pharmaceutical Biotechnology</i> , 2021, 22, 1106-1113.	0.9	8
877	Concurrent Nab-paclitaxel and Radiotherapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2021, 44, 469-474.	0.6	4
878	Extended Venous Resections for Borderline Resectable Pancreatic Head Adenocarcinoma: A Retrospective Studies of Nine Cases. <i>Healthcare (Switzerland)</i> , 2021, 9, 978.	1.0	0

#	ARTICLE	IF	CITATIONS
879	Factors affecting overall survival in ductal adenocarcinoma of the pancreatic head. Experience of one center. <i>Malignant Tumours</i> , 2021, 11, 20-28.	0.1	0
880	Intra-Arterial Therapies for Liver Metastatic Breast Cancer: A Systematic Review and Meta-Analysis. <i>CardioVascular and Interventional Radiology</i> , 2021, 44, 1868-1882.	0.9	1
881	Trial protocol: a randomised controlled trial to verify the non-inferiority of a partially covered self-expandable metal stent to an uncovered self-expandable metal stent for biliary drainage during neoadjuvant therapy in patients with pancreatic cancer with obstructive jaundice (PUN-NAC trial). <i>BMJ Open</i> , 2021, 11, e045698.	0.8	0
882	Local Control and Survival After Induction Chemotherapy and Ablative Radiation Versus Resection for Pancreatic Ductal Adenocarcinoma With Vascular Involvement. <i>Annals of Surgery</i> , 2021, 274, 894-901.	2.1	15
883	A genetic variant conferred high expression of CAV2 promotes pancreatic cancer progression and associates with poor prognosis. <i>European Journal of Cancer</i> , 2021, 151, 94-105.	1.3	10
884	Systematic review and meta-analysis of diagnostic performance of CT imaging for assessing resectability of pancreatic ductal adenocarcinoma after neoadjuvant therapy: importance of CT criteria. <i>Abdominal Radiology</i> , 2021, 46, 5201-5217.	1.0	10
885	Borderline resectable pancreatic cancer and vascular resections in the era of neoadjuvant therapy. <i>World Journal of Clinical Cases</i> , 2021, 9, 5398-5407.	0.3	4
886	Impact of Tumor Size on the Outcomes of Patients with Resectable Distal Pancreatic Cancer: Lessons Learned from a Series of 158 Radical Resections. <i>Annals of Surgical Oncology</i> , 2022, 29, 378-388.	0.7	8
887	Efficacy and Safety of Neoadjuvant Gemcitabine Plus Nab-Paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Cancer—A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2021, 13, 4326.	1.7	18
888	Clinical nutrition as part of the treatment pathway of pancreatic cancer patients: an expert consensus. <i>Clinical and Translational Oncology</i> , 2022, 24, 112-126.	1.2	12
889	Combined multiagent chemotherapy and radiotherapy is associated with prolonged overall survival in patients with non-operatively managed stage II-III pancreatic adenocarcinoma. <i>Hpb</i> , 2021, , .	0.1	2
890	CT radiomic features of photodynamic priming in clinical pancreatic adenocarcinoma treatment. <i>Physics in Medicine and Biology</i> , 2021, 66, 175006.	1.6	12
891	Fluorescence Imaging Using Enzyme-Activatable Probes for Real-Time Identification of Pancreatic Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 714527.	1.3	7
892	Clinical significance and predictors of complete or near-complete histological response to preoperative chemoradiotherapy in patients with localized pancreatic ductal adenocarcinoma. <i>Pancreatology</i> , 2021, 21, 1482-1490.	0.5	4
893	Utility of palliative EUS-guided biliary drainage using lumen-apposing metal stents: a prospective multicenter feasibility study (with video). <i>Gastrointestinal Endoscopy</i> , 2021, 94, 321-328.	0.5	10
894	Neutrophil-to-lymphocyte ratio and carbohydrate antigen 19-9 as prognostic markers for advanced pancreatic cancer patients receiving first-line chemotherapy. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 915-928.	0.8	10
895	Challenges and Future Perspectives of Immunotherapy in Pancreatic Cancer. <i>Cancers</i> , 2021, 13, 4235.	1.7	16
896	Combined treatment of patients with localized pancreatic cancer of elderly and senile age. <i>Meditsinskiy Sovet</i> , 2021, , 122-128.	0.1	0

#	ARTICLE	IF	CITATIONS
897	Analysis of the Curative Effect of Neoadjuvant Therapy on Pancreatic Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 695645.	1.3	3
898	Prognostic impact of splenic vessel involvement and tumor size in distal pancreatectomy for adenocarcinoma: a retrospective multicentric cohort study. <i>Langenbeck's Archives of Surgery</i> , 2022, 407, 153-165.	0.8	6
899	Drug Repurposing, an Attractive Strategy in Pancreatic Cancer Treatment: Preclinical and Clinical Updates. <i>Cancers</i> , 2021, 13, 3946.	1.7	15
900	Should we be reluctant to perform pancreatectomy in patients with chronic liver disease? A single center 10-year experience. <i>Acta Chirurgica Belgica</i> , 2021, , 1-7.	0.2	0
901	Intraobserver agreements in multidisciplinary team assessments of pancreatic cancer patients. <i>Journal of Surgical Oncology</i> , 2021, 124, 1402-1408.	0.8	3
903	Hyperglycemia as a risk factor in pancreatic cancer: A nested case-control study using prediagnostic blood glucose levels. <i>Pancreatology</i> , 2021, 21, 1112-1118.	0.5	7
904	Reproducibility and prognostic significance of area of residual tumor (ART) in post-neoadjuvant resections of pancreatic ductal adenocarcinoma. <i>Pancreatology</i> , 2021, 21, 1506-1515.	0.5	3
905	Vascular resections in minimally invasive surgery for pancreatic cancer. <i>Laparoscopic, Endoscopic, and Robotic Surgery</i> , 2022, 5, 3-9.	0.3	1
906	Impact of conversion surgery on survival in locally advanced pancreatic cancer patients treated with FOLFIRINOX chemotherapy. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2023, 30, 111-121.	1.4	7
907	Histotripsy Ablation Alters the Tumor Microenvironment and Promotes Immune System Activation in a Subcutaneous Model of Pancreatic Cancer. <i>IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control</i> , 2021, 68, 2987-3000.	1.7	31
908	Combining sonodynamic therapy with chemoradiation for the treatment of pancreatic cancer. <i>Journal of Controlled Release</i> , 2021, 337, 371-377.	4.8	21
909	Nab-paclitaxel plus S-1 with or without PD-1 inhibitor in pancreatic ductal adenocarcinoma with only hepatic metastases: a retrospective cohort study. <i>Langenbeck's Archives of Surgery</i> , 2021, , 1.	0.8	3
910	Neoadjuvant Treatment Strategies in Resectable Pancreatic Cancer. <i>Cancers</i> , 2021, 13, 4724.	1.7	18
911	Locally advanced pancreatic cancer: a reliable contraindication to resection in the modern era?. <i>Hpb</i> , 2021, , .	0.1	2
912	Inhibitor Library Screening Identifies Ispinesib as a New Potential Chemotherapeutic Agent for Pancreatic Cancers. <i>Cancer Science</i> , 2021, 112, 4641-4654.	1.7	4
913	Use of FOLFIRINOX or Nab-Paclitaxel Plus Gemcitabine for the Treatment of Locally Advanced Pancreatic Adenocarcinoma: A Single Institution Observational Study. <i>Cancers</i> , 2021, 13, 4939.	1.7	3
914	3D printing and pancreatic surgery. , 2022, , 101-127.		0
915	Updates on adjuvant and neoadjuvant treatment strategies for surgically resectable and borderline resectable pancreatic ductal adenocarcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110458.	1.4	7

#	ARTICLE	IF	CITATIONS
916	Neoadjuvant treatment of localized pancreatic adenocarcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 0-0.	0.6	1
917	A Prognostic Model of M6a-Related Lipid Metabolism-Associated Genes in Pancreatic Adenocarcinoma. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
918	S100A16 promotes metastasis and progression of pancreatic cancer through FGF19-mediated AKT and ERK1/2 pathways. <i>Cell Biology and Toxicology</i> , 2021, 37, 555-571.	2.4	28
921	Impact of Treatment Sequencing on Survival for Patients with Locally Advanced Gastric Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 2856-2865.	0.7	3
922	Plasma protein biomarkers for early detection of pancreatic ductal adenocarcinoma. <i>International Journal of Cancer</i> , 2021, 148, 2048-2058.	2.3	12
923	ASO Editorial: Nodal Status as a Clinical Tool in the Treatment of Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 1887-1888.	0.7	0
924	Effectiveness of introducing a 20-gauge core biopsy needle with a core trap in EUS-FNA/B for diagnosing pancreatic cancer. <i>BMC Gastroenterology</i> , 2021, 21, 8.	0.8	2
925	Meta-analysis of FOLFIRINOX-based neoadjuvant therapy for locally advanced pancreatic cancer. <i>Medicine (United States)</i> , 2021, 100, e24068.	0.4	13
926	The Role of Imaging in Current Treatment Strategies for Pancreatic Adenocarcinoma. <i>Korean Journal of Radiology</i> , 2021, 22, 23.	1.5	35
927	Adjuvant Therapy for Pancreatic Cancer. <i>Recent Results in Cancer Research</i> , 2012, 196, 65-88.	1.8	22
928	Radiotherapy of the Pancreas: State of the Art in 2012. <i>Recent Results in Cancer Research</i> , 2012, 196, 89-103.	1.8	1
929	Outcomes of Patients with Borderline Resectable Pancreatic Cancer Treated with Combination Chemotherapy. <i>Journal of Gastrointestinal Cancer</i> , 2021, 52, 529-535.	0.6	5
930	Neoadjuvant chemotherapy for primary resectable pancreatic cancer: a systematic review and meta-analysis. <i>Hpb</i> , 2020, 22, 821-832.	0.1	54
931	Neoadjuvant therapy for pancreatic cancer changes the composition of the pancreatic parenchyma. <i>Hpb</i> , 2020, 22, 1631-1636.	0.1	12
932	The quality of pain management in pancreatic cancer: A prospective multi-center study. <i>Pancreatology</i> , 2020, 20, 1511-1518.	0.5	14
933	Magnetic nanoparticle hyperthermia for treating locally advanced unresectable and borderline resectable pancreatic cancers: the role of tumor size and eddy-current heating. <i>International Journal of Hyperthermia</i> , 2020, 37, 108-119.	1.1	27
934	Extrapancreatic Nerve Plexus Invasion on Imaging Predicts Poor Survival After Upfront Surgery for Anatomically Resectable Pancreatic Cancer. <i>Pancreas</i> , 2020, 49, 675-682.	0.5	4
935	Recurrence in Patients Achieving Pathological Complete Response After Neoadjuvant Treatment for Advanced Pancreatic Cancer. <i>Annals of Surgery</i> , 2021, 274, 162-169.	2.1	25

#	ARTICLE	IF	CITATIONS
936	Surgical Complications in a Multicenter Randomized Trial Comparing Preoperative Chemoradiotherapy and Immediate Surgery in Patients With Resectable and Borderline Resectable Pancreatic Cancer (PREOPANC Trial). <i>Annals of Surgery</i> , 2022, 275, 979-984.	2.1	26
937	Neoadjuvant S-1 With Concurrent Radiotherapy Followed by Surgery for Borderline Resectable Pancreatic Cancer. <i>Annals of Surgery</i> , 2022, 276, e510-e517.	2.1	33
939	New Onset of DiabetEs in aSsociation with pancreatic ductal adenocarcinoma (NODES Trial): protocol of a prospective, multicentre observational trial. <i>BMJ Open</i> , 2020, 10, e037267.	0.8	11
940	Pancreatic Cancer: A Review of Risk Factors, Diagnosis, and Treatment. <i>Technology in Cancer Research and Treatment</i> , 2020, 19, 153303382096211.	0.8	107
941	Antiproliferative Effects of Matricine in Gemcitabine-Resistant Human Pancreatic Carcinoma Cells Are Mediated via Mitochondrial-Mediated Apoptosis, Inhibition of Cell Migration, Invasion Suppression, and Mammalian Target of Rapamycin (mTOR)-TOR/PI3K/AKT Signalling Pathway. <i>Medical Science Monitor</i> , 2019, 25, 2943-2949.	0.5	4
942	miRNA-339-5p Plays an Important Role in Invasion and Migration of Pancreatic Cancer Cells. <i>Medical Science Monitor</i> , 2019, 25, 7509-7517.	0.5	36
943	Regional Intra-Arterial vs. Systemic Chemotherapy for Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>PLoS ONE</i> , 2012, 7, e40847.	1.1	39
944	CXCL12 Chemokine Expression Suppresses Human Pancreatic Cancer Growth and Metastasis. <i>PLoS ONE</i> , 2014, 9, e90400.	1.1	74
945	Pancreatic Ductal Adenocarcinoma Contains an Effector and Regulatory Immune Cell Infiltrate that Is Altered by Multimodal Neoadjuvant Treatment. <i>PLoS ONE</i> , 2014, 9, e96565.	1.1	108
946	Prediction of in-hospital mortality after pancreatic resection in pancreatic cancer patients: A boosting approach via a population-based study using health administrative data. <i>PLoS ONE</i> , 2017, 12, e0178757.	1.1	17
947	Comparison between long and short-term venous patencies after pancreatoduodenectomy or total pancreatectomy with portal/superior mesenteric vein resection stratified by reconstruction type. <i>PLoS ONE</i> , 2020, 15, e0240737.	1.1	9
948	Neoadjuvant therapy for advanced pancreatic neuroendocrine tumors: an emerging treatment modality?. <i>Hormones</i> , 2015, 15, 15-22.	0.9	17
949	Current Controversies in the Stage-Specific Multidisciplinary Management of Pancreatic Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014, , e157-e164.	1.8	5
950	Pattern of care and survival of pancreatic ductal adenocarcinoma in a multi-disciplinary high-volume centre. <i>Gastroenterology & Hepatology (Bartlesville, Okla)</i> , 2018, 9, .	0.0	1
951	Disputable issues of biliary drainage procedures in malignant obstructive jaundice. <i>Annals of HPB Surgery</i> , 2019, 24, 111-122.	0.1	7
952	Overexpression of KLF5 is associated with poor survival and G1/S progression in pancreatic cancer. <i>Aging</i> , 2019, 11, 5035-5057.	1.4	25
953	LncRNA PVT1 promotes exosome secretion through YKT6, RAB7, and VAMP3 in pancreatic cancer. <i>Aging</i> , 2020, 12, 10427-10440.	1.4	48
954	Glypican-1-targeted and gemcitabine-loaded liposomes enhance tumor-suppressing effect on pancreatic cancer. <i>Aging</i> , 2020, 12, 19585-19596.	1.4	9

#	ARTICLE	IF	CITATIONS
955	Plasma and tumor levels of Linc-pint are diagnostic and prognostic biomarkers for pancreatic cancer. <i>Oncotarget</i> , 2016, 7, 71773-71781.	0.8	64
956	Prognostic value of GLUT-1 expression in pancreatic cancer: results from 538 patients. <i>Oncotarget</i> , 2017, 8, 19760-19767.	0.8	46
957	An endoscopic ultrasonography-guided interstitial brachytherapy based special treatment-planning system for unresectable pancreatic cancer. <i>Oncotarget</i> , 2017, 8, 79099-79110.	0.8	13
958	Plasma 25-hydroxyvitamin D levels, vitamin D intake, and pancreatic cancer risk or mortality: a meta-analysis. <i>Oncotarget</i> , 2017, 8, 64395-64406.	0.8	33
959	Postoperative course and prognostic value of circulating angiogenic cytokines after pancreatic cancer resection. <i>Oncotarget</i> , 2017, 8, 72315-72323.	0.8	10
960	Inhibition of the MEK/ERK pathway augments nab-paclitaxel-based chemotherapy effects in preclinical models of pancreatic cancer. <i>Oncotarget</i> , 2018, 9, 5274-5286.	0.8	24
961	Involvement of anti-tumor <i>miR-124-3p</i> and its targets in the pathogenesis of pancreatic ductal adenocarcinoma: direct regulation of <i>ITGA3</i> and <i>ITGB1</i> by <i>miR-124-3p</i> . <i>Oncotarget</i> , 2018, 9, 28849-28865.	0.8	35
962	Intensification of induction chemotherapy before consolidation chemoradiotherapy improves progression-free survival and time without treatment in patients with locally advanced pancreatic cancers. <i>Oncotarget</i> , 2018, 9, 31999-32009.	0.8	1
963	An angiotensin-like protein 2 autocrine signaling promotes EMT during pancreatic ductal carcinogenesis. <i>Oncotarget</i> , 2015, 6, 13822-13834.	0.8	47
964	Combination of radiotherapy and vaccination overcomes checkpoint blockade resistance. <i>Oncotarget</i> , 2016, 7, 43039-43051.	0.8	62
965	Pancreatic cancer: treatment approaches and trends. <i>Journal of Cancer Metastasis and Treatment</i> , 2018, 4, 30.	0.5	23
966	Pancreatic cancer from bench to bedside: molecular pathways and treatment options. <i>Annals of Translational Medicine</i> , 2016, 4, 165-165.	0.7	19
967	Neoadjuvant Therapy is Essential for Resectable Pancreatic Cancer. <i>Current Medicinal Chemistry</i> , 2020, 26, 7196-7211.	1.2	9
968	Adipose Triglyceride Lipase (ATGL) Expression Is Associated with Adiposity and Tumor Stromal Proliferation in Patients with Pancreatic Ductal Adenocarcinoma. <i>Anticancer Research</i> , 2017, 37, 699-704.	0.5	25
969	Phase I Study of Nab-Paclitaxel plus Gemcitabine as Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer. <i>Anticancer Research</i> , 2017, 37, 853-858.	0.5	41
970	Neoadjuvant therapy versus upfront surgery for borderline-resectable pancreatic cancer. <i>Minerva Chirurgica</i> , 2020, 75, 15-24.	0.8	3
971	Adjuvant Pancreatic Cancer Management: Towards New Perspectives in 2021. <i>Cancers</i> , 2020, 12, 3866.	1.7	17
972	Short-term effectiveness of radiochemoembolization for selected hepatic metastases with a combination protocol. <i>World Journal of Gastroenterology</i> , 2012, 18, 5249-59.	1.4	4

#	ARTICLE	IF	CITATIONS
973	Neoadjuvant strategies for pancreatic cancer. <i>World Journal of Gastroenterology</i> , 2014, 20, 9374-83.	1.4	17
974	Establishment of an orthotopic pancreatic cancer mouse model: Cells suspended and injected in Matrigel. <i>World Journal of Gastroenterology</i> , 2014, 20, 9476-9485.	1.4	47
975	Pancreatic cancer-improved care achievable. <i>World Journal of Gastroenterology</i> , 2014, 20, 10405.	1.4	16
976	McGill Brisbane Symptom Score for patients with resectable pancreatic head adenocarcinoma. <i>World Journal of Gastroenterology</i> , 2014, 20, 12226.	1.4	6
977	SIBLINGs and SPARC families: Their emerging roles in pancreatic cancer. <i>World Journal of Gastroenterology</i> , 2014, 20, 14747.	1.4	21
978	S-1 in the treatment of pancreatic cancer. <i>World Journal of Gastroenterology</i> , 2014, 20, 15110.	1.4	41
979	Perspectives in the treatment of pancreatic adenocarcinoma. <i>World Journal of Gastroenterology</i> , 2015, 21, 9297.	1.4	124
980	New challenges in perioperative management of pancreatic cancer. <i>World Journal of Gastroenterology</i> , 2015, 21, 2281.	1.4	55
981	Viro-immune therapy: A new strategy for treatment of pancreatic cancer. <i>World Journal of Gastroenterology</i> , 2016, 22, 748.	1.4	16
982	Updated therapeutic outcome for patients with periampullary and pancreatic cancer related to recent translational research. <i>World Journal of Gastroenterology</i> , 2016, 22, 10502.	1.4	3
983	Relationship between autophagy and perineural invasion, clinicopathological features, and prognosis in pancreatic cancer. <i>World Journal of Gastroenterology</i> , 2017, 23, 7232-7241.	1.4	33
984	Surgery for oligometastasis of pancreatic cancer. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2015, 27, 358-67.	0.7	28
985	Pancreatic cancer surgery: past, present, and future. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2015, 27, 332-48.	0.7	69
986	The role of radiotherapy in management of pancreatic cancer. <i>Journal of Gastrointestinal Oncology</i> , 2011, 2, 157-67.	0.6	31
987	Laparoscopic distal pancreatectomy for adenocarcinoma: safe and reasonable?. <i>Journal of Gastrointestinal Oncology</i> , 2015, 6, 406-17.	0.6	24
988	Should every patient with pancreatic cancer receive perioperative/neoadjuvant therapy?. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2016, 37, 211-213.	0.1	3
989	EUS-guided radiofrequency ablation: Where we are?. <i>Endoscopic Ultrasound</i> , 2020, 9, 277.	0.6	2
990	The borderline resectable/locally advanced pancreatic ductal adenocarcinoma staging with computed tomography/magnetic resonance imaging. <i>Endoscopic Ultrasound</i> , 2017, 6, 79.	0.6	3

#	ARTICLE	IF	CITATIONS
991	Incremental Role of Pancreatic Magnetic Resonance Imaging after Staging Computed Tomography to Evaluate Patients with Pancreatic Ductal Adenocarcinoma. <i>Cancer Research and Treatment</i> , 2019, 51, 24-33.	1.3	17
992	Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Cancer. <i>Journal of Cancer Therapy</i> , 2016, 07, 24-40.	0.1	2
993	Current role of palliative interventions in advanced pancreatic cancer. <i>World Journal of Gastrointestinal Surgery</i> , 2018, 10, 75-83.	0.8	19
994	Response evaluation following neoadjuvant treatment of pancreatic cancer patients. <i>World Journal of Gastrointestinal Surgery</i> , 2013, 5, 12.	0.8	12
995	Arterial complication of irreversible electroporation procedure for locally advanced pancreatic cancer. <i>World Journal of Gastrointestinal Oncology</i> , 2016, 8, 751.	0.8	4
996	Neoadjuvant radiotherapeutic strategies in pancreatic cancer. <i>World Journal of Gastrointestinal Oncology</i> , 2016, 8, 186.	0.8	13
997	Comparison of efficacy between adjuvant chemotherapy and chemoradiation therapy for pancreatic cancer: AJCC stage-based approach. <i>World Journal of Clinical Oncology</i> , 2020, 11, 747-760.	0.9	5
998	Neoadjuvant treatment for resectable pancreatic adenocarcinoma. <i>World Journal of Clinical Oncology</i> , 2016, 7, 1.	0.9	11
999	Health Is Belonging: Lived Experiences during Recovery after Pancreaticoduodenectomy. <i>ISRN Nursing</i> , 2012, 2012, 1-8.	1.2	9
1000	Neoadjuvant chemo-radiotherapy for patients with borderline resectable pancreatic cancer: a meta-analytical evaluation of prospective studies. <i>JOP: Journal of the Pancreas</i> , 2013, 14, 618-25.	1.5	24
1001	Cancer of Exocrine Pancreas. <i>UNIPA Springer Series</i> , 2021, , 645-674.	0.1	0
1003	Investigation of Conversion Surgery for Initial UR-PDAC: Is Adjuvant Chemotherapy Still Necessary?. <i>Japanese Journal of Gastroenterological Surgery</i> , 2021, 54, 665-678.	0.0	0
1004	Current and emerging therapeutic strategies in pancreatic cancer: Challenges and opportunities. <i>World Journal of Gastroenterology</i> , 2021, 27, 6572-6589.	1.4	14
1005	Development of a Biomarker-Based Scoring System Predicting Early Recurrence of Resectable Pancreatic Duct Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2022, 29, 1281-1293.	0.7	10
1006	Single-cell analysis of patient-derived PDAC organoids reveals cell state heterogeneity and a conserved developmental hierarchy. <i>Nature Communications</i> , 2021, 12, 5826.	5.8	59
1007	A personalized approach to pancreatic ductal adenocarcinoma and its application in surgical practice. <i>Personalized Medicine</i> , 2021, 18, 613-627.	0.8	1
1008	A transcriptional signature detects homologous recombination deficiency in pancreatic cancer at the individual level. <i>Molecular Therapy - Nucleic Acids</i> , 2021, 26, 1014-1026.	2.3	8
1010	Systemic and Regional Chemotherapy for Advanced and Metastasized Pancreatic Cancer. , 2011, , 347-355.		0

#	ARTICLE	IF	CITATIONS
1011	Adjuvant trials for pancreatic cancer: where are we going and what is needed?. Clinical Investigation, 2011, 1, 651-667.	0.0	0
1013	The quandary of autoimmune pancreatitis and pancreatic ductal adenocarcinoma: A case report and review of IgG4 immunostaining in a cohort of patients receiving neoadjuvant chemotherapy. International Journal of Hepatobiliary and Pancreatic Diseases, 2012, 2, 38.	0.2	0
1014	Long-term survivor of stage IVb pancreatic cancer with peritoneal dissemination treated with neoadjuvant chemoradiotherapy followed by pancreaticoduodenectomy. Suizo, 2012, 27, 62-68.	0.1	0
1015	La chirurgie du pancrÃ©as. Bulletin De L'Academie Nationale De Medecine, 2012, 196, 1803-1817.	0.0	0
1016	Langzeitverlauf nach operativer Tumorentfernung und Chemotherapie des duktaalen Pankreaskarzinoms. , 2013, , 415-420.		0
1017	Recent Developments and Current Issues in the Treatment of Pancreatic Cancer. Journal of Cancer Therapy, 2013, 04, 13-27.	0.1	1
1018	Systemische und regionale Chemotherapie beim fortgeschrittenen und metastasierten Pankreaskarzinom. , 2013, , 217-224.		0
1020	Development of multidisciplinary therapy including surgical resection and chemotherapy for pancreatic cancer through clinical trials. Suizo, 2013, 28, 12-20.	0.1	0
1021	Initially Unresectable Pancreas Cancer Treated with Adjuvant Surgery after Chemotherapy for Three Years and Nine Months from Initial Treatment. Japanese Journal of Gastroenterological Surgery, 2014, 47, 704-710.	0.0	0
1022	A Systematic Review of Neoadjuvant Therapy Compared to the "Resection First" Approach for Patients with Borderline Resectable Pancreatic Adenocarcinoma. Journal of Cancer Therapy, 2014, 05, 91-100.	0.1	1
1023	Carcinoma of the Pancreas. , 2014, , 1397-1415.e7.		3
1024	Category I: Nondiagnostic. , 2015, , 5-9.		0
1025	Category VI: Positive or Malignant. , 2015, , 73-86.		0
1026	Pankreastumoren. , 2015, , 557-567.		0
1027	New Onset of Painless Jaundice. , 2015, , 191-199.		0
1028	E28 Literaturhinweise und Internetadressen. , 2015, , e1-e79.		0
1029	A case of long term survival of pancreatic cancer with paraaortic nodal metastasis. Suizo, 2015, 30, 137-143.	0.1	0
1030	Neoadjuvant Therapy for Borderline Resectable Pancreatic Head Cancer. Difficult Decisions in Surgery: an Evidence-based Approach, 2016, , 567-582.	0.0	0

#	ARTICLE	IF	CITATIONS
1031	Management Controversies and Treatment Strategies for Borderline Resectable Pancreatic Cancer. Cancer Treatment and Research, 2016, 168, 59-75.	0.2	0
1032	Management of Borderline Resectable Pancreatic Cancer. Difficult Decisions in Surgery: an Evidence-based Approach, 2016, , 599-608.	0.0	0
1033	Systemic and Regional Chemotherapy for Advanced and Metastasized Pancreatic Cancer. , 2016, , 243-251.		0
1034	Long Term Complete Response of Unresectable Locally Advanced Pancreatic Cancer after CCRT and Gemcitabine Chemotherapy. The Korean Journal of Pancreas and Biliary Tract, 2016, 21, 209-215.	0.0	1
1036	Borderline Resectable Pancreatic Cancer. , 2017, , 1-21.		0
1037	Radiofrequency Ablation of Pancreatic Mass. , 2017, , 43-66.		0
1038	Malignant Strictures of the Esophagus, Stomach, and Duodenum: Evaluation and Management. , 2017, , 69-79.		0
1039	Exosomes: Navigating a New Route in Pancreatic Cancer. Journal of Biomolecular Research & Therapeutics, 2017, 06, .	0.2	0
1040	Neoadjuvant Therapy for Pancreatic Cancer: a Review of the Evidence. Japanese Journal of Gastroenterological Surgery, 2017, 50, 614-623.	0.0	0
1042	Neoadjuvant Chemotherapy in Pancreatic Cancer. , 2017, , 1-16.		0
1043	Venous Resection in Pancreatic Ductal Adenocarcinoma: Impact of Surgical Experience on Early Postoperative Courses. Anticancer Research, 2017, 37, 4205-4213.	0.5	3
1044	Periampullary and Pancreatic Adenocarcinoma. , 0, , .		0
1045	Which patients with locally advanced pancreatic cancer treated with induction chemotherapy are most likely to benefit from post-induction chemoradiotherapy?. International Journal of Hepatobiliary and Pancreatic Diseases, 2018, 8, 1.	0.2	0
1046	Contrast-Enhanced Endoscopic Ultrasound (CE-EUS). Clinical Gastroenterology, 2018, , 459-471.	0.0	0
1047	Neoadjuvant treatment in non- metastatic pancreatic cancer, an option to be considered. Gastroenterology & Hepatology (Bartlesville, Okla), 2018, 9, .	0.0	2
1048	Treatment Sequencing for Borderline Resectable Pancreatic Cancer. , 2019, , 55-65.		0
1049	Literatur zu Giordano/Wenz: Strahlentherapie kompakt, 3. Auflage. , 2019, , e.1-e.39.		0
1051	Advances in Radiation Therapy for Gastrointestinal Cancers. , 2019, , 421-443.		0

#	ARTICLE	IF	CITATIONS
1052	Pankreaskarzinom. , 2019, , 101-105.		0
1053	Delivery of Neoadjuvant Versus Adjuvant Therapy in Localized Pancreatic Cancer. , 2019, , 67-84.		0
1054	New Onset of Painless Jaundice. , 2020, , 239-246.		0
1055	Adenocarcinoma of the Pancreas. , 2020, , 415-435.		0
1056	A prognostic nomogram for pancreatic ductal adenocarcinoma patientsâ€™ all-cause survival in a Surveillance, Epidemiology, and End Results analysis. Translational Cancer Research, 2020, 9, 3586-3599.	0.4	1
1057	Endoscopic ultrasound-guided fiducial marker placement for neoadjuvant chemoradiation therapy for resectable pancreatic cancer. World Journal of Gastrointestinal Oncology, 2020, 12, 768-781.	0.8	4
1058	High Expression of MUC15 Is Correlated with Poor Prognosis of Pancreatic Cancer and Promotes Migration, Invasion, and Chemo-Resistance In Vitro. Medical Science Monitor, 2020, 26, e926432.	0.5	2
1059	KRas4BG12C/D/PDE6Î´ Heterodimeric Molecular Complex: A Target Molecular Multicomplex for the Identification and Evaluation of Nontoxic Pharmacological Compounds for the Treatment of Pancreatic Cancer. , 0, , .		2
1060	Duodenopancreatectomia: anÃ¡lise histopatolÃ³gica de tumores periampulares. , 2020, 99, 366-373.	0.0	0
1061	Phase I Study of Preoperative Chemoradiotherapy Using Gemcitabine Plus Nab-Paclitaxel for Patients Who Have Localized Pancreatic Ductal Adenocarcinoma With Contact or Invasion to Major Arteries. Pancreas, 2021, 50, 1230-1235.	0.5	0
1062	Translational Approaches in Surgical Treatment. Molecular and Translational Medicine, 2020, , 233-239.	0.4	0
1063	Successful conversion surgery of distal pancreatectomy with celiac axis resection (DP-CAR) with double arterial reconstruction using saphenous vein grafting for locally advanced pancreatic cancer: a case report. Surgical Case Reports, 2020, 6, 302.	0.2	3
1064	Prognostic value of the preoperative fibrinogen-to-albumin ratio in pancreatic ductal adenocarcinoma patients undergoing R0 resection. World Journal of Gastroenterology, 2020, 26, 7382-7404.	1.4	13
1065	ImplementaciÃ³n de un centro de referencia regional en cirugÃa pancreÃ¡tica. Experiencia tras 631 procedimientos. CirugÃa EspaÃ±ola, 2020, , .	0.1	0
1067	A phaseâ€I study of preoperative (neoadjuvant) chemotherapy with gemcitabine plus nabâ€™paclitaxel for resectable pancreatic cancer. Molecular and Clinical Oncology, 2020, 14, 26.	0.4	2
1068	Therapy Response Imaging in Hepatobiliary and Pancreatic Malignancies. Medical Radiology, 2020, , 117-137.	0.0	0
1069	Oligopeptide Transporter-1 is Associated with Fluorescence Intensity of 5-Aminolevulinic Acid-Based Photodynamic Diagnosis in Pancreatic Cancer Cells. Yonago Acta Medica, 2020, 63, 154-162.	0.3	2
1071	Evaluation of Early Prognostic Factors in Patients With Pancreatic Ductal Adenocarcinoma Receiving Gemcitabine Together With Nab-paclitaxel. Cancer Diagnosis & Prognosis, 2021, 1, 399-409.	0.3	2

#	ARTICLE	IF	CITATIONS
1072	Analysis of KRAS Mutation Subtype in Tissue DNA and Cell-Free DNA Using Droplet Digital PCR and the Function of Cell-Free DNA as a Recurrence Predictive Marker in Pancreatic Cancer. <i>Biomedicines</i> , 2021, 9, 1599.	1.4	0
1073	Integrated transcriptome meta-analysis of pancreatic ductal adenocarcinoma and matched adjacent pancreatic tissues. <i>PeerJ</i> , 2020, 8, e10141.	0.9	34
1074	Self-expanding metal stents (SEMS) provide superior outcomes compared to plastic stents for pancreatic cancer patients undergoing neoadjuvant therapy. <i>Journal of Gastrointestinal Oncology</i> , 2012, 3, 309-13.	0.6	47
1075	A 71-year-old man with a large cystic pancreatic mass. <i>Gastrointestinal Cancer Research: GCR</i> , 2012, 5, 29-31.	0.8	0
1076	The influence of radiation therapy dose escalation on overall survival in unresectable pancreatic adenocarcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2014, 5, 77-85.	0.6	10
1077	microRNA-137 modulates pancreatic cancer cells tumor growth, invasion and sensitivity to chemotherapy. <i>International Journal of Clinical and Experimental Pathology</i> , 2014, 7, 7442-50.	0.5	26
1078	MicroRNA-200c overexpression inhibits chemoresistance, invasion and colony formation of human pancreatic cancer stem cells. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 6533-9.	0.5	39
1079	miR-23a-5p inhibits cell proliferation and invasion in pancreatic ductal adenocarcinoma by suppressing ECM1 expression. <i>American Journal of Translational Research (discontinued)</i> , 2019, 11, 2983-2994.	0.0	13
1080	Does Neoadjuvant Therapy Improve Outcome in Resectable PC? <i>Gastrointestinal Cancers Symposium 2019. JOP: Journal of the Pancreas</i> , 2019, 20, 155-158.	1.5	0
1081	Pimavanserin: A Novel Autophagy Modulator for Pancreatic Cancer Treatment. <i>Cancers</i> , 2021, 13, 5661.	1.7	6
1084	Dramatic Reduction of Distant Pancreatic Metastases Using Local Light Activation of Verteporfin with Nab-Paclitaxel. <i>Cancers</i> , 2021, 13, 5781.	1.7	2
1085	Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: Role of the Radiologist and Oncologist in the Era of Precision Medicine. <i>Diagnostics</i> , 2021, 11, 2166.	1.3	7
1086	Neoadjuvant therapy alters the collagen architecture of pancreatic cancer tissue via Ephrin-A5. <i>British Journal of Cancer</i> , 2022, 126, 628-639.	2.9	11
1087	Neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic cancer: a meta-analysis of randomised controlled trials. <i>European Journal of Cancer</i> , 2022, 160, 140-149.	1.3	90
1088	Deregulation of Transcription Factor Networks Driving Cell Plasticity and Metastasis in Pancreatic Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 753456.	1.8	11
1089	Long-term nationwide trends in the treatment of and outcomes among pancreatic cancer patients. <i>European Journal of Surgical Oncology</i> , 2022, 48, 1087-1092.	0.5	6
1090	Implementation of a regional reference center in pancreatic surgery. Experience after 631 procedures. <i>Cirugía Española (English Edition)</i> , 2021, 99, 745-756.	0.1	0
1091	Surgery After Response to Chemotherapy for Locally Advanced Pancreatic Ductal Adenocarcinoma: A Guide for Management. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 459-467.	2.3	5

#	ARTICLE	IF	CITATIONS
1092	Current role of endoscopic ultrasound in the diagnosis and management of pancreatic cancer. <i>World Journal of Gastrointestinal Endoscopy</i> , 2022, 14, 35-48.	0.4	5
1093	The Role of MRI Pancreatic Protocol in Assessing Response to Neoadjuvant Therapy for Patients With Borderline Resectable Pancreatic Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 796317.	1.3	4
1094	Prognosis of Upfront Surgery for Pancreatic Cancer: A Systematic Review and Meta-Analysis of Prospective Studies. <i>Frontiers in Oncology</i> , 2021, 11, 812102.	1.3	3
1095	TNFSF9 promotes metastasis of pancreatic cancer by regulating M2 polarization of macrophages through Src/FAK/p-Akt/IL-1 β signaling. <i>International Immunopharmacology</i> , 2022, 102, 108429.	1.7	12
1096	Pancreatic Cancer: Current Multimodality Treatment Options and the Future Impact of Molecular Biological Profiling. <i>Visceral Medicine</i> , 2022, 38, 20-29.	0.5	7
1097	Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 1220-1230.	0.8	274
1098	Identification of solute carrier family genes related to the prognosis and tumor-infiltrating immune cells of pancreatic ductal adenocarcinoma. <i>Annals of Translational Medicine</i> , 2022, 10, 57-57.	0.7	3
1099	Could Total Neoadjuvant Therapy Followed by Surgical Resection Be the New Standard of Care in Pancreatic Cancer? A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2022, 11, 812.	1.0	6
1100	Pancreatic Ductal Adenocarcinoma: New Insights into the Actions of Vitamin A. <i>Oncology Research and Treatment</i> , 2022, 45, 291-298.	0.8	7
1101	Immortalization-upregulated protein promotes pancreatic cancer progression by regulating NPM1/FHL1-mediated cell-cycle-checkpoint protein activity. <i>Cell Biology and Toxicology</i> , 2023, 39, 2069-2087.	2.4	2
1102	Cost-effectiveness of neoadjuvant FOLFIRINOX versus gemcitabine plus nab-paclitaxel in borderline resectable/locally advanced pancreatic cancer patients. <i>Cancer Reports</i> , 2022, 5, e1565.	0.6	4
1103	The Role of Keratin17 in Human Tumours. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 818416.	1.8	11
1104	KRAS gene mutation quantification in the resection or venous margins of pancreatic ductal adenocarcinoma is not predictive of disease recurrence. <i>Scientific Reports</i> , 2022, 12, 2976.	1.6	3
1105	Integrated single-cell multiomics analysis reveals novel candidate markers for prognosis in human pancreatic ductal adenocarcinoma. <i>Cell Discovery</i> , 2022, 8, 13.	3.1	23
1106	Neoadjuvant Treatment for Resectable and Borderline Resectable Pancreatic Cancer: Chemotherapy or Chemoradiotherapy?. <i>Frontiers in Oncology</i> , 2021, 11, 744161.	1.3	5
1107	A Novel Ferroptosis-Related lncRNAs Signature Predicts Clinical Prognosis and Is Associated With Immune Landscape in Pancreatic Cancer. <i>Frontiers in Genetics</i> , 2022, 13, 786689.	1.1	15
1108	Prediction of local tumor control and recurrence-free survival in patients with pancreatic cancer undergoing curative resection after neoadjuvant chemoradiotherapy. <i>Journal of Surgical Oncology</i> , 2022, 126, 292-301.	0.8	5
1109	Hepatic Arterial Infusion Pump Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma: A Systematic Review and Meta-Analysis. <i>Annals of Surgical Oncology</i> , 2022, 29, 5528-5538.	0.7	14

#	ARTICLE	IF	CITATIONS
1111	Analysis of N6-methyladenosine-related lncRNAs in the tumor immune microenvironment and their prognostic role in pancreatic cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, , 1.	1.2	1
1112	Adjuvant therapy for margin positive pancreatic cancer: A propensity score matched analysis. <i>Pancreatology</i> , 2022, 22, 396-400.	0.5	1
1113	Predictive risk factors for early recurrence in patients with localized pancreatic ductal adenocarcinoma who underwent curative-intent resection after preoperative chemoradiotherapy. <i>PLoS ONE</i> , 2022, 17, e0264573.	1.1	4
1114	Genome-wide DNA hypomethylation drives a more invasive pancreatic cancer phenotype and has predictive occult distant metastasis and prognosis potential. <i>International Journal of Oncology</i> , 2022, 60, .	1.4	2
1115	Recurrence and Prognostic Value of Circulating Tumor Cells in Resectable Pancreatic Head Cancer: A Single Center Retrospective Study. <i>Frontiers in Surgery</i> , 2022, 9, 832125.	0.6	1
1116	An evaluation of adjuvant chemotherapy following neoadjuvant chemotherapy and resection for borderline resectable and locally advanced pancreatic cancer. <i>American Journal of Surgery</i> , 2022, 224, 51-57.	0.9	4
1117	Outcomes of patients with borderline resectable and resectable pancreatic adenocarcinoma treated with neoadjuvant three-week course chemoradiotherapy using capecitabine-based versus gemcitabine-based concurrent chemotherapy. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 2557-2566.	0.6	1
1118	TYMS 3' UTR Polymorphism: A Novel Association with FOLFIRINOX-Induced Neurotoxicity in Pancreatic Cancer Patients. <i>Pharmaceutics</i> , 2022, 14, 77.	2.0	1
1119	High Expression of Bloom Syndrome Helicase is a Key Factor for Poor Prognosis and Advanced Malignancy in Patients with Pancreatic Cancer: A Retrospective Study. <i>Annals of Surgical Oncology</i> , 2022, 29, 3551.	0.7	2
1120	Elderly Patients with Nondistant Metastatic Pancreatic Head Adenocarcinoma Cannot Benefit from More Radical Surgery. <i>International Journal of Endocrinology</i> , 2022, 2022, 1-11.	0.6	0
1124	Prognosis of pancreatic head cancer with different patterns of lymph node metastasis. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2022, 29, 1004-1013.	1.4	6
1128	Neoadjuvant therapy in pancreatic cancer: review article. <i>JOP: Journal of the Pancreas</i> , 2015, 16, 110-4.	1.5	0
1129	PET imaging of glycogen synthase kinase-3 in pancreatic cancer xenograft mouse models.. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 12, 1-14.	1.0	0
1130	Recent advances in the biosynthesis, structure-activity relationships, formulations, pharmacology, and clinical trials of fisetin. <i>EFood</i> , 2022, 3, .	1.7	20
1131	Neoadjuvant therapy in pancreatic ductal adenocarcinoma: a competing risk analysis. <i>Surgical Practice</i> , 0, , .	0.1	0
1132	Updates on Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Adenocarcinoma. <i>Advances in Oncology</i> , 2022, 2, 35-45.	0.1	0
1134	Downstaging of Pancreatic Adenocarcinoma With Either Neoadjuvant Chemotherapy or Chemoradiotherapy Improves Survival. <i>Annals of Surgical Oncology</i> , 2022, 29, 6015-6028.	0.7	6
1135	Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma: A Physiopathologic and Pharmacologic Review. <i>Cancers</i> , 2022, 14, 2486.	1.7	29

#	ARTICLE	IF	CITATIONS
1136	Evaluation of potential of miR-8073 and miR-642 as diagnostic markers in pancreatic cancer. <i>Molecular Biology Reports</i> , 2022, 49, 6475-6481.	1.0	2
1137	Multi-Phase, Contrast-Enhanced Computed Tomography-Based Radiomic Prognostic Marker of Non-Metastatic Pancreatic Ductal Adenocarcinoma. <i>Cancers</i> , 2022, 14, 2476.	1.7	3
1138	GPR120 promotes metastasis but inhibits tumor growth in pancreatic ductal adenocarcinoma. <i>Pancreatology</i> , 2022, , .	0.5	1
1139	Prognostic Impact of Radiological Splenic Artery Involvement in Pancreatic Ductal Adenocarcinoma of the Body and Tail. <i>Annals of Surgical Oncology</i> , 2022, 29, 7047-7058.	0.7	6
1140	Dose-escalated proton therapy with elective nodal irradiation and concomitant chemotherapy for unresectable, borderline resectable, or medically inoperable pancreatic cancer: a phase II trial. <i>Journal of Gastrointestinal Oncology</i> , 2022, 13, 1395-1401.	0.6	2
1141	Trends in the surgical treatment for pancreatic cancer in the last 30 years. <i>BioScience Trends</i> , 2022, 16, 198-206.	1.1	4
1142	Endothelin-axis antagonism enhances tumor perfusion in pancreatic cancer. <i>Cancer Letters</i> , 2022, 544, 215801.	3.2	3
1143	Loss of Heterozygosity for KrasG12D Promotes Malignant Phenotype of Pancreatic Ductal Adenocarcinoma by Activating HIF-21±-c-Myc-Regulated Glutamine Metabolism. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6697.	1.8	3
1144	Association between microRNAs and chemoresistance in pancreatic cancer: Current knowledge, new insights, and forthcoming perspectives. <i>Pathology Research and Practice</i> , 2022, 236, 153982.	1.0	2
1145	Germline Aberrations in Pancreatic Cancer: Implications for Clinical Care. <i>Cancers</i> , 2022, 14, 3239.	1.7	11
1146	A Rare Case of Synchronous Intraductal Papillary Mucinous Neoplasm-Associated Pancreatic Adenocarcinoma and Signet Ring Cell Gastric Adenocarcinoma. <i>American Journal of Case Reports</i> , 0, 23, .	0.3	1
1147	Biocompatible nanosponges for drug targeting in pancreatic cancer. <i>Materials Today: Proceedings</i> , 2022, 68, 867-872.	0.9	0
1148	Use and outcomes from neoadjuvant chemotherapy in borderline resectable pancreatic ductal adenocarcinoma in an Australasian population. <i>Asia-Pacific Journal of Clinical Oncology</i> , 0, , .	0.7	1
1149	Tumor microenvironmental <sc>15â€PGDH</sc> depletion promotes fibrotic tumor formation and angiogenesis in pancreatic cancer. <i>Cancer Science</i> , 2022, 113, 3579-3592.	1.7	5
1150	Towards Accurate and Precise Image-Guided Radiotherapy: Clinical Applications of the MR-Linac. <i>Journal of Clinical Medicine</i> , 2022, 11, 4044.	1.0	8
1151	Deepâ€Penetrating Tripleâ€Responsive Prodrug Nanosensitizer Actuates Efficient Chemoradiotherapy in Pancreatic Ductal Adenocarcinoma Models. <i>Small</i> , 2022, 18, .	5.2	12
1152	Detection of actionable mutations in cytological specimens obtained by endoscopic ultrasound-guided fine needle aspiration with rapid onsite evaluation in pancreatic cancer. <i>Annals of Diagnostic Pathology</i> , 2022, 60, 152008.	0.6	2
1153	Pancreatic Ductal Adenocarcinoma. , 2023, , 160-176.		0

#	ARTICLE	IF	CITATIONS
1154	Genomic profiling amplifies the utility of endoscopic ultrasound-guided fine needle biopsy by identifying clinically applicable druggable mutations in pancreatic cancer. <i>Annals of Diagnostic Pathology</i> , 2022, 60, 152016.	0.6	2
1155	Delayed Gastric Emptying Does Not Influence Cancer-Specific Survival after Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma. <i>Journal of Clinical Medicine</i> , 2022, 11, 4200.	1.0	0
1156	Neoadjuvant therapy for resectable pancreatic cancer: a narrative review. <i>Journal of Pancreatology</i> , 2022, 5, 69-77.	0.3	2
1157	A 47-Year-Old Man with Advanced Distal Pancreatic Carcinoma and an Initial Partial Response to Chemotherapy Requiring Celiac Axis Reconstruction of the Common Hepatic Artery and Left Gastric Artery. <i>American Journal of Case Reports</i> , 0, 23, .	0.3	0
1158	Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of pancreatic cancer. <i>Journal of the National Cancer Center</i> , 2022, 2, 205-215.	3.0	5
1159	Study protocol for a prospective, open-label, single-arm, phase II study on the combination of tislelizumab, nab-paclitaxel, gemcitabine, and concurrent radiotherapy as the induction therapy for patients with locally advanced and borderline resectable pancreatic cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
1160	Neoadjuvant treatment of pancreatic adenocarcinoma: Chemoradiation or stereotactic body radiation therapy?. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2022, 26, 858-864.	0.6	2
1161	Aberrant transcription factors in the cancers of the pancreas. <i>Seminars in Cancer Biology</i> , 2022, 86, 28-45.	4.3	5
1162	Total Neoadjuvant Treatment for Pancreatic Ductal Adenocarcinoma Is Associated With Limited Lymph Node Yield but Improved Ratio. <i>Journal of Surgical Research</i> , 2022, 280, 543-550.	0.8	5
1163	The Effectiveness of Chemoradiotherapy in Elderly Patients with Pancreatic Cancer: A Population-Based Study Based on the SEER Database. <i>Advances in Therapy</i> , 2022, 39, 5043-5057.	1.3	0
1164	Neoadjuvant Chemotherapy-Chemoradiation for Borderline-Resectable Pancreatic Adenocarcinoma: A UK Tertiary Surgical Oncology Centre Series. <i>Cancers</i> , 2022, 14, 4678.	1.7	3
1165	Induction Chemotherapy with FOLFIRINOX for Locally Advanced Pancreatic Cancer: A Simple Scoring System to Predict Effect and Prognosis. <i>Annals of Surgical Oncology</i> , 2023, 30, 2401-2408.	0.7	4
1166	Radiotherapy for Pancreatic Adenocarcinoma. <i>Hematology/Oncology Clinics of North America</i> , 2022, , .	0.9	2
1167	Single vein resection in surgery for pancreatic ductal carcinoma as a criterion of resectability. <i>Siberian Journal of Oncology</i> , 2022, 21, 25-31.	0.1	0
1168	A Case Report on Longitudinal Collection of Tumour Biopsies for Gene Expression-Based Tumour Microenvironment Analysis from Pancreatic Cancer Patients Treated with Endoscopic Ultrasound Guided Radiofrequency Ablation. <i>Current Oncology</i> , 2022, 29, 6754-6763.	0.9	3
1169	Immune checkpoint blockade enhances chemophototherapy in a syngeneic pancreatic tumor model. <i>APL Bioengineering</i> , 2022, 6, .	3.3	5
1170	A case of pathological complete response with liposomal irinotecan+5-FU/LV for unresectable locally advanced pancreatic cancer. <i>Surgical Case Reports</i> , 2022, 8, .	0.2	0
1171	System analysis based on the pyroptosis-related genes identifies GSDMC as a novel therapy target for pancreatic adenocarcinoma. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	14

#	ARTICLE	IF	CITATIONS
1172	Neoadjuvant chemotherapy improves outcomes in resectable pancreatic adenocarcinoma. <i>Surgery in Practice and Science</i> , 2022, 11, 100136.	0.2	0
1173	Imaging-Based Biomarkers for Pancreatic Cancer. , 2022, , 229-240.		0
1174	Establishment of the diagnostic and prognostic nomograms for pancreatic cancer with bone metastasis. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
1175	Neoadjuvant therapy in resectable pancreatic cancer: A promising curative method to improve prognosis. <i>World Journal of Gastrointestinal Oncology</i> , 0, 14, 1903-1917.	0.8	4
1176	Systematic analysis of expression profiles and prognostic significance of the FGF gene family in pancreatic adenocarcinoma. <i>Oncology Letters</i> , 2022, 24, .	0.8	1
1177	CD44V3, an Alternatively Spliced Form of CD44, Promotes Pancreatic Cancer Progression. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12061.	1.8	4
1178	Focal pancreatic parenchyma atrophy is a harbinger of pancreatic cancer and a clue to the intraductal spreading subtype. <i>Pancreatology</i> , 2022, 22, 1148-1158.	0.5	8
1179	Impact of Microscopic Confirmation on Therapeutic Management of Pancreatic Cancer Patients: Lessons from an Italian Regional Tumor Registry. <i>Cancers</i> , 2022, 14, 5372.	1.7	0
1180	Ductal Adenocarcinoma: Downstaging. , 2022, , 99-139.		0
1181	MS-5, a Naphthalene Derivative, Induces Apoptosis in Human Pancreatic Cancer BxPC-3 Cells by Modulating Reactive Oxygen Species. <i>Biomolecules and Therapeutics</i> , 2022, , .	1.1	0
1183	CDC48/SNAI2 Complex Activates CD44 to Promote Proliferation and Invasion of Pancreatic Ductal Adenocarcinoma. <i>Cancers</i> , 2022, 14, 5434.	1.7	1
1184	Liposomal co-delivery system encapsulating celastrol and paclitaxel displays highly enhanced efficiency and low toxicity against pancreatic cancer. <i>Journal of Drug Delivery Science and Technology</i> , 2022, 78, 103947.	1.4	0
1185	A cancer-associated fibroblast gene signature predicts prognosis and therapy response in patients with pancreatic cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
1186	Columbianetin acetate inhibits the occurrence and development of pancreatic cancer cells by down-regulating the expression of Meiotic nuclear divisions 1. <i>Biocell</i> , 2023, 47, 297-307.	0.4	0
1187	Cancer nanomedicine in preoperative therapeutics: Nanotechnology-enabled neoadjuvant chemotherapy, radiotherapy, immunotherapy, and phototherapy. <i>Bioactive Materials</i> , 2023, 24, 136-152.	8.6	14
1188	Efficacy and safety of immune checkpoint inhibitors in advanced pancreatic cancer: A real world study in Chinese cohort. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, .	1.4	3
1189	Neoadjuvant chemotherapy drives intratumoral T cells toward a proinflammatory profile in pancreatic cancer. <i>JCI Insight</i> , 2022, 7, .	2.3	8
1190	Neoadjuvant therapy in pancreatic neuroendocrine neoplasms: A systematic review and meta-analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1

#	ARTICLE	IF	CITATIONS
1191	Neoadjuvant chemotherapy and radiotherapy outcomes in <scp>borderlineâ€resectable</scp> and <scp>locallyâ€advanced</scp> pancreatic cancer patients. <i>Cancer Medicine</i> , 2023, 12, 7713-7723.	1.3	3
1192	Pancreatic Cancer 3D Cell Line Organoids (CLOs) Maintain the Phenotypic Characteristics of Organoids and Accurately Reflect the Cellular Architecture and Heterogeneity In Vivo. <i>Organoids</i> , 2022, 1, 168-183.	1.8	1
1193	Neoadjuvant chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: Meta-analysis and trial sequential analysis of randomized controlled trials. <i>Annals of Hepato-biliary-pancreatic Surgery</i> , 2023, 27, 28-39.	0.1	7
1194	A Novel Molecular Signature of Cancer-Associated Fibroblasts Predicts Prognosis and Immunotherapy Response in Pancreatic Cancer. <i>International Journal of Molecular Sciences</i> , 2023, 24, 156.	1.8	4
1195	Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2023, 8, 157-168.	3.7	73
1196	Liquid biopsy leads to a paradigm shift in the treatment of pancreatic cancer. <i>World Journal of Gastroenterology</i> , 0, 28, 6478-6496.	1.4	6
1197	<scp>P53</scp> immunolabeling in <scp>EUSâ€FNA</scp> biopsy can predict low resection rate and early recurrence in resectable or borderline resectable pancreatic cancer treated with neoadjuvant therapy. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2023, 30, 802-814.	1.4	3
1198	Landmarks in pancreatic cancer studies. <i>Cancer Cell International</i> , 2022, 22, .	1.8	1
1199	Sarcopenia is an Independent Prognostic Factor in Patients With Pancreatic Cancer â€“ a Meta-analysis. <i>Academic Radiology</i> , 2023, 30, 1552-1561.	1.3	5
1200	A retrospective preliminary study of intrapancreatic late enhancement as a noteworthy imaging finding in the early stages of pancreatic adenocarcinoma. <i>European Radiology</i> , 0, , .	2.3	1
1201	Vasculitis, CA19-9, and PNI differentially predict response and surgical outcome in pancreatic ductal adenocarcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2023, , .	0.4	1
1202	Does Surgical Resection Significantly Prolong the Long-Term Survival of Patients with Oligometastatic Pancreatic Ductal Adenocarcinoma? A Cross-Sectional Study Based on 18 Registries. <i>Journal of Clinical Medicine</i> , 2023, 12, 513.	1.0	4
1203	Comparison the efficacy and safety of different neoadjuvant regimens for resectable and borderline resectable pancreatic cancer: a systematic review and network meta-analysis. <i>European Journal of Clinical Pharmacology</i> , 0, , .	0.8	2
1204	Neoadjuvant radiohormonal therapy for oligo-metastatic prostate cancer: safety and efficacy outcomes from an open-label, dose-escalation, single-center, phase I/II clinical trial. <i>Frontiers of Medicine</i> , 2023, 17, 231-239.	1.5	2
1205	Quantitative analysis of mouse pancreatic ductal adenocarcinoma using FLIM on tissue sections. , 2023, , .		0
1206	Evaluation and prognostic significance of tumor budding in pancreatic ductal adenocarcinomas. <i>Indian Journal of Pathology and Microbiology</i> , 2023, 66, 38.	0.1	4
1207	Synergistic Combination of Irinotecan and Rapamycin Orally Delivered by Nanoemulsion for Enhancing Therapeutic Efficacy of Pancreatic Cancer. <i>Pharmaceutics</i> , 2023, 15, 473.	2.0	1
1211	Treatment of pancreatic cancer in 2022. , 2023, 1, .		0

#	ARTICLE	IF	CITATIONS
1212	<p>1212 TWIST1 is a prognostic factor for neoadjuvant chemotherapy for patients with resectable pancreatic cancer: a preliminary study. <i>Surgery Today</i>, 2023, 53, 633-639.</p>	0.7	1
1213	<p>1213 Research trends and hotspots of neoadjuvant therapy in pancreatic cancer: a bibliometric analysis based on the Web of Science Core Collection. <i>Clinical and Experimental Medicine</i>, 2023, 23, 2473-2485.</p>	1.9	2
1214	<p>1214 Radioterapia: papel actual en el c�ncer de p�ncreas. <i>latreia</i>, 2012, 25, 149-158.</p>	0.1	0
1215	<p>1215 Hypoxia, a Targetable Culprit to Counter Pancreatic Cancer Resistance to Therapy. <i>Cancers</i>, 2023, 15, 1235.</p>	1.7	9
1216	<p>1216 Emerging role of interaction between m6A and main ncRNAs in gastrointestinal (GI) cancers. <i>Frontiers in Immunology</i>, 0, 14, .</p>	2.2	0
1219	<p>1219 A detailed insight of the tumor targeting using nanocarrier drug delivery system. <i>Drug Delivery</i>, 2023, 30, .</p>	2.5	22
1221	<p>1221 Clinical application of MR-Linac in tumor radiotherapy: a systematic review. <i>Radiation Oncology</i>, 2023, 18, .</p>	1.2	9
1222	<p>1222 Multidisciplinary team diagnosis and treatment of pancreatic cancer: Current landscape and future prospects. <i>Frontiers in Oncology</i>, 0, 13, .</p>	1.3	0
1223	<p>1223 The current understanding of the immune landscape relative to radiotherapy across tumor types. <i>Frontiers in Immunology</i>, 0, 14, .</p>	2.2	5
1224	<p>1224 Circulating tumour cells in gastrointestinal cancers: food for thought?. <i>British Journal of Cancer</i>, 2023, 128, 1981-1990.</p>	2.9	3
1225	<p>1225 Can combined use of tumor markers in pancreatic cancer be a solution to short- and long-term consequences?: A retrospective study. <i>Medicine (United States)</i>, 2023, 102, e33325.</p>	0.4	1
1226	<p>1226 Circulating tumor DNA in molecular assessment feasibly predicts early progression of pancreatic cancer that cannot be identified via initial imaging. <i>Scientific Reports</i>, 2023, 13, .</p>	1.6	3
1227	<p>1227 Distal Pancreatectomy with En-bloc Celiac Axis Resection (dp-car) for Locally Advanced Pancreatic Cancer. <i>Annals of Surgery</i>, 0, Publish Ahead of Print, .</p>	2.1	2
1228	<p>1228 Current State and Future Directions of Radiation Therapy for Pancreas Adenocarcinoma. <i>Surgical Oncology Clinics of North America</i>, 2023, 32, 399-414.</p>	0.6	1
1229	<p>1229 Pancreatectomy with venous vascular resection for pancreatic cancer: Impact of types of vein resection on timing and pattern of recurrence. <i>European Journal of Surgical Oncology</i>, 2023, 49, 1457-1465.</p>	0.5	2
1230	<p>1230 PSMD12 interacts with CDKN3 and facilitates pancreatic cancer progression. <i>Cancer Gene Therapy</i>, 2023, 30, 1072-1083.</p>	2.2	1
1231	<p>1231 Irreversible electroporation augments �2-glucan induced trained innate immunity for the treatment of pancreatic ductal adenocarcinoma. , 2023, 11, e006221.</p>		0
1232	<p>1232 Diagnostic Categories and Key Features for Pathological Diagnosis of Endoscopic Ultrasound-Guided Fine Needle Aspiration Biopsy Samples of Pancreatic Lesions. <i>Pancreas</i>, 2022, 51, 1105-1111.</p>	0.5	2

#	ARTICLE	IF	CITATIONS
1235	Current Status of Vascular Resections in Pancreatic Cancer Surgery. , 2023, , 107-114.		0
1237	Human arginase I: a potential broad-spectrum anti-cancer agent. 3 Biotech, 2023, 13, .	1.1	0
1276	Resectable Pancreatic Cancer: Neoadjuvant and Adjuvant Therapy. , 2023, , 1-18.		0
1280	Can diffusion-weighted MRI improve response assessment of neo-adjuvant therapy in pancreatic cancer?. European Radiology, 0, , .	2.3	0
1284	Epigenetic therapeutic strategies in pancreatic cancer. International Review of Cell and Molecular Biology, 2024, , 1-40.	1.6	0